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IDENTIFICATION OF DIFFERENTIALLY EXPRESSED 
GENES IN HPV-ASSOCIATED CANCERS USING GENE 
EXPRESSION, TISSUE, AND MICRORNA 
MICROARRAYS 
 
Ivan Martinez, PhD 
University of Pittsburgh, 2007 
 
ABSTRACT 
 
Infections with high-risk human papillomaviruses (HPVs) have been 
implicated in the pathogenesis of cervical carcinoma and a subset of squamous 
cell carcinoma of the head and neck (SCCHN). In this study, we compared the 
cellular gene expression profiles of HPV16-positive and HPV-negative 
oropharyngeal carcinomas with those of the normal oral epithelium. Using a high-
density oligonucleotide microarray containing 22,215 human transcripts, we 
showed that 397 and 162 genes were differentially expressed in HPV16-positive 
and HPV-negative SCCHN, respectively, compared to the normal oral epithelium. 
Our studies also identified 59 differentially expressed genes in HPV16-positive 
SCCHN as compared to both HPV-negative SCCHN and normal oropharyngeal 
tissues. Such up-regulated genes included those involved in nuclear structure 
and meiosis (SYCP2), DNA repair (RFC5), and transcription regulation 
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(ZNF238). Genes involved in proteolysis (KLK8) and signal transduction 
(CRABP2) were found to be down-regulated in HPV-positive SCCHN. Our results 
reveal specific gene expression patterns in HPV16-positive oropharyngeal 
squamous carcinomas and suggest that HPV infection could play an important 
etiologic role in these tumors. In another study using the same high-density 
microarray platform, we have analyzed the cellular gene expression profiles of 
five HPV-16 and two HPV-18 positive cervical cell lines, one HPV-negative 
cervical carcinoma cell line, and normal cervical tissue. Our results showed that 
877 and 536 genes were differentially expressed in the HPV-positive cell lines 
compared to the normal cervix tissue and the HPV-negative cervical carcinoma 
cell line C-33A, respectively. We also found that a total of 57 genes were 
differentially expressed in the HPV-positive cell lines as compared to both the 
normal cervix and C-33A. Differentially expressed genes including those involved 
in cell proliferation such as the L-type amino acid transporter 1 (LAT1, also 
known as SLC7A5) and gene expression regulation like nucleosome assembly 
protein 1-like 3 (NAP1L3) were found to be affected for the first time in cervical 
cell lines. In situ hybridization of LAT1 and NAP1L3 mRNA performed using 
tissue-arrays (containing ~50 different cervical tumor samples per slide) showed 
that these genes are also affected in their expression in tumor tissues. These 
results could lead to the identification of new cellular pathways affected by the 
presence of HPV in cervical cells. We have also carried out studies to determine 
whether the expression of human microRNAs (miRNAs; small non-coding RNAs 
that have the ability to regulate gene expression) are affected by the presence of 
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HPV DNA. For this purpose, we analyzed the expression of miRNAs in HPV-16 
positive cervical cell lines and tissues. Twenty-seven miRNAs were differentially 
expressed in cervical cell lines containing integrated HPV-16 DNA compared to 
the normal cervix, while, only 6 miRNAs were differentially expressed in a cell 
line containing episomal HPV-16 DNA compared to the normal cervix. 
Furthermore, 10 miRNAs were affected in their expression in cell lines containing 
integrated HPV-16 DNA compared to C-33A. Interestingly, microRNA-218 (miR-
218) was specifically underexpressed in cell lines, cervical lesions and cancer 
tissues containing integrated HPV-16 DNA as compared to both the HPV-
negative cell line C-33A and the normal cervix. Expression of the HPV-16 E6 
oncogene in transfected cells reduced miR-218 expression, and conversely, RNA 
interference of E6/E7 oncogenes in an HPV-16 positive cell line increased miR-
218 expression. We also showed that miR-218 expression parallels that of the 
tumor suppressor gene SLIT2 whose intron encodes miR-218. Furthermore, 
exogenous expression of miR-218 in HPV-16 positive cell lines decreased 
expression of the epithelial-specific gene LAMB3 which is involved in cell 
migration and tumorigenicity. These findings demonstrate specific regulation of 
cellular miRNAs in the presence of an HPV oncogene and may contribute to a 
better understanding of molecular mechanisms involved in cervical 
carcinogenesis. 
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GENERAL INTRODUCTION 
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1.1 THE BIOLOGY OF HUMAN PAPILLOMAVIRUSES 
 
 
 Papillomaviruses (from the Latin papilla: ‘pustule’ and the Greek suffix –
oma: ‘tumor’) are members of the papovaviridae family which also include simian 
vacuolating virus and polyomavirus (Fields, et al., 1990). Papillomaviruses have 
been found in a wide variety of animals including humans where they can infect 
basal epithelial cells of mucosal or cutaneous tissues (Burd, 2003). Human 
Papillomavirus (HPV) infection is one of the most common sexually transmitted 
diseases not only in the United Sates but worldwide. In the United States, the 
incidence of new HPV infections is probably 1 to 5.5 million people per year and 
the prevalence could be as high as 20 million people (Cates, 1999). There are 
more than 200 different types of HPVs where only 85 have been well 
characterized at the genomic level (Burd, 2003).  
 
 HPVs are small double-stranded circular DNA viruses of approximately 
7,900 base pairs (bp).  HPV DNA interacts with cellular histone proteins to form a 
chromatin-like complex (Favre, 1975). HPV particles are non-enveloped with a 
diameter between 55-60 nm and are composed of 72 capsomers (Baker, et al., 
1991). Only one of the DNA strand of HPVs encodes proteins. The coding strand 
contains early and late genes depending upon their time of expression during the 
viral life cycle (Sanclemente, et al., 2002). The HPV-16 genome can be divided 
into three different regions: First, the ~1,000 bp non-coding Long Control Region 
(LCR) that contains the core promoter (p97) of early genes, enhancer and 
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silencer sequences, origin of replication and DNA replication regulatory 
sequences; second, an ~4,000 bp early region that contains the open reading 
frames [ORFs] of E1, E2, E4, E5, E6, and E7 genes that are involved in viral 
replication, immortalization and proliferation of the host cell; and third, a ~3,000 
bp region that contains the L1 and L2 ORFs that express the viral capsid proteins 
(Fig. 1) (Burd, 2003). The HPV early region includes the E6 and E7 genes that 
are involved in cellular transformation. The E6 and E7 genes have overlapping 
sequences that are differentially spliced (sharing the same 3’ end) and use the 
same polyadenylation signal; (Seedorf, et al., 1985).  
 
 The HPV life cycle is very unique in comparison to other virus families. 
HPV replication process requires epidermal or mucosal epithelial cells that still 
retain the ability to proliferate. Since epithelial cells undergo proliferation only 
near the basal membrane and then differentiate during migration to the 
suprabasal layers, infection of basal epithelium cells with HPV occurs only upon 
micro-abrasion of the epithelium (for example during sexual intercourse).  The 
virus is known to bind to cell surface ligands (Sanclemente, et al., 2002; zur 
Hausen, 2002). There is no evidence of specific HPV receptors, but some of the 
α6-integrin and heparan sulphate family molecules may be involved in this 
process (Evander, et al., 1997;Giroglou, et al., 2001). After viral-receptor 
recognition, HPV is decapsidated and the genome is transported inside the  
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Fig. 1. THE HUMAN PAPILLOMAVIRUS GENOME 
 
A 
 
B 
 
© Dell G. et. al. Cell. Mol. Life Sci. 58 (2001) 1923-1942. 
 
(A) Circular HPV DNA showing the positions of the early expressed genes (E6, E7, 
E1, E2, E4 and E5), the late expressed gene (L1 and L2) and the long control 
region (LCR). (B) Top line shows the arrangement of the ORFs within the HPV 
genome. The bent arrows represent transcription start sites. Polyadenylation 
signals are indicated by an A. The bottom line shows an expanded view of the 
long control region (LCR) with the TATA box and Sp1-binding site indicated by T 
and S, respectively. 
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nucleus (Duensing, et al., 2002). Several studies have shown that the HPV life 
cycle is divided into non-productive and productive stages. The non-productive 
stage occurs in the basal layer of the epithelium. HPVs express early genes such 
as E1 and E2 in a regulated manner and maintain a low genomic copy number 
between 50 to 100 extrachromosomal molecules per cell (McMurray, et al., 
2001). When infected cells start their migration to the suprabasal layer during the 
process of differentiation, HPV initiates a productive stage of infection which 
manifests as an enhancement of genomic replication and the expression of late 
genes to produce viral particles (Chow, et al., 1994). Some of the cellular 
transcription factors that regulate HPV gene expression in this process are the 
Activator Protein-1 (AP-1), Yin-Yang-1 (YY1), octamer binding factor family 
members, nuclear factor-1 (NF-1) and stimulatory protein-1 (Sp1) (Andersen, et 
al., 1997;Saunders, et al., 1998). The ability of HPV to produce virions without 
cell lysis allows it to produce more than one cycle of infection in the same 
epithelium (Fig. 2) (Sanclemente, et al., 2002). 
 
1.2 HUMAN PAPILLOMAVIRUSES AND CERVICAL CANCER 
 
 
 Cervical cancer is the second most common cause of death in women 
after breast cancer world-wide (Jin, et al., 1999). Cervical carcinogenesis 
involves two main types of epithelial transformation. The transformation of basal 
cells in the squamous epithelium starts with a noninvasive low-grade squamous 
intraepithelial lesion (LG-SIL), leading to a high-grade squamous intraepithelial  
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Fig. 2. THE HUMAN PAPILLOMAVIRUS LIFE CYCLE 
 
 
 
 
Modified from © Zur Hausen et. al. 2002 Nature Reviews Cancer 
 
 
Infection requires the availability of a basal layer cell. This usually occurs in 
microlesions of skin or mucosa. The infected cell divides and the population 
spreads laterally. Some of the progeny migrate into the suprabasal differentiating 
cell layers, where viral genes are activated, viral DNA is replicated and capsid 
proteins are formed. Viral particle formation ensues. Particles are released at the 
surface and might then infect additional tissues. 
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lesion (HG-SIL), and ultimately evolving into invasive squamous cell carcinoma 
(SCC) (Alazawi, et al., 2002). Adenocarcinomas and adenosquamous 
carcinomas (AC) originate from glandular endocervical columnar cells (Burk, et 
al., 2003). Molecular and clinical evidence suggest a tight link between some 
types of HPV infection and cervical neoplasias. HPVs have been classified into 
two groups depending on their association with cervical cancer or precursor 
lesions. Low-risk HPVs (6, 11, 42, 43, and 44) are often found in cervical 
intraepithelial neoplasias grade 1 (CIN1), or CIN2 (also known as LG-SIL). High-
risk HPVs (16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70) are 
often found in CIN3 (HG-SIL) or cervical cancer (Burd, 2003). The most common 
type of HPV found in cervical cancer in the United States and Europe is type 16 
(50%), followed by 18, 31 and 45 (30%) (Walboomers, et al., 1999). High-risk 
HPV DNA has been found in 99.7% of cervical squamous cell cancers world-
wide (Walboomers, et al., 1999). Therefore, the association between HPV 
infection and human cervical cancer is provides an important model to 
understand the interaction between human carcinogenesis and etiological 
agents. 
 
Three viral genes of HPVs, E5, E6 and E7 are involved in cellular 
transformation. The HPV-16 E5 gene (located downstream of the E2 ORF) 
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encodes a 84 amino acid hydrophobic membrane protein that can dimerize (Kell, 
et al., 1994). This protein is localized in the endoplasmic reticulum and golgi, as 
well as in the cytoplasmic membrane (Burkhardt, et al., 1989;Conrad, et al., 
1993;Sparkowski, et al., 1995). The main function of E5 is the stimulation of cell 
growth via the up-regulation in the activity of growth factor receptors (McMurray, 
et al., 2001). Recent studies have shown that E5 inhibits the induction of 
apoptosis after DNA damage (Zhang, et al., 2002). E5 expression may be 
important only in the early steps of transformation since this gene is normally 
disrupted during HPV integration (zur Hausen, 2002). The HPV-16 E6 gene 
encodes a 151 amino acid protein with two zinc finger domains that is expressed 
at the earliest stages of HPV infection (McMurray, et al., 2001). The main 
function of E6 protein is to modify the cell growth-regulatory pathways creating a 
cellular environment that facilitates viral replication in cells that are already 
differentiated (Syrjanen, et al., 1999). Some of the cellular pathways affected by 
E6 involve its binding and degradation of the tumor suppressor gene p53 via 
ubiquitin-protein ligase (Thomas, et al., 1999), the up-regulation of telomerase 
activity (Klingelhutz, et al., 1996), and the alteration of transcription regulation by 
binding the transcriptional activator p300/CBP (Patel, et al., 1999). There is also 
evidence that E6 protein can regulate the transcription of minimal promoters that 
contain a TATA box (Sedman, et al., 1991). The HPV-16 E7 gene encodes a 98 
amino acid protein that contains casein kinase II phosphorylation sites at serine 
residues 31 and 32 (McMurray, et al., 2001). Similar to E6, E7 also alters cellular 
pathways by several means: binding to the retinoblastoma tumor suppressor 
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protein, pRB, and destabilizing and degrading this cell cycle regulatory protein 
(Dyson, et al., 1989), binding to histone deacetylase 1 (HDAC-1) to repress 
transcription (Brehm, et al., 1999), binding to AP-1 transcription factors such as 
c-Jun (Antinore, et al., 1996), direct interaction with the TATA-binding protein 
(TBP) and the TBP-associated factor-110 to modify transcriptional regulation 
(TAF-110) (Mazzarelli, et al., 1995), and reactivation of DNA synthesis by 
creating a physical complex with cyclin E-cdk2 (McIntyre, et al., 1996). 
  
The precise molecular mechanisms involved in HPV-dependent cellular 
transformation are not fully undestood. An important molecular event involves the 
relatively random integration of the HPV DNA into the host genome in cervical 
tumors (Durst, et al., 1985). This integration event is not a normal part of the viral 
life cycle but is an apparently accidental event that promotes cell transformation 
(Munger, et al., 2002). Upon integration of the HPV DNA into the genome, the E1 
and E2 genes are usually disrupted, leading to the loss of expression of the E1 
and E2 proteins (Fields, et al., 1990). The expression of E2 is required not only 
for HPV DNA replication, but also to repress transcription of the E6 and E7 
oncogenes intiating from the p97 promoter (zur Hausen, 1991). Moreover, recent 
studies have shown that even the presence of HPV-16 in an episomal state can 
create chromosomal instability in an organotypic raft culture model (Duensing, et 
al., 2001). This early event during cell proliferation by extrachromosomal HPV-16 
probably occurs when the basal expression of E6 and E7 is sufficient to 
deregulate the mitotic machinery and induce the production of abnormal 
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centrosome numbers (Duensing, et al., 2002). Chromosomal abnormalities such 
as aneuploidy or tetraploidy resulting from a reduction in mitotic fidelity are 
present in cervical cell lines and cervical cancers (Southern, et al., 2001). It has 
been proposed that this type of genomic instability can promote integration of 
HPV genome (Kessis, et al., 1996). HPV-induced genomic instability and viral 
integration may mimic DNA damage and may lead to the activation of various 
excision-repair and homologous recombination processes. 
 
1.3 HUMAN PAPILLOMAVIRUSES AND ORAL CANCER 
 
 Every year ~40,000 new cases of Squamous Cell Carcinoma of the Head 
and Neck (SCCHN) are diagnosed in the United States (Furniss, et al., 2007). 
Estimates for 2006 showed 40,500 new cases with 11,170 deaths (27.6%) 
(American Cancer Society, Cancer Facts and Figures 2006, Atlanta; American 
Cancer Society; 2006). The two main risk factors for head and neck cancer 
development are tobacco and alcohol, although some other factors such as 
radiation exposure, poor oral hygiene and unbalanced nutrient diets have also 
been associated with such cancers (Dobrossy, 2005;Portugal, et al., 1997). 
Although the first suggestion that HPV may play a role in the development of oral 
cancer was proposed by Lüning and collaborators in 1985 (Loning, et al., 1985), 
only recently a number of molecular and epidemiological studies have provided a 
strong correlation between high-risk HPV infection of the oral mucosa 
(specifically the oropharyngeal region) and the development of SCCHN (Gillison, 
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et al., 2000;Schwartz, et al., 1998;Steinberg, et al., 1996). The International 
Agency for Research into cancer (IARC) in 2003 determined that the infection of 
HPV is highly likely to play an etiologic role in SCCHN (Herrero, et al., 2003). 
Interestingly, several studies showed that there are clear differences in HPV 
positivity between regions of the oral cavity. The association of HPV infection is 
notably strong in the tonsil mucosa (Dahlstrand, et al., 2004; Klussmann, et al., 
2003;Venuti, et al., 2004). One cause for this predisposition may be a favorable 
environment for HPV replication in the invaginated folds within the tonsillar crypts 
(Tran, et al., 2007). Another difference between HPV-associated SCCHN and 
other oral cancers is a relatively better prognosis and risk reduction from death of 
approximately 50% in HPV-positive tumors (Ritchie, et al., 2003). One possible 
explanation for this is the fact that the tumor suppresor gene p53 (frequently 
mutated in HPV-negative SCCHN) is generally not mutated in HPV-associated 
SCCHN.  Since the function of p53 is not totally inactivated by the HPV E6 
oncogene,the response of such tumors to radiotherapy is better since p53 may 
help in cellular apoptosis (Kumar, et al., 2003). Also, there is a background 
prevalence of HPV DNA in the oral mucosa of otherwise healthy individuals 
without any evidence of cancer (Gillison, et al., 2001).   
 
 The notion that HPV-associated SCCHN is completely analogous to 
cervical carcinoma may not be very accurate, and more information on the 
molecular carcinogenesis and gene expression profiles may yield clues into the 
similarities and differences between these two diseases. For example unlike 
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cervical cancer, SCCHN is primarily associated with a single oncogenic subtype 
HPV-16 (Gillison, et al., 2000;Schwartz, et al., 1998). Also, the apparent time 
interval between infection and development of carcinoma appears to differ 
between SCCHN and cervical carcinoma, and epidemiologic analyses have 
indicated an older age of patients comprising the SCCHN subgroup versus 
cervical carcinoma patients (Gillison, et al., 2000;Schwartz, et al., 1998). Finally, 
the prognosis for head and neck cancer has not changed greatly in the last two 
decades, so a better understanding of the molecular differences between HPV-
positive and HPV-negative SCCHN will be useful for future treatment procedures 
such as HPV vaccination or closer follow-up of specific therapies. 
 
1.4 MICROARRAY TECHNOLOGY 
 
 One of the most recent technologies used to understand complex global 
mRNA expression profiles is the microarray or “gene chips” (Schena, et al., 1996; 
Zhu, et al., 1998). Despite being a very recent technology, it has quickly become 
a powerful tool for research, including disease characterization, biological 
classification and pharmacogenomics. A microarray is defined as a collection of 
microscopic spots of specific nucleic acid sequences (typically referred to as 
probes) distributed in a grid-like format that is attached to a solid surface (Butte, 
2002;Conway, et al., 2003). The sample or samples that are hybridized to these 
probes (typically referred to as targets) are normally labeled with some types of 
fluorescent dyes, which emit signals that can be quantified at different wave 
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lengths using scanners (Li, et al., 2002;Nakanishi, et al., 2001). There are two 
main types of microarray platforms: spotted microarrays (low density) and 
oligonucleotide microarrays (high density) (Brown, et al., 1999). In the spotted 
microarrays, the probes that are spotted on the surface of the slide or membrane 
can be single- or double-stranded oligonucleotides, complementary DNA (cDNA) 
or PCR fragments. In contrast, the high density oligonucleotide microarrays 
normally use probes that are synthezised in situ by different chemical reaction 
like photolithography (Butte, 2002;Li, et al., 2002). The differences in spot density 
between these two types of microarrays are shown in Fig. 3. At the same time, 
there are several types of labeled targets that can be used for the hybridization of 
the probes, including RNA, genomic DNA, cDNA, complementary RNA (cRNA) 
or PCR products (Slonim, 2002;Xiang, et al., 2003). In all the cases, the goal is to 
hybridize the target sample(s) specifically to the complementary sequence of 
different probes present in the microarray. After comparing the differences in 
fluorescent intensities between the samples and the respective controls, the 
microarray experiments reveal differential expression of genes between the 
samples (overexpression or underexpression) (Li, et al., 2002;Nakanishi, et al., 
2001). 
  
 Before identifying differential expression between several samples, 
normalization procedures are utilized in order to normalize the data from different 
samples and reduce diffrerences in hybridization efficency, dye incorporation, 
degradation of the sample, etc. There are different types of  
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Fig. 3. DIFFERENCES BETWEEN LOW AND HIGH 
DENSITY MICROARRAYS 
 
 
 
 
 
 
 
 
 
Low density microarray High density microarray
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normalization strategies. The most commonly used are: total intensity 
normalization (assumes that all the samples have the same amount of RNA, 
therefore, the total intensity calculated from all the spots on an array should be 
the same), regression normalization (assumes that a significant number of genes 
are expressed similarly between the samples, so the data is modified to be equal 
to one) and ratio statistics (assumes that house-keeping genes have the same 
expression level in different samples, so the data is adjusted to such genes after  
obtaining the mean expression ratios) (Datta, et al., 2003;Dopazo, et al., 
2001;Eisen, et al., 1998).  
 
 After normalization, the data can be manipulated using statistical analyses 
such as clustering algorithms (to obtain cluster of genes that are expressed in a 
similar fashion) or using differential expression algorithms (to obtain genes that 
are expressed at different levels with some degree of statistical significance) 
(Saeed, et al., 2003). Finally, after statistical analyses of the microarray data, the 
most common techniques to validate this information (to avoid false positive 
results) are Northern blotting and semi-quantitative or quantitative real-time RT-
PCR. The genes selected for such verification may include those that are highly 
overexpressed or underexpressed in the microarray analysis, genes with a level 
of expression that is known from previous studies, or genes selected for a 
specific purpose of the study. 
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1.5 MicroRNAs AND CANCER 
 
 The recent discovery of small non-coding RNAs named microRNAs 
(miRNAs) that have the ability to regulate different cellular processes in several 
organisms including humans, is probably one of the most important discoveries 
in biology. This “second RNA revolution” (after the discovery of enzymatic activity 
of some RNAs in the 1980s) (Zaug, et al., 1986) could potentially open a new 
layer of complexity in the regulation of gene expression in eukaryotic cells. The 
first miRNA discovered was lin-4 in C. elegans in the year 1993 by Lee, 
Feinbaum and Ambros (Lee, et al., 1993). Most of the scientific community 
ignored the relevance of this discovery for several years (predicting that this type 
of genetic regulation was exclusive to C. elegans) until the second miRNA 
named let-7 was discovered in 2000, and soon afterwards it was found that this 
miRNA was conserved across species from D. melanogaster to humans 
(Pasquinelli, et al., 2000). Recently, there has been an explosion in miRNA 
research. The number of human miRNAs reported in the miRbase database 
(http://microrna.sanger.ac.uk/sequences/) up to March 2007 has reached 482, 
and an additional 1,000 miRNAs have been predicted based on computational 
analysis. 
 
 The processing and maturation of miRNAs occurs in different cellular 
compartments. Most miRNAs are transcribed by RNA polymerase II, have a cap, 
and are polyadenylated (Kim, 2005). Nevertheless, there is still the possibility 
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that some miRNAs may be transcribed by RNA polymerase III. Following 
transcription, the large primary (pri)-miRNA transcripts (several kilobases) are 
processed into precursor (pre)-miRNAs by the protein Drosha in the nucleus 
(Lewis, et al., 2005). Pre-miRNAs are hairpin-like structures of ~80 nt with 
characteristic 2 nt 3’ overhangs. In animals, pre-miRNAs are exported to the 
cytoplasm by exportin 5 (Khvorova, et al., 2003;Kim, 2005), with GTP-binding co-
factor Ran, where they are further processed to generate mature miRNA 
duplexes by the protein Dicer. MiRNA duplexes (~ 22 nt) associate with the RNA-
induced silencing complex  (RISC) but only one strand, the mature miRNA 
(normally the strand with less thermodynamic stability in the 5’ end), remains 
bound to RISC and is delivered to its target (Khvorova, et al., 2003;Kim, 
2005;Schwarz, et al., 2003). The fate of target mRNAs depends on the degree of 
complementarity with the miRNA. Commonly, the 5’ 2-8 nt of the miRNA (called 
the seed sequence) is complementary to the target, and the remaining miRNA 
contains many mismatches. A low degree of complementarity results in 
translational repression, while a high degree of complementarity results in 
cleavage of the mRNA followed by its eventual destruction (Fig. 4) (Kim, 2005). 
 
 The location of miRNAs in the genome is variable but around 70% of 
known mammalian miRNAs are located in three different types of transcription 
units (Kim, 2005;Rodriguez, et al., 2004): in the exonic regions of a non-coding 
transcript, in the intronic region of a non-coding transcript, and in the intronic  
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Fig. 4. THE BIOGENESIS OF MicroRNAs 
 
© Esquela-Kerscher A. and Slack FJ. 2006. Nature Reviews Cancer 
  
 
MicroRNA (miRNA) genes are generally transcribed by RNA Polymerase II (Pol II) 
in the nucleus to form large pri-miRNA transcripts. These pri-miRNA transcripts 
are processed by the RNase III enzyme Drosha to release the ~70-nucleotide pre-
miRNA precursor product. RAN–GTP and exportin 5 transport the pre-miRNA into 
the cytoplasm. Subsequently, another RNase III enzyme, Dicer, processes the pre-
miRNA to generate a transient ~22- nucleotide miRNA:miRNA* duplex. This duplex 
is then loaded into the miRNA-associated multiprotein RNA-induced silencing 
complex (miRISC) (light blue), and the mature single-stranded miRNA (red) is 
preferentially retained in this complex. The mature miRNA then binds to 
complementary sites in the mRNA target to negatively regulate gene expression.  
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region of a protein coding transcript. Additionally, there are a small number of 
miRNAs that overlap with the exons or introns of alterantively spliced genes.  
Also, other miRNAs are occasionally found in the 3’ UTR of coding mRNAs. One 
interesting characteristic of mammalian miRNAs is that approximately 50% of 
them are clustered with other miRNAs, suggesting that these groups of miRNAs 
are transcribed as a single polycistronic transcription unit.   
   
 The first demonstration of a possible link between miRNAs and human 
cancer was provided by Croche and collaborators in 2002 when they discovered 
a frequent down-regulation of miR-15 and miR-16 in chronic lymphocytic 
leukemias (Calin, et al., 2002). MiRNAs have also been proposed to function as 
oncogenes or tumor suppressor genes. For example, reduced expression of 
miRNAs that target oncogenes will result in tumor suppression. Conversely, 
overexpression of miRNAs that target tumor suppressors will result in oncogenic 
activity and tumor formation. Recently, some miRNAs such as miR-15a and miR-
16-1 have been shown to negatively regulate the Bcl-2 oncogene that is 
commonly overexpressed in many cancers (Cimmino, et al., 2005). The let-7 
family of miRNAs regulates the ras oncogenes (Johnson, et al., 2005). Ras 
genes contain activating mutations in about 15-30% of cancers. The miRNAs 
controlling the expression of this oncogene therefore serve as important 
regulators of cellular proliferation. In some cancers, downregulation of the let-7 
family miRNAs results in reciprocal upregulation of Ras. This downregulation is 
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most pronounced in lung cancers (Johnson, et al., 2005), but is also sporadically 
observed in other tissues (Johnson, et al., 2005). Oncogenes can also regulate 
the expression of miRNAs. C-myc regulates the miRNA cluster miR-17-92 that in 
turn targets E2F1 (O'Donnell, et al., 2005). Upregulation of this cluster was 
demonstrated for B cell lymphomas. C-myc is often upregulated in cancers, and 
it serves as a transcription factor for the miR-17-92 cluster (O'Donnell, et al., 
2005). Because C-myc can also directly regulate E2F1, C-myc-mediated 
repression of E2F1 via the miR-17-92 cluster serves to fine-tune E2F1 regulation 
(O'Donnell, et al., 2005).  
 
 Another model to study the influence of miRNAs in cancer has been 
provided by transgenic and knock-out mouse models. Recently, a transgenic 
mouse that specifically overexpresses miR-155 in B cells showed the 
development of polyclonal pre-leukaemic pre-B-cell proliferation followed by B-
cell malignancy (Costinean, et al., 2006). This model suggests that the 
deregulation of some miRNAs in cancer could be one of the first steps in the 
process of carcinogenesis. Finally, miRNA microarray profiling has become an 
important tool in an effort to understand the importance of miRNA expression 
patterns and their implication in human cancers. The first study of global miRNA 
expression in human and mouse tissue using miRNA microarrays was published 
by Liu and collaborators in 2004 (Liu, et al., 2004). 
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 1.6 THESIS OUTLINE 
 
Chapter 1 consists of a general introduction to the biology and viral life cycle of 
HPVs followed by the correlation between infection by these viruses and the 
pathology of cervical and head and neck carcinomas. This chapter also 
describes the evolution of the microarray technology specifically used for global 
gene expression analysis. Finally, we describe the biology of microRNAs and its 
implication in human cancer. 
 
Chapter 2 describes the differential gene expression profiles of squamous cell 
carcinoma of the head and neck (SCCHN) tumors containing HPV DNA 
compared to HPV-negative SCCHN tumors or normal head and neck tissues by 
using high-density microarrays. After the verification of the microarray data by 
other types of analyses, we found specific gene expression changes and gene 
clustering in HPV-positive SCCHN supporting the idea that this type of head and 
neck malignancy may contain alterations in different pathways compared to HPV-
negative SCCHN. 
  
Chapter 3 describes the differential gene expression profiles of HPV-positive 
cervical cell lines in comparison to an HPV-negative cell line (C-33A) and normal 
cervical tissue. After the detection of viral oncogene expression and physical 
state of the HPV DNA (episomal or integrated) in the HPV-positive cell lines, we 
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analyzed the global expression of these cell lines by using high-density 
microarrays. After the verification of the microarray data with other molecular 
tools, we found specific gene expression changes in HPV-positive cervical cell 
lines supporting the idea that the presence of HPV DNA is enough to change the 
expression landscape of the host cells.  
 
 
Chapter 4 describes the differential expression of microRNAs (miRNAs) in 
cervical carcinoma cell lines and cervical carcinomas containing HPV-16 DNA in 
comparison to a HPV-negative cervical carcinoma cell line or normal cervical 
tissue.  After the verification of the microarray data with other molecular tools, we 
found that one miRNA named miR-218 was specifically downregulated by the 
HPV-16 E6 oncogene. Finally, we found that miR-218 possibly targets the mRNA 
of the Laminin 5 β3 gene (LAMB3) which as been implicated in cervical cancer 
and HPV infection. 
 
Chapter 5 discusses the results of the research described in previous chapters 
and describes the future goals of these different projects. 
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Chapter 2 
 
IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN HPV-
POSITIVE AND HPV-NEGATIVE OROPHARYNGEAL SQUAMOUS CELL 
CARCINOMAS 
 
 
 
Work described in this section was published in the European Journal of Cancer 
(Eur J Cancer. 2007, 2:415-432) with authors Ivan Martinez, Jun Wang, Kenosha 
F. Hobson, Robert L. Ferris and Saleem A. Khan  
R.L. Ferris and J. Wang provided tissue samples and performed RNA extraction. 
K.F. Hobson performed part of data analysis. I. Martinez performed all the 
experiments described in this section. I. Martinez, R.L. Ferris and S.A. Khan 
wrote the manuscript. 
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2.1 INTRODUCTION 
 
There are approximately 500,000 new cases of squamous cell carcinoma 
of the head and neck (SCCHN) worldwide and 45,000 cases in the United States 
per year (Greenlee, et al., 2001;Vikram, et al., 1984).  SCCHN is usually 
associated with such risk factors as heavy consumption of alcohol and/or 
tobacco. The survival in SCCHN patients is still poor and has not improved 
recently despite the advances in detection and therapies. It is well-established 
that human papillomaviruses (HPVs) are involved in the pathogenesis of cervical 
cancer (Dell, et al., 2001;Walboomers, et al., 1999;zur Hausen, 2000;zur 
Hausen, 2002). Recently, molecular epidemiologic studies have shown a strong 
correlation between oncogenic HPV infections and a subset of oropharyngeal 
cancers (Gillison, et al., 2000;Ritchie, et al., 2003;Schwartz, et al., 
1998;Steinberg, et al., 1996;Wong, et al., 2000). It is not currently understood 
whether these HPV infections are an independent etiologic factor or a co-factor in 
the development of such tumours. Interestingly, a relative risk reduction from 
death of approximately 50% has been observed in HPV-associated tumours 
compared to those without detectable HPV DNA (Ritchie, et al., 2003).  
  
 HPVs are small double-stranded DNA viruses of approximately 7900 base 
pairs (bp). At present, more than 150 different types of HPV have been identified, 
and the high risk HPV types 16 and 18 are associated with a majority of cases of 
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cervical cancer (zur Hausen, 2000;zur Hausen, 2002). Replication of HPVs 
requires the viral E1 and E2 proteins as well as host replication factors (Chow, et 
al., 1994;Fuchs, et al., 1994). The E2 protein also downregulates the 
transcription of the viral E6 and E7 oncogenes, which are transcribed from the 
p97 promoter (Mansur, et al., 1993;McBride, et al., 1991;McCance, 2005). The 
E6 and E7 oncoproteins of high-risk HPVs are involved in cellular transformation 
(Mansur, et al., 1993;McBride, et al., 1991;McCance, 2005;Munger, et al., 
1993;Stoppler, et al., 1994). Most benign and low-grade cervical lesions contain 
HPV DNA in an extrachromosomal state (Durst, et al., 1985).  However, in most 
cases of cervical carcinomas the HPV DNA is usually found integrated into the 
host chromosomes, frequently disrupting the E1 and E2 genes (Durst, et al., 
1985;Meissner, 1999;zur Hausen, 2000;zur Hausen, 2002). This results in 
increased expression of the viral E6 and E7 oncogenes (Yee, et al., 1985). The 
E6 protein promotes ubiquitination and consequently proteasomal degradation of 
the cellular tumour suppressor proteins p53 and PDZ domain-containing disc 
large protein (DLG) (Dell, et al., 2001;Lechner, et al., 1992;Mantovani, et al., 
1999;Scheffner, et al., 1990;zur Hausen, 2002). E6 is also known to interact with 
a number of other cellular proteins and activates telomerase (zur Hausen, 
2000;zur Hausen, 2002). The E7 protein binds to and inactivates the function of 
pRB and related p107 and p130 proteins (Dell, et al., 2001;zur Hausen, 2002). 
E7 also interacts with additional cellular proteins such as TBP, histone H1 
kinase, cyclin E, etc (Fuchs, et al., 1994;Mansur, et al., 1993;McCance, 
2005;Munger, et al., 1993;Stoppler, et al., 1994). The E6 and E7 proteins are 
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also known to alter cellular gene expression but the precise molecular 
mechanisms involved are not well-understood (Mansur, et al., 1993;Munger, et 
al., 1993;Stoppler, et al., 1994). In addition, E6/E7 expression promotes 
chromosomal instability, foreign DNA integration and other mutagenic events in 
the cell (Dell, et al., 2001;Jeon, et al., 1995;McCance, 2005;zur Hausen, 2000). 
Although several studies have suggested a possible role for HPV infection in a 
subset of SCCHN, very little is known about the molecular events involved in 
carcinogenesis. Although the distribution of episomal and integrated HPV forms 
in precancerous and cancerous lesions of the head and neck has not been 
determined, limited evidence suggests a similar physical state as observed in 
cervical carcinoma. Molecular studies of HPV-associated SCCHN are necessary 
for a better understanding of the physical state and potential role of this virus in 
carcinogenesis, and for the development of new, more targeted therapeutic 
strategies.  
 
Recently, DNA microarrays have been successfully used to identify global 
patterns of gene expression in different human neoplasias, including head and 
neck cancers (Golub, et al., 1999;Jeon, et al., 2004;van 't Veer, et al., 2002;van 
de Vijver, et al., 2002). In the case of breast cancer studies, a set of 70 genes 
correctly predicted the nature and progression of the disease as well as the 
outcome (van 't Veer, et al., 2002;van de Vijver, et al., 2002). These studies 
support the idea that changes in the molecular profiles of gene expression are 
early events during carcinogenesis and such global expression profiles can be 
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used effectively to predict the course of the disease. Recently, investigators have 
used microarrays to analyze gene expression changes in SCCHN tissues and 
cell lines, but little is known about the gene expression changes in HPV-
associated SCCHN (Gillison, et al., 2001;Guo, et al., 2002;Ibrahim, et al., 
2003;Kuo, et al., 2002;Leethanakul, et al., 2003). The identification of molecular 
portrait of gene expression profiles in HPV-positive and HPV-negative SCCHN, 
including their differences, could result in a better understanding of critical events 
during carcinogenesis. 
 
This study was undertaken to identify changes in cellular gene expression 
profiles in HPV-positive and HPV-negative SCCHN as compared to normal 
tissues as well as to each other. Our microarray analysis showed considerable 
differences in the gene expression profiles that were specifically associated with 
these two types of cancers. Several of the differentially expressed genes were 
found to be involved in cell cycle regulation (CDKN2A), nuclear structure and 
meiosis (SYCP2), DNA replication and repair (RFC5), transcription regulation 
(ZNF238), cell differentiation (KLK8) and epidermis development (CRABP2). 
Unsupervised clustering analysis also showed that genes located in specific 
chromosomal regions such as 1p31-p36 and 12q21-24 were specifically 
overexpressed in HPV-positive oropharyngeal squamous carcinomas.  
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2.2 MATERIAL AND METHODS 
 
Tissue samples and cell lines 
 
 A total of 11 samples were analysed in this study: Three HPV-positive 
(SK20, SK30, SK31), four HPV-negative (SK32, SK33, SK34, SK35), and four 
normal oral mucosa (SK16, SK17, SK36, SK37).  Tumours and normal mucosal 
specimens were snap-frozen and stored at -800C until further use. Collection of 
tissues was performed under an IRB-approved Tissue Banking protocol, and 
written informed consent was obtained from each patient prior to sample 
collection.  The SCCHN samples were from the oropharynx (tonsil and base of 
tongue), while the normal oral mucosa specimens were obtained from patients 
undergoing removal of the oropharyngeal tissues: tonsils, soft palate and uvula 
for sleep apnea. None of the patients received prior chemotherapy or 
radiotherapy. Cervical carcinoma cell lines were obtained from the American 
Type Culture Collection (ATCC) and maintained in Dulbecco’s modified Eagle 
medium (C-33A) or RPMI 1640 (CaSki) supplemented with 10% fetal bovine 
serum (FBS) at 37°C in the presence of 5% CO2. 
 
Isolation of RNA and RT-PCR analysis  
 
 Total RNA from all frozen tumour samples and oropharyngeal mucosal 
tissues was isolated using the RNeasy Mini Kit (Qiagen Inc.) according to the 
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manufacturer’s protocol.  The mucosa was carefully dissected from any 
subjacent muscle or lymphoid tissue before RNA extraction, so that only normal 
squamous epithelium was studied. The RNA pellet was dried under a vacuum 
and resuspended in 30-50 µl of DEPC treated water. The integrity of RNA 
samples was confirmed by analysing 1 µg of total RNA on 1.2% (w/v) denaturing 
formaldehyde-agarose gels. Before DNA synthesis, RNA was treated with 
deoxyribonuclease I, Amplification Grade (Invitrogen) for 15 min at room 
temperature to avoid DNA contamination. DNase I was inactivated by incubation 
with 25 mM EDTA at 65ºC for 10 min. We examined the expression of the HPV-
16 E6 and E7 genes in the above samples by RT-PCR (Ferris, et al., 2005) using 
the following primers: HPV-16 E6 (forward) 5'- ATGCACCAAAAGAGAACTGC -3' 
and (reverse) 5'- TTACAGCTGGGTTTCTCTAC -3' (477-bp PCR product); HPV-
16 E7 (forward) 5’-GTAACCTTTTGTTGCAAGTGTGACT-3’ and (reverse) 5’-
GATTATGGTTTCTGAGAACAGATGG-3’ (137-bp RT-PCR product). The 
expression of the cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
house-keeping gene was used as a positive control using the following primers: 
GAPDH (forward) 5’- ACCACAGTCCATGCCATCAC-3’ and (reverse) 5’- 
TCCACCACCCTGTTGCTGTA-3’ (452-bp RT-PCR product). All RT-PCR 
reactions were done using the Thermoscript One-step System kit (Invitrogen 
Corp.). The cDNA synthesis was performed at 37°C for 1 hour in a final volume 
of 20 µl using 1 µg of total RNA template, 0.5 µg of oligo (dT)15, 10 mM dNTPs, 
30 U of RNase inhibitor and 200 units of MMLV reverse transcriptase. PCR was 
performed in a 50 µl volume containing 50 mM KCl, 10 mM Tris (pH 8.3), 1.5 mM 
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MgCl2, 0.01 % gelatin (w/v), 200 µM deoxynucleoside triphosphate (dNTP) mix, 
0.4 µM of each primer and 2.5 units of the Taq DNA polymerase. The DNA was 
denatured at 94°C for 5 min, followed by 40 PCR amplification cycles that 
consisted of denaturation (94°C, 1 min), annealing (58-60°C, 1 min) and 
extension (72°C, 2 min). An additional extension step of 72°C for 5 min was 
included at the end of the reaction.  
 
Quantitative real-time RT-PCR analysis 
 
 We validated the microarray data by quantitative real-time RT-PCR (QRT-
PCR) analysis of a few representative genes using the QuantiTect SYBR Green 
one-step RT-PCR kit (QIAGEN, Valencia, CA).  Approximately 400 ng of DNase 
I-treated total RNA from the samples was mixed with 25 µl of 2 X QuantiTect 
SYBR Green RT-PCR Master Mix, 0.5 µM of specific forward and reverse 
primers and RNase-free water in a final volume of 50 µl. The amount of 
fluorescence emitted by SYBR Green I was quantified by the ABI Prism 7700 
system software (Applied Biosystems, Foster City, CA). The genes and primers 
used for this analysis are shown in Table 1. The following RT-PCR cycle 
parameters were used: reverse transcription at 50°C for 30 min, hot-start DNA 
polymerase activation 95°C for 15 min, 40 cycles of denaturation at 94°C for 15 
sec each, annealing at 58°C for 30 sec and extension at 72°C for 30 sec. Each 
reaction was run in triplicate in a 96-well plate. Relative expression of the target 
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gene was calculated using the 2 delta CT method described previously (Livak, et 
al., 2001): (Relative expression = 2-∆CT; where ∆CT = CT (Target gene) – CT (endogenous 
control gene)) where GAPDH was used as the endogenous control gene. 
 
cRNA synthesis and microarray analysis 
 
 Microarray analysis was carried out using the high-density oligonucleotide 
U133A GeneChip® expression microarray (Affymetrix, Santa Clara, CA) that 
contains 22,215 transcript sets representing 14,820 human genes. RNA isolated 
from the samples described above was further purified by using the RNeasy 
Total RNA Isolation Kit (QIAGEN, Valencia, CA) to remove contaminating DNA.  
Twenty micrograms of total RNA from each sample were used to generate 
double-stranded (ds) cDNA using the Superscript II Choice system (GIBCO-BRL, 
Rockville, MD). First-strand synthesis was carried out using a T7-(dT)24 primer 
(Sigma-GenoSys, The Woodlands, TX) and Superscript II reverse transcriptase. 
This primer includes the promoter sequence for the T7 RNA polymerase.  The 
second-strand synthesis was performed using RNase H and DNA polymerase I. 
The resulting ds cDNA was used to synthesize cRNA using biotin-labeled 
ribonucleotides and T7 RNA polymerase utilizing the BioArray HighYield RNA 
transcript labelling kit (ENZO Life Sciences, Inc. Farmingdale, NY). The cRNA 
was fragmented to 35-200 bases length and hybridized to the Human Genome 
U133A GeneChip® expression microarray in the Affymetrix Hybridization Oven 
(Affymetrix, Santa Clara, CA). The GeneChips were washed, and then stained 
 31
TABLE 1. PRIMER SEQUENCES FOR QUANTITATIVE RT-PCR 
 
Gene title Forward primer 5'-3' Reverse primer 5'-3' 
cellular retinoic acid binding protein 2 
(CRABP2) 
TGCAGGGTCTTGCTTTCTTT GGGCTAGGACTGCTGACTTG 
 
cyclin-dependent kinase inhibitor 2A 
(CDKN2A) 
 
AGTGAGCACTCACGCCCTAA 
 
CCCCTGAGCTTCCCTAGTTC 
 
kallikrein 8 (KLK8) 
 
ACCAGTCCCCGAGAGAATTT 
 
ACAGACCATGCCATCTGTGA 
 
replication factor C (activator 1) 5, 
36.5kDa (RFC5) 
 
GTCACCAGCAGGTTCCAAAT 
 
TCCTGCATGAAAACAAGTGC 
 
synaptonemal complex protein 2 
(SYCP2) 
 
CATGTCACCGAAGCAAGTGT 
 
GAAGTCTTCTGGGCTTGGAC
T 
 
zinc finger protein 238 (ZNF238) 
 
TTTCCTTTGAGGGGATAGGG 
 
TCAAAAGACAATGCAGTGTT
GA 
 
glyceraldehyde-3-phosphate 
dehydrogenase (G3PDH) 
 
CAGCCTCAAGATCATCAGCA 
 
TGTGGTCATGAGTCCTTCCA 
 
 
 
 
 
 
 
 
 
 
 32
with streptavidin-phycoerythrin (SAPE) to generate fluorescent signals from 
biotin-labeled cRNA. The GeneChips were scanned using an Affymetrix 
GeneArray® scanner (Affymetrix, Santa Clara, CA). Each probed array was 
scanned twice to calculate an average of two images, define the probe cells and 
compute intensity for each cell. Fragmentation, hybridization, staining and scan 
were performed by the Pitt Array Facility, University of Pittsburgh. 
 
Microarray data analysis 
 
The .CEL image files obtained from the Affymetrix Microarray Suite 5.0 
were converted to .DCP files using the program dChip version 1.2 
(www.dchip.org). Two different statistical tests, Significance Analysis of 
Microarray (SAM) program version 1.21 (www.stat.stanford.edu/~tibs/SAM/) and 
Gene Expression Data Analysis (GEDA) program, were used to analyze the 
microarray data in order to identify differentially expressed genes that were 
robust enough to appear in both the analyses.  For SAM analysis, the dChip 
program was used to generate normalized intensity signal data. The invariant set 
normalization method used by dChip program is one of the most commonly used 
normalization method for analysing the data in the SAM program (Saviozzi, et al., 
2004). In SAM analysis, a false discovery rate (FDR) of less than 5 percent and a 
difference of at least 2-fold was chosen to identify the total number of 
differentially expressed genes. We also utilized the GEDA tool developed at the 
University of Pittsburgh (James Lyons-Weiler, University of Pittsburgh Cancer 
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Institute, http://bioinformatics.upmc.edu) for statistical analysis.  For this, non-
normalized intensity signal data from dChip (PM-only model) were normalized 
(log-base2 transformation, median within arrays, Global Mean Adjustment among 
arrays) and analysed with a t-Test at level alpha = 0.05.  This normalization 
method is specifically used by the GEDA program.  Genes with an expression 
ratio of at least 2-fold difference relative to the controls were considered to be 
differentially expressed in GEDA analysis. After analyzing the data with the two 
statistical tests, we overlapped the lists of differentially expressed genes in order 
to generate a list of differentially expressed genes using software developed by 
Dr. Jim Lund at the University of Kentucky 
(http://elegans.uky.edu/MA/progs/Compare.html). All the microarray experiments 
were designed in accordance with the MIAME guidelines (Brazma, et al., 2001).
 
For unsupervised hierarchical clustering analysis, we first filtered the 
genes using a threshold of 0.05 in the ratio of the standard deviation and the 
mean of a gene’s expression values across all samples (Coefficient of Variation), 
and then applied an algorithm for similarity measurements using Pearson’s 
correlation coefficient (Li, et al., 2001).  
 
2.3 RESULTS 
 
Expression of the HPV-16 early genes in SCCHN samples by RT-PCR analysis 
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 RT-PCR analysis was carried out to test for the presence and expression 
of HPV early genes in all the SCCHN samples and the control normal oral 
tissues. RNA from CasKi and C-33A cervical carcinoma cell lines was used as 
positive and negative control, respectively, for HPV-16 gene expression. The E6 
(with different splicing variants) and E7 viral oncogene transcripts were present in 
the HPV-16 positive SCCHN samples SK20, SK30 and SK31 but not in the HPV-
negative SCCHN samples SK32, SK33, SK34, and SK35 or the normal oral 
mucosa samples SK16, SK17, SK36 and SK37 (Fig. 5). The above results 
confirmed the appropriate expression of the HPV-16 oncogenes in the three 
HPV-positive SCCHN samples.   
 
Microarray analysis of genes differentially expressed in the HPV-positive SCCHN 
samples compared to the normal oral tissue 
 
 In order to identify differentially expressed genes in HPV-16 positive 
SCCHN samples (SK20, SK30 and SK31) as compared to the normal oral tissue 
samples (SK16, SK17, SK36 and SK37), we utilized the Affymetrix U133A 
GeneChip. Normalization and differential gene expression analyses were carried 
out as described in material and methods. A total of 1,329 and 1,431 genes 
showed up- and down-regulation, respectively, using a pooled variance t-Test 
analysis when all the HPV-16 positive SCCHN samples were compared to the 
normal oral tissues (supplementary data, Table A). On the other hand, 470 and 
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Fig. 5. ANALYSIS OF HPV16 E6 AND E7 GENE EXPRESSION 
IN OROPHARYNGEAL TISSUE SAMPLES BY RT-PCR 
 
 
CaSki (HPV-16 positive) and C-33A (HPV-negative) cervical cell lines were used as 
controls. Expression of E6 splicing variants (E6, 477 bp, E6*I, 293 bp, E6*II, 176 
bp) and E7 (137 bp) genes was found only in SK20, SK30 and SK31 SCCHN 
samples. The integrity of all the RNA samples was validated by amplification of 
the house-keeping gene GAPDH (452 bp). 
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424 genes were found to be up- and down-regulated, respectively, using the 
SAM-Test analysis (supplementary data, Table B). When the results of the above 
two statistical tests were overlapped, 228 genes were found to be upregulated 
and 169 downregulated in HPV-16 positive SCCHN samples as compared to the 
normal oral tissues (Fig. 6). A list of differentially expressed genes representing 
various cellular pathways is shown in Table 2.  A complete list of genes is shown 
in the supplementary data, Table C. Our analysis identified genes that have 
previously been shown to be overexpressed in HPV-infected cervical or oral 
epithelial cells such as those involved in DNA replication and cell cycle 
regulation: cyclin-dependent kinase inhibitor 2A (CDKN2A), minichromosome 
maintenance deficient genes (MCM2, MCM3), topoisomerase (DNA) II alpha 
170-kDa (TOP2A) and proliferating cell nuclear antigen (PCNA) (Li, et al., 
2004;Ren, et al., 2002;Santin, et al., 2005). These findings suggest that some 
carcinogenic pathways are frequently affected in HPV-positive cervical as well as 
HPV-positive oral cancers. Our experiments also identified several genes that 
were previously implicated in tumourigenesis of different tissues but not in 
SCCHN. Examples of these include the upregulation of genes involved in cell 
differentiation or DNA repair such as secreted frizzled-related protein 4 (SFRP4), 
and RAD51 associated protein 1 (RAD51AP1) (Horvath, et al., 2004;Iwanaga, et 
al., 2006). Our results also showed the downregulation of genes involved in 
proteolysis such as protease serine 3 (PRSS3) and chemotaxis, such as 
chemokine (C-C motif) ligand 14 (CCL14), for the first time in HPV-positive 
SCCHN (Table 2).  
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Fig. 6. Summary of differentially expressed genes identified 
by microarray analysis using two different statistical analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV+
ORAL
CARCINOMAS
HPV-
ORAL
CARCINOMAS
NORMAL
ORAL
TISSUES
228 UP-REG 79 UP-REG
123
UP-REG
169 DOWN-REG 83 DOWN-REG
42
DOWN-REG
 
The ovals represent the 3 groups of samples used in our study. The overlapping 
regions indicate the number of genes found to be up- or down-regulated between 
two different groups of samples. 
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Genes differentially expressed in HPV-negative SCCHN compared to the normal 
oral mucosa  
 
 Using the pooled variance t-Test analysis, we found that 1,052 genes 
were upregulated and 850 downregulated in HPV-negative SCCHN samples 
compared to the normal oral tissues (supplementary data, Table D). The SAM 
test identified 244 upregulated and 310 downregulated genes in the HPV-
negative SCCHN samples (supplementary data, Table E). A comparison of the 
differentially expressed genes revealed that 79 upregulated and 83 
downregulated genes were common in both the pooled variance t-Test and SAM 
analyses (supplementary data, Table F) (Fig. 6). A list of differentially expressed 
genes representing various cellular pathways is shown in Table 3. Upregulated 
genes involved in cell-cell signaling such as parathyroid hormone-like hormone 
(PTHLH ) or angiogenesis such as endothelial cell growth factor 1 (ECGF1), as 
well as downregulated genes involved in signal transduction or apoptosis such as 
insulin-like growth factor binding protein 5 (IGFBP5) and programmed cell death 
4 (neoplastic transformation inhibitor) (PDCD4) were identified in our studies 
similar to those found in previous SCCHN studies, providing a good correlation 
with our results (Kornberg, et al., 2005;Lin, et al., 2002). We also found 
differentially expressed genes that were not previously reported in SCCHN, 
although they were implicated in other types of tumours. Such upregulated genes 
included  those involved in cell proliferation and transcription regulation such as 
aldo-keto reductase family 1, member C3 (AKR1C3), and small nuclear RNA           
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TABLE 2. GENES FOUND DIFFERENTIALLY EXPRESSED IN 
HPV-POSITIVE SCCHN VERSUS NORMAL ORAL EPITHELIUM 
 
Gene Title Gene Symbol Pooled 
variance t-
Test fold 
change 
SAM-
Test fold 
change 
Up-regulated genes  
Apoptosis  
     lectin, galactoside-binding, soluble, 1 (galectin 1) LGALS1 3.22 2.44 
Cell Adhesion    
     collagen, type XI, alpha 1 COL11A1 6.29 8.84 
Development  
     IGF-II mRNA-binding protein 3 IMP-3 3.28 5.06 
DNA Replication  
     CDC7 cell division cycle 7 (S. cerevisiae) CDC7 5.38 2.34 
     MCM2 minichromosome maintenance deficient 2, mitotin MCM2 4.39 3.36 
     MCM3 minichromosome maintenance deficient 3 MCM3 3.86 2.00 
Cell Cycle Regulation    
     cyclin E2 CCNE2 4.23 2.23 
     cyclin-dependent kinase inhibitor 2A CDKN2A 16.59 8.04 
     proliferating cell nuclear antigen PCNA 7.78 2.04 
     retinoblastoma-like 1 (p107) RBL1 6.09 2.37 
Transcription Regulation    
     interferon regulatory factor 1 IRF1 6.28 2.66 
Wnt Receptor Signaling Pathway    
     secreted frizzled-related protein 4 SFRP4 4.45 5.61 
DNA Repair    
     RAD51 associated protein 1 RAD51AP1 3.65 2.14 
     topoisomerase (DNA) II alpha 170kDa TOP2A 4.07 3.60 
Miscellaneous    
     lumican LUM 4.18 3.41 
     mesoderm specific transcript homolog (mouse) MEST 8.88 3.01 
     squamous cell carcinoma antigen recognised by T cells 3 SART3 8.44 2.10 
Chromatin assembly and modification    
     centromere protein F, 350/400ka (mitosin) CENPF 3.60 2.00 
     SWI/SNF related, matrix associated, member 3 SMARCA3 5.54 2.45 
Down-regulated genes    
Apoptosis    
     programmed cell death 4 (neoplastic transformation inhibitor) PDCD4 -3.02 -3.84 
Immune response    
     chemokine (C-C motif) ligand 14 / chemokine ligand 15 CCL14 / -5.23 -2.10 
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CCL15 
     interleukin 18 (interferon-gamma-inducing factor) IL18 -4.47 -4.18 
     trefoil factor 3 (intestinal) TFF3 -2.61 -10.42 
Cell Adhesion    
     alpha-2-glycoprotein 1, zinc AZGP1 -3.07 -13.77 
Cell Cycle Regulation    
     Ras association (RalGDS/AF-6) domain family 1 RASSF1 -3.96 -2.51 
Cell Differentiation    
     deleted in malignant brain tumors 1 DMBT1 -4.04 -9.31 
     NDRG family member 2 NDRG2 -2.64 -2.56 
     transglutaminase 3 TGM3 -7.14 -7.55 
Cellular Metabolism    
     aldehyde dehydrogenase 1 family, member A1 ALDH1A1 -4.60 -4.85 
     sulfotransferase family, cytosolic, 2B, member 1 SULT2B1 -2.33 -3.00 
     UDP glucuronosyltransferase 1 family, A10 / A8 / A7 / A6 UGT1A -3.71 -2.56 
DNA Repair    
     mutL homolog 3 (E. coli) MLH3 -2.53 -2.06 
Signal Transduction    
     insulin-like growth factor binding protein 6 IGFBP6 -3.69 -7.74 
Transcription Regulation    
     BarH-like homeobox 2 BARX2 -2.96 -3.71 
Miscellaneous    
     envoplakin EVPL -3.26 -3.55 
     huntingtin interacting protein-1-related HIP1R -3.72 -2.65 
     protease, serine, 3 (mesotrypsin) PRSS3 -3.88 -7.21 
     kallikrein 11 KLK11 -3.70 -7.28 
     kallikrein 13 KLK13 -4.41 -12.15 
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activating complex, polypeptide 1, 43-kDa (SNAPC1), while downregulated 
genes included those involved in apoptosis or RNA processing such as clusterin 
(CLU) and RNA binding motif protein 3 (RBM3) (Dresios, et al., 2005;Penning, et 
al., 2006;Scaltriti, et al., 2004;Sutherland, et al., 2005;Xie, et al., 2002). 
 
Identification of genes differentially expressed between HPV-positive and HPV-
negative SCCHN 
 
 To identify pathways unique to the pathogenesis of HPV positive and 
negative SCCHN, we compared the gene expression profiles in these two types 
of cancers. The pooled t-Test analysis revealed that a total of 1,040 genes were 
upregulated and 1,363 downregulated in the HPV-positive SCCHN samples 
compared to the HPV-negative SCCHN samples (supplementary data, Table G). 
Using the SAM test, we identified 347 upregulated and 175 downregulated genes 
in the HPV-positive SCCHN compared to HPV-negative SCCHN (supplementary 
data, Table H). A comparison of the results obtained using the above two tests 
was done to identify genes present in both of these analyses. This showed that 
124 genes were upregulated and 42 downregulated in HPV-16 positive SCCHN 
as compared to the HPV-negative SCCHN (Fig. 6). A list of differentially 
expressed genes representing various cellular pathways is shown in Table 4 (a 
complete list of genes is shown in the supplementary data, Table I). 
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TABLE 3. GENES FOUND DIFFERENTIALLY EXPRESSED IN 
HPV-NEGATIVE SCCHN VERSUS NORMAL ORAL EPITHELIUM 
 
Gene Title Gene Symbol Pooled 
variance t-
Test fold 
change 
SAM-
Test fold 
change 
Up-regulated genes  
Angiogenesis  
     endothelial cell growth factor 1 (platelet-derived) ECGF1 2.90 2.23 
Cell Adhesion  
     Cadherin, EGF LAG seven-pass G-type receptor 1 CELSR1 2.67 2.21 
     cadherin 3, type 1, P-cadherin (placental) CDH3 2.51 3.72 
     calcium/calmodulin-dependent serine protein kinase CASK 3.47 2.05 
     laminin, beta 1 LAMB1 3.36 2.18 
Cell Cycle Regulation  
     cyclin A1 CCNA1 2.16 2.03 
     exostoses (multiple) 1 EXT1 3.25 2.99 
Cell-Cell Signaling    
     parathyroid hormone-like hormone PTHLH 2.61 9.26 
DNA Replication    
     DNA replication complex GINS protein PSF1 PSF1 2.03 2.27 
Transcription Regulation    
     basonuclin 1 BNC1 2.83 2.27 
     polymerase (RNA) II (DNA directed) polypeptide H POLR2H 2.59 2.03 
     small nuclear RNA activating complex, polypeptide 1, 43kDa SNAPC1 2.16 2.42 
Immune Response    
     CCAAT/enhancer binding protein (C/EBP), beta CEBPB 2.11 2.24 
     Fc fragment of IgG, low affinity IIa, receptor (CD32) FCGR2A 2.89 2.39 
     interferon-induced protein with tetratricopeptide repeats 1 IFIT1 2.81 2.07 
Development    
     S100 calcium binding protein A7 (psoriasin 1) S100A7 2.58 4.15 
Miscellaneous    
     aldo-keto reductase family 1, member B10 (aldose reductase) AKR1B10 3.05 4.47 
     aldo-keto reductase family 1, member C3 AKR1C3 2.69 2.90 
     chromosome 5 open reading frame 13 C5orf13 2.16 2.09 
     phosphoribosylglycinamide formyltransferase GART 2.55 2.13 
Down-regulated genes    
Cell Adhesion    
     chemokine (C-X-C motif) ligand 12 CXCL12 -2.18 -2.84 
     claudin 10 CLDN10 -2.62 -4.50 
Cell-Cell Signaling    
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     sprouty homolog 2 (Drosophila) SPRY2 -2.65 -2.37 
Cell Cycle Regulation    
     transforming, acidic coiled-coil containing protein 1 TACC1 -2.58 -2.01 
Cell Differentiation    
     four and a half LIM domains 1 FHL1 -2.74 -2.03 
Cellular Metabolism    
     glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase 
GNE -2.46 -2.00 
     glycine amidinotransferase GATM -3.71 -3.72 
Transcription Regulation    
     single-stranded DNA binding protein 2 SSBP2 -2.77 -2.02 
     thioredoxin interacting protein TXNIP -2.43 -2.03 
Miscellaneous    
     cytochrome P450, family 3, subfamily A, polypeptide 5 CYP3A5 -2.13 -4.45 
     heat shock 70kDa protein 1A HSPA1A -4.49 -2.04 
     lymphoid-restricted membrane protein LRMP -3.06 -4.24 
     serine threonine kinase 39 (STE20/SPS1 homolog, yeast) STK39 -2.24 -2.28 
RNA Processing    
     RNA binding motif (RNP1, RRM) protein 3 RBM3 -2.32 -2.56 
Signal Transduction    
     insulin-like growth factor binding protein 5 IGFBP5 -3.04 -2.36 
     protein kinase, cAMP-dependent, catalytic, beta PRKACB -3.36 -2.29 
     Ras-related associated with diabetes RRAD -3.02 -3.86 
     RAP1A, member of RAS oncogene family RAP1A -3.77 -2.27 
Development    
     chordin-like 1 CHRDL1 -2.44 -2.44 
     dystrophin (muscular dystrophy, Duchenne and Becker types) DMD -2.45 -2.14 
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 Interestingly, a subgroup of 40 upregulated and 19 downregulated genes 
identified in HPV-positive versus HPV-negative SCCHN analysis, was also found 
in a comparison between HPV-positive SCCHN and normal oral tissues. Thus, it 
is likely that the expression of this group of genes (Table 5) is specifically 
affected by the presence of HPV. Such upregulated genes included those 
involved in nuclear structure and meiosis (synaptonemal complex protein 2 
[SYCP2]), DNA repair (replication factor C 5 [RFC5]), and DNA methylation (DNA 
[cytosine-5-]-methyltransferase 1 [DNMT1]). Genes involved in proteolysis 
(kallikrein 7, 8, 10 [KLK7, KLK8, KLK10]) and signal transduction (cellular retinoic 
acid binding protein 2 [CRABP2]) were found to be downregulated in HPV-
positive SCCHN compared to both HPV-negative SCCHN and normal oral 
tissues in these analyses. 
 
Identification of differentially expressed genes present in all SCCHN samples in 
comparison to normal oral tissues 
 
 We also identified genes whose expression is similarly affected in both 
HPV- positive and HPV-negative SCCHN as compared to the normal oral 
mucosa. Based on the pooled t-Test and SAM test analyses, we found that 55 
genes were upregulated and 42 downregulated in HPV-positive as well as HPV-
negative SCCHN as compared to the normal oral mucosa. A list of differentially 
expressed genes representing various cellular pathways is shown in Table 6 (a 
complete list of genes is shown in the supplementary data, Table J). These  
 45
TABLE 4. GENES FOUND DIFFERENTIALLY EXPRESSED IN 
HPV-POSITIVE SCCHN VERSUS HPV-NEGATIVE SCCHN 
 
Gene Title Gene Symbol Pooled 
variance t-
Test fold 
change 
SAM-
Test fold 
change 
Up-regulated genes  
Apoptosis  
     baculoviral IAP repeat-containing 1 BIRC1 3.08 2.11 
     baculoviral IAP repeat-containing 3 BIRC3 4.65 4.56 
     CD2 antigen (p50), sheep red blood cell receptor CD2 3.56 2.60 
Cell Cycle  
     B-cell CLL/lymphoma 2 BCL2 2.43 2.53 
     cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B 2.87 2.07 
     cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C 2.83 3.04 
     dual specificity phosphatase 4 DUSP4 3.56 2.07 
Transcription Regulation    
     BCL2-associated transcription factor 1 BCLAF1 7.29 2.70 
     Splicing factor proline/glutamine rich SFPQ 3.64 2.57 
     thymus high mobility group box protein TOX TOX 3.64 2.16 
     zinc finger protein 238 ZNF238 6.28 2.04 
Immune response  
     lymphotoxin beta (TNF superfamily, member 3) LTB 2.56 2.22 
     major histocompatibility complex, class II, DP beta 1 HLA-DPB1 2.51 2.40 
     major histocompatibility complex, class II, DQ alpha 1/ 2 HLA-DQA1/A2 2.47 3.29 
Cell Adhesion    
     vascular cell adhesion molecule 1 VCAM1 4.63 3.96 
Signal Transduction    
     phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 2.87 2.35 
     RAS guanyl releasing protein 1 RASGRP1 2.50 2.09 
DNA Repair    
     RecQ protein-like (DNA helicase Q1-like) RECQL 3.90 2.16 
Miscellaneous    
     ecotropic viral integration site 2A EVI2A 3.33 2.11 
     tubulin, gamma complex associated protein 3 TUBGCP3 4.92 2.14 
Down-regulated genes    
Cellular Metabolism    
     aldo-keto reductase family 1, member B10 AKR1B10 -3.73 -7.30 
     aldo-keto reductase family 1, member C3 AKR1C3 -3.23 -4.44 
     solute carrier family 7, member 5 SLC7A5 -2.25 -2.08 
     UDP glucuronosyltransferase 2 family, polypeptide B4 UGT2B4 -4.97 -2.71 
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Cell Proliferation    
     block of proliferation 1 BOP1 -2.48 -2.19 
Signal Transduction    
     inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 -2.05 -2.05 
Cell Cycle    
     cyclin A1 CCNA1 -2.18 -2.31 
Chromatin assembly and modification    
     histone 1, H2bg HIST1H2BG -2.63 -2.70 
Protein modification    
     carboxypeptidase A4 CPA4 -2.58 -2.14 
Immune response    
     interleukin 1 receptor accessory protein IL1RAP -2.24 -2.01 
     killer cell lectin-like receptor subfamily G, member 1 KLRG1 -5.70 -2.18 
     serine (or cysteine) proteinase inhibitor, clade B, member 4 SERPINB4 -2.0 -2.38 
Cell Differentiation    
     S100 calcium binding protein A7 (psoriasin 1) S100A7 -2.7 -6.69 
     small proline-rich protein 1B (cornifin) SPRR1B -3.40 -2.28 
Translation Regulation    
     eukaryotic translation initiation factor 3, subunit 8, 110kDa EIF3S8 -2.27 -2.14 
     eukaryotic translation initiation factor 5A EIF5A -6.05 -2.79 
Transcription Regulation    
     achaete-scute complex-like 2 (Drosophila) ASCL2 -4.19 -2.08 
     bolA-like 2 (E. coli) BOLA2 -2.09 -2.02 
Miscellaneous    
     corneodesmosin CDSN -2.97 -2.62 
     seven transmembrane domain protein NIFIE14 -5.28 -2.05 
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TABLE 5. GENES FOUND DIFFERENTIALLY EXPRESSED 
EXCLUSIVELY IN HPV-POSITIVE SCCHN VERSUS HPV-
NEGATIVE SCCHN OR NORMAL ORAL EPITHELIUM 
Gene Title Gene Symbol Pooled 
variance t-
Test fold 
change 
SAM-
Test fold 
change 
Up-regulated genes  
Apoptosis  
     tumor necrosis factor, alpha-induced protein 3 TNFAIP3 2.40 2.58 
Cell Cycle  
     synaptonemal complex protein 2 SYCP2 13.58 12.54 
Transcription Regulation    
     DNA (cytosine-5-)-methyltransferase 1 DNMT1 6.22 2.22 
     nuclear factor (erythroid-derived 2)-like 3 NFE2L3 2.85 2.67 
     sin3-associated polypeptide, 30kDa SAP30 2.23 2.12 
     suppressor of zeste 12 homolog (Drosophila) SUZ12 2.86 2.17 
Cell Differentiation    
     B cell RAG associated protein GALNAC4S-6ST 2.47 2.62 
Immune response  
     CD200 antigen CD200 3.10 3.00 
     chemokine (C-X-C motif) ligand 11 CXCL11 2.05 3.52 
     chemokine (C-X-C motif) ligand 9 CXCL9 2.87 3.93 
     lymphocyte antigen 75 LY75 4.19 4.41 
     phospholipase A2, group IVC PLA2G4C 4.12 2.27 
Cell Proliferation    
     chemokine (C-X-C motif) ligand 10 CXCL10 2.18 2.55 
     cysteine and glycine-rich protein 2 CSRP2 3.36 2.34 
     pim-2 oncogene PIM2 2.44 2.07 
Cell Adhesion    
     collagen, type VII, alpha 1 COL7A1 2.61 3.35 
     collagen, type XXI, alpha 1 COL21A1 15.43 3.80 
     thrombospondin 4 THBS4 3.09 3.30 
Signal Transduction    
     chemokine (C-X-C motif) receptor 4 CXCR4 3.37 4.18 
     chemokine orphan receptor 1 CMKOR1 2.34 2.67 
     inositol 1,4,5-trisphosphate 3-kinase B ITPKB 2.83 2.14 
     lymphoid enhancer-binding factor 1 LEF1 3.27 3.87 
     phosphoinositide-3-kinase, regulatory subunit 3 PIK3R3 3.15 2.37 
     Ras association (RalGDS/AF-6) domain family 4 RASSF4 3.06 3.45 
     SMAD, mothers against DPP homolog 5 (Drosophila) SMAD5 2.88 2.67 
DNA Repair    
     replication factor C (activator 1) 5, 36.5kDa RFC5 5.01 2.18 
     thymidylate synthetase TYMS 3.01 2.09 
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Chromatin assembly and modification  
     SMC5 structural maintenance of chromosomes 5-like 1 SMC5L1 2.88 2.14 
Protein modification    
     CDC-like kinase 4 CLK4 7.15 3.21 
     glutaminyl-peptide cyclotransferase (glutaminyl cyclase) QPCT 2.37 3.43 
     proteasome subunit, beta type, 9 PSMB9 2.15 2.07 
     tyrosine kinase 2 TYK2 3.68 2.66 
Miscellaneous    
     butyrophilin, subfamily 3, member A3 BTN3A3 2.04 2.20 
     chromosome 18 open reading frame 1 C18orf1 4.05 3.89 
     chromosome X open reading frame 45 CXorf45 5.59 3.53 
     Endothelin converting enzyme 1 ECE1 2.68 2.30 
     fatty acid desaturase 2 FADS2 9.05 2.23 
     inositol polyphosphate-5-phosphatase F INPP5F 3.67 2.92 
     spastin SPAST 4.91 2.15 
     stress 70 protein chaperone, microsome-associated, 60kDa STCH 2.57 2.33 
Down-regulated genes    
Cellular Metabolism    
     cytidine deaminase CDA -2.07 -5.50 
     monoamine oxidase A MAOA -2.69 -2.34 
     UDP glucuronosyltransferase 1 family, polypeptide A6 UGT1A6 -2.04 -3.85 
Cell Proliferation    
     amphiregulin (schwannoma-derived growth factor) AREG -3.12 -2.55 
     CD5 antigen (p56-62) CD5 -4.31 -2.15 
Signal Transduction    
     cellular retinoic acid binding protein 2 CRABP2 -4.32 -6.28 
     wingless-type MMTV integration site family, member 4  WNT4 -3.91 -2.13 
Chromatin assembly and modification    
     H2B histone family, member S H2BFS -2.91 -2.67 
     histone 1, H2bd HIST1H2BD -2.59 -2.47 
Cell Differentiation    
     glucosaminyl (N-acetyl) transferase 2, I-branching enzyme GCNT2 -3.32 -2.51 
     kallikrein 7 (chymotryptic, stratum corneum) KLK7 -2.49 -4.68 
     kallikrein 8 (neuropsin/ovasin) KLK8 -10.36 -4.6 
     kallikrein 10 KLK10 -4.23 -6.75 
     keratin, hair, acidic, 1 KRTHA1 -2.49 -2.29 
Transcription Regulation    
     paired-like homeodomain transcription factor 2 PITX2 -3.08 -6.26 
Cell Adhesion    
     lymphocyte antigen 6 complex, locus D LY6D -2.24 -4.29 
     plakophilin 3 PKP3 -3.08 -2.57 
Miscellaneous    
     kinesin family member 1C KIF1C -2.62 -2.04 
     solute carrier family 24, member 3 SLC24A3 -3.01 -2.04 
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TABLE 6. GENES FOUND DIFFERENTIALLY EXPRESSED IN 
ALL SCCHN SAMPLES VERSUS NORMAL ORAL EPITHELIUM 
 
Gene Title Gene Symbol Pooled 
variance t-
Test fold 
change 
SAM-
Test fold 
change 
Up-regulated genes       
DNA Replication       
     CDC6 cell division cycle 6 homolog (S. cerevisiae) CDC6 3.75 2.07 
Cell Proliferation       
     hepatoma-derived growth factor, related protein 3 HDGFRP3 6.32 2.87 
     keratin 16 (focal non-epidermolytic palmoplantar keratoderma) KRT16 2.78 3.51 
Transcription Regulation       
     signal transducer and activator of transcription 1, 91kDa STAT1 5.01 2.94 
Signal Transduction       
     CD14 antigen CD14 2.15 2.23 
     insulin-like growth factor 2 receptor IGF2R 4.72 2.52 
     secreted protein, acidic, cysteine-rich (osteonectin) SPARC 6.22 4.18 
Immune Response       
     Fc fragment of IgG, low affinity IIIb, receptor (CD16b) FCGR3B 2.63 3.29 
     interferon, alpha-inducible protein 27 IFI27 2.21 2.68 
     interferon-induced protein 44 IFI44 2.88 2.51 
Development       
     chondroitin sulfate proteoglycan 2 (versican) CSPG2 2.85 3.59 
     collagen, type I, alpha 1 COL1A1 2.23 3.39 
     keratin 14 (epidermolysis bullosa simplex) KRT14 6.93 3.12 
Cell adhesion       
     matrix metalloproteinase 3 (stromelysin 1, progelatinase) MMP3 5.02 2.55 
     periostin, osteoblast specific factor POSTN 5.47 10.09 
     transforming growth factor, beta-induced, 68kDa TGFBI 2.76 2.05 
Miscellaneous       
     cathepsin L2 CTSL2 2.20 6.18 
     plasminogen activator, urokinase PLAU 4.01 3.33 
     secreted phosphoprotein 1 (osteopontin, bone sialoprotein I) SPP1 7.00 18.90 
     serine (or cysteine) proteinase inhibitor, clade H SERPINH1 5.74 2.43 
Down-regulated genes       
Apoptosis       
     clusterin CLU -3.20 -4.54 
     growth arrest and DNA-damage-inducible, beta GADD45B -3.10 -2.55 
     mal, T-cell differentiation protein MAL -2.14 -2.50 
Cell adhesion       
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     annexin A9 ANXA9 -2.54 -2.17 
     multimerin 1 MMRN1 -3.70 -4.51 
Immune response       
     cysteine-rich protein 1 (intestinal) CRIP1 -7.21 -5.16 
     cysteine-rich secretory protein 3 CRISP3 -5.75 -69.68 
     interleukin 2 IL2 -2.97 -3.16 
     prostate stem cell antigen PSCA -4.63 -8.65 
Signal Transduction       
     proline-rich protein HaeIII subfamily 1-2 PRH1-2 -3.17 -20.84 
Cellular Metabolism       
     amylase, alpha 1A; salivary / 1B / 1C / 2A/ 2B AMY1 -5.15 -7.67 
     glycerol-3-phosphate dehydrogenase 1-like GPD1L -3.25 -3.43 
Protein Modification       
     ubiquitin-like 3 UBL3 -2.28 -2.67 
Transcription Regulation       
     p300/CBP-associated factor PCAF -2.51 -2.43 
     paternally expressed 3 PEG3 -6.73 -6.01 
Development       
     keratin 4 KRT4 -2.72 -2.82 
     sciellin SCEL -2.28 -2.55 
Miscellaneous       
     ATP-binding cassette, sub-family A (ABC1), member 8 ABCA8 -2.54 -3.05 
     dual specificity phosphatase 5 DUSP5 -2.54 -2.97 
     nucleobindin 2 NUCB2 -3.50 -3.12 
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genes may represent common pathways altered during SCCHN irrespective of 
the presence or absence of HPVs. The upregulated genes included those 
involved in cell cycle regulation, epidermis development and cell adhesion such 
as signal transducer and activator of transcription 1 (STAT1), keratin 14, 16 
(KRT14, KRT16) and transforming growth factor, beta-induced, 68-kDa (TGFBI). 
Also, downregulated genes found in both types of SCCHN samples included 
those involved in chromatin remodeling, cell-cell adhesion and apoptosis such as 
p300/CBP-associated factor (PCAF), annexin A9 (ANXA9) and mal, T-cell 
differentiation protein (MAL). 
 
Identification of several gene expression clusters in HPV-positive, HPV-negative 
SCCHN and normal oral tissues 
 
 Unsupervised hierarchical cluster analysis was developed using all 
SCCHN specimens as well as normal oral tissues. After normalization and 
filtering with different criteria (described in materials and methods), we obtained a 
set of 8,286 genes with significant variation in their expression in one or more of 
the total of three types of samples (HPV-positive SCCHN, HPV-negative 
SCCHN, and control oral mucosa). From these filtered genes, we identified five 
clusters that showed differences in gene expression not only between all the 
SCCHN samples and the normal oral epithelium but also between HPV-positive 
SCCHN and HPV-negative SCCHN (Fig. 7). Interestingly, some of the genes 
found in this analysis were also found in the supervised statistical analysis such 
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as ZNF238, DNMT1, MCM3, aldo-keto reductase family 1, member C3 
(AKR1C3), growth factor receptor-bound protein 10 (GRB10), tyrosine kinase 2 
(TYK2) and squamous cell carcinoma antigen recognized by T cells 3 (SART3)  
(underlined in Fig. 7). After this analysis, we mapped the chromosomal location 
of the genes found in these clusters in order to visualize genomic regions that 
could contain a significant number of genes altered in their expression in HPV-
positive SCCHN as compared to HPV-negative SCCHN as well as the normal 
oral epithelium. Fig. 8 shows that several such genes are present in 
chromosomal regions 1p34-p36 and 12q21-q24 (a complete list of the clustered 
genes is shown in the supplementary data, Table K). The genes found in the 
1p34-p36 region are involved in repression of splicing (FUS interacting protein 1 
[FUSIP1]), histone and nucleosomal binding (nuclear autoantigenic sperm 
protein [NASP], high-mobility group nucleosomal binding domain 2 [HMGN2]) 
and intracellular vesicle traffic (taxilin alpha [TXLNA]). On the other hand, the 
genes found in the chromosome region 12q21-q24 are involved in JAK/STAT-
signaling pathway (cysteine and glycine-rich protein 2 [CSRP2]), regulation of 
nuclear architecture (thymopoietin [TMPO/LAP2]), myotonic dystrophy kinase 
cascade (citron [CIT]) and regulation of mRNA splicing and HIV gene expression 
and replication (squamous cell carcinoma antigen recognized by T cells 3 
[SART3]). 
  
 
 53
Fig. 7. UNSUPERVISED HIERARCHICAL CLUSTER 
ANALYSIS IN OROPHARYNGEAL TISSUE SAMPLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From a total of 22,215 transcripts on the microarray, 8,286 genes showed 
variations in expression across all the samples. From this group of filter genes, 
we identified 7 clusters of genes that show differential expression between the 3 
groups of samples (HPV-positive SCCHN, HPV-negative SCCHN and normal oral 
mucosa). Genes also found in the supervised statistical analysis are underlined. 
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Fig. 8. CHROMOSOMAL LOCATION OF GENES FOUND TO 
BE DIFFERENTIALLY EXPRESSED IN THE HIERARCHICAL 
CLUSTER ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
1p31-p36 
12q21-24 
 
Squares to the right of the chromosomes indicate genes with increased 
expression in HPV-positive oropharyngeal squamous carcinomas as compared to 
HPV-negative carcinomas or the normal oral epithelium (clusters 1, 2 and 3). 
Circles to the left of the chromosomes indicate genes with reduced expression in 
HPV-positive oropharyngeal squamous carcinomas as compared to the HPV-
negative and normal samples (clusters 4 and 5). The chromosome map was 
obtained and modified from the Department of Pathology, University of 
Washington web page 
http://www.pathology.washington.edu/research/cytopages/idiograms/human/ 
(Idiogram Album: Human copyright © 1994 David Adler). 
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Validation of microarray expression data by real-time quantitative RT-PCR 
analysis 
 
 We carried out quantitative real-time RT-PCR (QRT-PCR) analysis of a 
few representative genes in order to validate the differential gene expression 
profiles obtained by microarray analysis. Four genes found to be upregulated 
(CDKN2A, SYCP2, RFC5, ZNF238) and two genes found to be downregulated 
(KLK8, CRABP2) in HPV-positive SCCHN samples as compared to both the 
HPV-negative SCCHN as well as normal oral tissues were selected for validation 
(Fig. 9). The QRT-PCR analysis confirmed that CDKN2A and SYCP2 were up-
regulated in all the HPV-positive SCCHN samples as compared to the HPV-
negative SCCHN and normal epithelium, whereas RFC5 and ZNF238 were 
found to be up-regulated in two out of three HPV-positive SCCHN (Fig. 9). 
Similarly, the KLK8 and CRABP2 genes were downregulated in HPV-positive 
SCCHN.  However, there was variation in the extent of differential expression of 
the above genes in individual samples (Fig. 9).  The above data showed that the 
results of QRT-PCR were consistent with those of the microarray analysis, 
although variations were observed in the fold-difference between these two types 
of analyses.   
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2.4 DISCUSSION 
 
Recently, an improved understanding of SCCHN has resulted from studies 
on carcinogenic (tobacco, alcohol, etc.) versus viral (HPV, EBV, etc.) exposures. 
Several investigators have compared these subgroups in order to identify the 
pathway (s) and potential therapeutic targets which are unique to these tumours, 
which are often localized to distinct head and neck sub sites.  Indeed, our study 
is unique since we focused specifically on tumours from the oropharyngeal site, 
in order to compare gene expression profiles between HPV-16 positive SCCHN 
tumours and normal squamous oropharyngeal mucosa.  
 
 To date, no study has described such a tri-partite analysis, including the 
epithelial squamous cells from which both tumours were derived. This 
significantly strengthens our ability to conclude that oncogenic signaling identified 
in HPV-positive and HPV-negative SCCHN is appropriately attributed to the 
transformation process and not to the genes expressed in oropharyngeal 
squamous cells.  Although the number of specimens used in our study is small, a 
unique feature of this study is that we have exclusively utilized tissues derived 
from the oropharyngeal site. While HPV infection can be identified throughout 
tumours of the head and neck, a disproportionate frequency is found in the 
oropharynx (approximately 50%). Thus, identifying tumours in this region 
eliminates other sub site causes of tumour heterogeneity which have been 
observed by others.  Finally, detailed statistical analysis using multiple tests of  
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Fig. 9. VALIDATION OF MICROARRAY DATA IN 
OROPHARYNGEAL TISSUE SAMPLES BY QUANTITATIVE RT-
PCR 
 
 
Total RNA from tissue samples was used to verify four upregulated genes (cyclin-
dependent kinase inhibitor 2A [CDKN2A], synaptonemal complex protein 2 
[SYCP2], zinc finger protein 238 [ZNF238] and replication factor C 5 [RFC5]), and 
two downregulated genes (cellular retinoic acid binding protein 2 [CRABP2], 
kallikrein 8 [KLK8]) that were differentially expressed based on the microarray 
data. All reactions were performed in triplicates and the error bar represents the 
standard deviation. Relative expression of the target gene was calculated using 
the 2 delta CT method, where GAPDH was used as the endogenous control gene. 
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significance enhances our ability to identify genes that are expressed uniquely in 
HPV-16 positive tumours.  We have also carried out quantitative RT-PCR 
analysis to validate the expression of some of the genes found to be differentially 
expressed in the microarray analysis (Fig. 9). This provides additional confidence 
in the genes identified by the microarray analysis.   
 
After confirming the expression of the HPV-16 E6 and E7 genes in HPV-
positive, HPV-negative SCCHN and normal squamous mucosal samples, we 
proceeded with the global gene expression analysis. After analyzing the 
microarray data with two different normalizations and statistical tests (pooled 
variance t-Test and SAM-Test) in order to identify differentially expressed genes 
that were robust enough to appear in both analyses, we found that 228 genes 
were upregulated and 169 downregulated in HPV-positive SCCHN samples as 
compared to the normal oral tissues. The upregulated genes included those 
involved in DNA replication and cell cycle regulation such as CDKN2A 
(p16INK4a), MCM2, PCNA, TOP2A and RBL1 that have been previously 
identified to be affected in HPV-infected cervical and oral carcinomas (Li, et al., 
2004;Ren, et al., 2002;Santin, et al., 2005). Several studies have shown either 
direct or indirect regulation of these genes by the tumour suppressor protein p53 
(RBL1, PCNA, TOP2A) or by E2F transcription factors (CDKN2A and MCM2) 
(Ren, et al., 2002;Wei, et al., 2006). One possible explanation for the 
transcriptional deregulation of this group of genes may be the degradation of p53 
and pRB (that bind and repress the activity of the family of E2F transcription 
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factors) by the viral oncogenes E6 and E7, respectively. Interestingly, we also 
found several genes differentially expressed in our microarray analysis in HPV-
positive SCCHN compared to the normal tissue that have been shown to be 
regulated by p53 or E2F such as the tumour necrosis factor receptor superfamily, 
member 10b (TNFRSF10B), mutS homolog 6 (MSH6), caldesmon 1 (CALD1), 
p300/CBP-associated factor (PCAF), collagen, type IV, alpha 1 (COL4A1), 
nidogen 2 (NID2), astrotactin 2 (ASTN2), cytochrome P450, family 4, subfamily 
F, polypeptide 3 (CYP4F3), DNA-damage-inducible transcript 4 (DDIT4), 
chondroitin sulfate proteoglycan 2 (CSPG2), insulin-like growth factor binding 
protein 6 (IGFBP6), keratin 17 (KRT17), CDC6 cell division cycle 6 homolog 
(CDC6), replication factor C4, 37kDa (RFC4), flap structure-specific 
endonuclease 1 (FEN1) and SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, member 3 (SMARCA3) (see 
supplementary data, table C) (Kannan, et al., 2001;Ren, et al., 2002;Wei, et al., 
2006;Zhao, et al., 2000). These data are consistent with the results of previous 
studies and support the notion that HPV-positive SCCHN has a specific 
transcription profile depends partly on E6 and E7 expression. Specific E6 or E7 
knockdown studies will clarify the validity of this conclusion. After comparing the 
HPV-positive SCCHN samples against the normal oral tissues, we also identified 
a group of differentially expressed genes previously implicated in tumourigenesis 
of different tissues but not in SCCHN. These included the upregulated genes 
SFRP4 and RAD51AP1 and the downregulated gene PRSS3 (Table 2). SFRP4 
has been found to be upregulated in prostate cancers and in microsatellite stable 
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endometrial cancers (Horvath, et al., 2004;Risinger, et al., 2005). This protein 
has also been implicated in the inhibition of the Wnt-signaling cascade that is 
involved in the regulation of cellular proliferation (Horvath, et al., 2004). 
RAD51AP1 is an S phase cell cycle checkpoint gene that has recently been 
found to be directly induced by E2F1 (Iwanaga, et al., 2006). The overexpression 
of RAD51AP1 further supports the idea that dysregulation of E2F inducible 
transcripts occurs in HPV-positive SCCHN due to the inactivation of pRB by E7 
expression. PRSS3 is a member of the serine protease family that shares 
significant homology with trypsinogen 1 and 2 and has been classified as a 
tumour suppressor gene in several types of cancers such as esophageal 
squamous cell carcinomas, gastric adenocarcinomas and non-small cell lung 
cancers (Marsit, et al., 2005). There is also some evidence that PRSS3 is 
downregulated by promoter hypermethylation in lung cancers (Marsit, et al., 
2005). Interestingly our results show that DNMT1, which is responsible for 
transcriptional silencing through DNA methylation, is upregulated in HPV-positive 
SCCHN suggesting possible hypermethylation of genes including PRSS3 by this 
enzyme. 
 
 After statistical analysis of the data obtained with HPV-negative SCCHN, 
we found 79 upregulated and 83 downregulated genes as compared to the 
normal oropharyngeal squamous mucosa (supplementary data, Table F). The 
upregulated genes such as PTHLH and ECGF1, and downregulated genes such 
as IGFBP5 and PDCD4 were also reported in previous SCCHN studies providing 
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a validation of our results (Kornberg, et al., 2005;Lin, et al., 2002). At the same 
time, we found novel upregulated genes such as AKR1C3 and SNAPC1 and 
downregulated genes such as CLU and RBM3 that were previously not known to 
be differentially expressed in SCCHN. AKR1C3 is a hydroxysteroid 
dehydrogenases involved in the regulation of local concentration of androgens 
and estrogens in hormone dependent tissues like prostate, breast and 
endometrium (Penning, et al., 2006). AKR1C3 has been found overexpressed at 
the mRNA and protein level in prostate cancer specifically in the stromal cells 
(Penning, et al., 2006). SNAPC1 is a subunit of the TBP-TAF complex involved in 
the transcription of both RNA polymerase II and III dependent small nuclear RNA 
genes. SNAPC1 has been linked to the tumourigenesis of breast cancers (Xie, et 
al., 2002). CLU is a multifunctional gene which is involved in spermatogenesis 
and in the control of the immunological complement cascade (Scaltriti, et al., 
2004). It has recently been shown that CLU is downregulated in low- and high-
grade human prostate cancers and it may be involved in supporting cell survival 
and the induction of programmed cell death (Scaltriti, et al., 2004). RBM3, a 
glycine-rich RNA-binding protein induced by cold-stress, has recently been found 
to have apoptotic modulatory capabilities with a possible role as a tumour 
suppressor gene (Sutherland, et al., 2005). Interestingly, there is evidence that 
RBM3 can change the expression of some microRNAs and enhance global 
protein synthesis suggesting an involvement of a homeostatic mechanism that 
regulates global levels of protein synthesis under normal and cold-stress 
conditions (Dresios, et al., 2005).  
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 We found 124 upregulated and 42 downregulated genes in HPV-positive 
SCCHN as compared to HPV-negative SCCHN (supplementary data, Table I). 
Among this group of genes, we found a subset of genes (41 upregulated and 19 
downregulated) that were also differentially expressed in HPV-positive SCCHN 
as compared to the normal oropharyngeal mucosa. It is likely that the differential 
expression of these 60 genes (Table 5) is a consequence of the presence of 
HPV-16. This group of genes included the upregulated genes SYCP2, RFC5, 
ZNF238 and DNMT1, and the downregulated genes KLK8 and CRABP2. SYCP2 
is part of the synaptonemal complex involved in forming lateral elements and 
cross bridges that contribute to pairing of sister chromatids during meiosis and 
probably are involved in the interaction between chromatin and nuclear envelope 
(Shakib, et al., 2005). There is evidence that HPV infection in cervical cells 
promotes morphological changes in the nuclear membrane as well as 
condensation of chromatin attached to the inner part of the nuclear membrane 
(Bollmann, et al., 2005). Thus, it is possible that SYCP2 may be involved in 
chromatin-nuclear envelope interactions in HPV-positive SCCHN.  
 
 A recent study by Slebos and colleagues also reported up-regulation of 
the SYCP2 and cyclin-dependent kinase inhibitor 2C (CDKN2C) in HPV-positive 
SCCHN as compared to HPV-negative SCCHN, similar to our data obtained 
using the two statistical methods (Slebos, et al., 2006).  Since the data presented 
by Slebos and colleagues were based solely on the use of the SAM statistical 
method, we also compared the differentially expressed genes in our study 
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identified only by using this method (supplementary Table H).  This analysis 
showed that the CDKN2A, NEFH and FLJ12973 genes were similarly affected in 
both the studies.  This further strengthens the likelihood that the above genes 
play important roles in the carcinogenesis of HPV-related SCCHN.  Based on the 
use of SAM statistical method alone, we found that the SMARCA2 gene was up-
regulated in HPV-positive SCCHN as compared to the HPV-negative SCCHN 
(Table H).  This gene belongs to a family of proteins involved in transcriptional 
regulation by conformational changes of nucleosomes (Yamamichi, et al., 2005). 
The closely-related and functionally similar SMARCA3 gene was found to be up-
regulated in the study of Slebos and colleagues (Slebos, et al., 2006). Similarly, 
while replication factor C 5 (RFC5) was found to be overexpressed in HPV-
positive SCCHN in our study (Table 5), Slebos and colleagues reported 
overexpression of RFC4. Theses genes encode part of the RFC protein complex 
required, in conjunction with PCNA, in chromosomal DNA replication by DNA 
polymerase delta and epsilon. RFC5 protein not only interacts directly with PCNA 
but also with RAD24 which is involved in DNA damage checkpoint control in 
Saccharomyces cerevisiae (Kim, et al., 2003;Naiki, et al., 2000). These findings 
suggest a possible role of RFC5 upon infection of the oropharyngeal tissue with 
HPVs that may promote a DNA damage response.  
 
 The transcription factor ZNF238 (also known as RP58) is a component of 
a C2H2-type DNA-binding zinc finger protein that acts as a repressor of 
transcriptionally silent heterochromatin regions. Interestingly, the DNA 
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methyltransferase protein Dnmt3a directly interacts with ZNF238 and promotes 
the repression of specific genes by histone deacetylation independently of its 
methyltransferase activity (Fuks, et al., 2001). The overexpression of ZNF238 
could explain the downregulation of several genes in HPV-positive SCCHN as a 
consequence of chromatin condensation by histone deacetylation. KLK8, which 
is overexpressed in HPV-positive SCCHN, is a member of the human kallikrein 
gene family of serine proteases with a diverse physiologic function in many 
tissues. KLK8 is implicated in terminal differentiation of keratinocytes and in the 
modulation of interaction between cells and fibronectin in extracellular matrix 
required for tumour growth and invasion. Several studies show different patterns 
of KLK8 expression such as its downregulation in breast cancers, and in 
contrast, its overexpression in cervical cancers (Cane, et al., 2004;Yousef, et al., 
2004). CRABP2 is a transcription factor that functions as a cytoplasmic retinoic 
acid binding protein that is highly expressed in human skin. Similar to our results 
showing its downregulation in HPV-positive SCCHN, CRABP2 is also 
downregulated in prostate cancer (Okuducu, et al., 2005). Finally, in the 
unsupervised hierarchical cluster analysis, we were able to identify a group of 
genes in five different clusters with significant variation between HPV-positive 
SCCHN as compared to HPV-negative SCCHN as well as normal oropharyngeal 
epithelium (Fig.7). Some of the genes found to be differentially expressed in our 
statistical analysis were also found in these clusters such as ZNF238, DNMT1, 
MCM3, AKR1C3, GRB10, TYK2 and SART3  (underlined in Fig. 7). The absence 
of other clustered genes in our supervised statistical analysis could be explained 
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by differences in expression levels below the 2-fold cut-off or by a value below 
the statistical significance that is considered by every test and overlapping 
processes. We also identified the localization of the various differentially 
expressed genes to particular chromosomes (Fig. 8). Two regions in 
chromosome 1 (p34-p36) and 12 (q21-q240) showed a significant number of 
differentially expressed genes. This may suggest common regulatory pathways 
involved in the regulation of some of these genes.  
 
 Our studies also identified genes whose expression is similarly affected in 
both HPV-positive and HPV-negative SCCHN as compared to the normal 
oropharyngeal tissue. For example, STAT1 is overexpressed while PCAF is 
downregulated in both types of SCCHN. These genes may represent common 
pathways that are altered in oropharyngeal carcinogenesis. STAT1 is a 
transcription factor that participates in cellular events such as IFN signaling, 
development of the mammary gland and embryogenesis. It is considered a 
tumour suppressor gene since its activation is associated with growth arrest, but 
studies in head and neck cancers showed an overexpression of STAT1 in well or 
moderately differentiated tumours in vivo (Arany, et al., 2003;Calo, et al., 2003). 
Our findings contrast with the recent publication of Xi and colleagues showing the 
downregulation of STAT1 in SCCHN through the hypermethylation of its 
promoter (Xi, et al., 2006).  
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 In summary, our data demonstrates specific changes in cellular gene 
expression profiles in HPV-positive SCCHN which also express the viral 
oncogenes. We have identified several genes such as those involved in nuclear 
structure and meiosis (SYCP2), cell differentiation (CRABP2), DNA repair 
(RFC5), transcription regulation (ZNF238) and epidermis development (KLK8) 
that were differentially expressed specifically in HPV-positive SCCHN as 
compared to both the HPV-negative SCCHN and normal oropharyngeal mucosa 
that could be used as potential biomarkers for the development of HPV-
associated SCCHN. 
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Chapter 3 
 
GENE EXPRESSION PROFILES OF HUMAN PAPILLOMAVIRUS-POSITIVE 
CERVICAL CELL LINES USING MICROARRAY ANALYSIS 
 
 
 
Work described in this section will be submitted to the European Journal of 
Cancer with authors Ivan Martinez and Saleem A. Khan  
I. Martinez performed all the experiments described in this section. I. Martinez 
and S.A. Khan wrote the manuscript 
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3.1 INTRODUCTION 
 
 Cervical cancer is the second most common cause of death in women 
worldwide after breast cancer (Jin, et al., 1999). Cervical carcinogenesis involves 
two main types of epithelial transformation. The transformation of basal cells in 
the squamous epithelium starts with a noninvasive low-grade squamous 
intraepithelial lesion (LG-SIL), leading to a high-grade squamous intraepithelial 
lesion (HG-SIL), and ultimately evolving into invasive squamous cell carcinoma 
(SCC) (Alazawi, et al., 2002). Adenocarcinomas and adenosquamous 
carcinomas (AC) originate from glandular endocervical columnar cells (Burk, et 
al., 2003). Molecular and clinical evidence suggests a tight link between high-risk 
HPV infection and cervical cancer (zur Hausen, 2002). High-risk HPV DNAs 
(types 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70) have 
been found in 99.7% of squamous cell cancers of the cervix (Walboomers, et al., 
1999). HPV infection is also implicated in approximately 25% of cases of oral 
cancers (Gillison, et al., 2001). HPV-16 is the most common type associated with 
cervical cancer in the United States and Europe (50%), followed by types 18, 31 
and 45 (Walboomers, et al., 1999). Certain high-risk types such as HPV-16 and 
HPV-18 show differences in their oncogenic potential and also in their apoptotic 
stimuli sensitivity (Aguilar-Lemarroy, et al., 2001;Badaracco, et al., 2002). Also, 
HPV-16 is more commonly associated with SCC, whereas HPV-18 is 
predominantly associated with AC (Burk, et al., 2003). 
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 Three HPV proteins, E5, E6 and E7, have been implicated in cellular 
transformation. The HPV-16 E5 protein can stimulate cell growth via upregulation 
of the activity of growth factor receptors (McMurray, et al., 2001). Recent studies 
have shown that E5 inhibits the induction of apoptosis in response to DNA 
damage (Zhang, et al., 2002). E5 expression is likely to be important in the early 
steps of transformation since this gene is normally disrupted during viral 
integration (zur Hausen, 2002). The E6 proteins of high- risk HPVs can modify 
cellular growth regulatory pathways creating an environment that facilitates viral 
replication in differentiated cells (Syrjanen, et al., 1999). E6 promotes the 
degradation of the tumor suppressor p53 protein involving the ubiquitin-protein 
ligase, upregulates telomerase activity, and affects transcriptional regulation by 
binding to the transcriptional activator p300/CBP (Klingelhutz, et al., 1996;Patel, 
et al., 1999;Thomas, et al., 1999). There is also evidence that E6 protein can 
regulate transcription from minimal promoters containing a TATA box (Sedman, 
et al., 1991). The E7 protein of high-risk HPVs interacts with the retinoblastoma 
tumor suppressor protein (pRB) and promotes degradation of this cell cycle 
regulatory protein (Dyson, et al., 1989). The E7 protein disrupts the 
transcriptionally inactive pRB-E2F complex resulting in the upregulation of E2-
responsive genes involved in cell cycle progression and entry into the S-phase 
(Muller, et al., 2001;Wu, et al., 1993). The HPV E7 protein also binds directly to 
histone deacetylase 1 (HDAC-1) and represses cellular transcription (Brehm, et 
al., 1999). E7 also binds to the AP-1 transcription factor, interacts directly with 
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the TATA-binding protein (TBP) and the TBP-associated factor-110 (TAF-110) to 
modify transcriptional regulation, and reactivates DNA synthesis through its 
interaction with cyclin E-cdk2 (Antinore, et al., 1996;Mazzarelli, et al., 
1995;McIntyre, et al., 1996). 
  
The HPV genome is usually integrated into the cellular genome in high-
grade lesions and in cervical carcinomas (Durst, et al., 1985). This generally 
results in the disruption of the viral E2 gene which is a negative regulator of the 
E6 and E7 oncogene expression (zur Hausen, 1991). However, E6 and E7 
expression is also known to occur in cells containing episomal viral DNA 
(Bechtold, et al., 2003). In other cases, the viral genome usually contains 
mutations in the viral long control region (LCR) that results in the upregulation of 
E6/E7 expression (May, et al., 1994). This is consistent with recent studies 
showing that the presence of HPV-16 in an episomal state promotes 
chromosomal instability in an organotypic raft culture model (Duensing, et al., 
2001). This early events in cellular transformation which involve low-level 
expression of E6 and E7 in basal cells is sufficient to deregulate mitotic 
machinery and to produce abnormal number of centrosomes (Duensing, et al., 
2002). Chromosomal abnormalities such as tetraploidy or aneuploidy resulting 
from reduced mitotic fidelity are observed in HPV-positive cervical cell lines and 
cervical cancers (Southern, et al., 2001). It has been hypothesized that such 
genomic instability may promote integration of the HPV genome (Kessis, et al., 
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1996). These events also mimic DNA damage and may activate DNA repair and 
recombination processes. 
 
 Recently, studies on cellular gene expression profiles have been greatly 
facilitated by the development of high-density cDNA and oligonucleotide 
microarrays (Schena, et al., 1996;Zhu, et al., 1998). A few microarray studies 
have been done to analyze the global gene expression patterns of epithelial cells 
infected with HPV, such as HPV-transfected human keratinocytes, HPV-positive 
cervical carcinoma cell lines, snap-frozen HPV-positive cervical tumor biopsies, 
and early stage primary HPV-positive cervical cell lines (Ahn, et al., 2004;Chang, 
et al., 2000;Chen, et al., 2003;Duffy, et al., 2003;Lee, et al., 2004;Santin, et al., 
2005). Due to the use of different types of microarray platforms and statistical 
analyses, there are considerable differences in the results of such studies. In the 
present study, we have used a high-density oligonucleotide microarray from 
Affymetrix (U133A) and two different types of statistical analyses to investigate 
the global gene expression profiles in HPV-16 as well as HPV-18 positive 
cervical cell lines containing either integrated or episomal forms of HPV DNA. 
Our results show dysregulation of genes involved in several cellular pathways 
such as cell cycle regulation, tumor suppression, cell adhesion, gene silencing by 
methylation and immune response that may play important roles in cervical 
carcinogenesis.   
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3.2 MATERIAL AND METHODS 
 
Cervical cell lines characteristics 
  
 Cervical cancer cell lines CaSki and SiHa (containing HPV-16) as well as 
HeLa (HPV-18) and C-33A (HPV-negative) have been previously described 
(Meissner, 1999). Three clonal populations of the HPV-16 cervical cell line W12 
(generated from a low-grade squamous intraepithelial lesion), 20863 (episomal 
HPV-16), 20861 and 201402 (integrated HPV-16) were obtained from the 
laboratories of Drs. Margaret Stanley and Paul Lambert (Medical Research 
Council, UK and University of Wisconsin, USA, respectively) (Jeon, et al., 
1995;Stanley, et al., 1989). The L-18 cell line containing episomal HPV-18 was 
created by transfecting normal human foreskin keratinocytes with recircularized 
HPV-18 DNA and was obtained from Dr. Laimonis A. Laimins (Northwestern 
University, USA) (Frattini, et al., 1997). The characteristics of various cell lines 
are described in Table 7. Cervical carcinoma cell lines were maintained in 
Dulbecco’s modified Eagle medium (SiHa, HeLa and C-33A) or RPMI 1640 
(CaSki) supplemented with 10% fetal bovine serum (FBS) at 37°C in the 
presence of 5% CO2. Cell lines 201402, 20863, 20861 and L-18 were maintained 
in E medium with 10% FBS in the presence of murine 3T3 J2 fibroblast feeder 
cells previously treated with mitomycin C (Stanley, et al., 1989). Before DNA or 
RNA isolation, fibroblast feeders were removed with versene (phosphate-
buffered saline with 0.5 mM EDTA, Gibco BRL). 
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 DNA extraction and Southern blot analysis of the physical state of HPV-16 and 
HPV-18 DNA 
 
DNA isolation from cell lines 20863 (episomal HPV-16) and L-18 
(episomal HPV-18) was performed by Hirt’s method to enrich extrachromosomal 
DNA (Hirt, 1967). This procedure was also used with the cell line 20861 
(integrated HPV-16) to maintain the same DNA extraction conditions. After DNA 
extraction, Southern blot analysis was performed as follows: 8 µg of DNA from 
each cell line was digested with a panel of restriction endonucleases (BglII, 
BamHI, NcoI, and KpnI for HPV-16 and BglII, EcoRV, NcoI and BamHI for HPV-
18), where the first enzyme does not cleave the HPV genome, the second 
enzyme cuts the DNA once and the third enzyme cuts the DNA twice. After 
electrophoresis through 0.7% agarose gels, the DNA was denatured and 
transferred to Gene Screen hybridization transfer membrane (PerkinElmer, 
Boston, MA). DNA was UV cross-linked to the membrane, and hybridization was 
performed at 68°C overnight using a 32P-labeled pUC19-HPV-16 or pUC19-HPV-
18 plasmid as the probe. After hybridization, membranes were washed and 
subjected to autoradiography at -70°C (Maniatis, et al., 1982).  
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TABLE 7     
Cell lines characteristics 
 
   
Cell line Source HPV 
genotype 
Genomic physical 
state 
Viral copy 
number 
CaSki Cervical 
carcinoma 
16 integrated in 
tandem repeats 
60-600 
SiHa Cervical 
carcinoma 
16 integrated 1-2 
201402 LG-SIL 16 integrated 5 
20863 LG-SIL 16 episomal 100 
20861 LG-SIL 16 integrated 30 
HeLa Cervical 
adenocarcinoma 
18 integrated 10-50 
L-18 transfected 
keratinocytes 
18 episomal 100-200 
C-33A Cervical 
carcinoma 
- - - 
LG-SIL, low-grade squamous intraepithelial lesion   
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RNA extraction    
 
Total RNA was isolated from monolayer cell cultures at approximately 
80% confluence using ULTRASPEC RNA isolation system (Biotecx Lab, Inc. 
Houston, TX) according to the manufacturer’s instructions. The RNA pellet was 
dried under a vacuum and resuspended in 30-50 µl of DEPC treated water.  
 
Northern blot analysis 
  
 Northern blot analysis was carried out to identify transcripts encoded by 
HPVs in various cell lines. Ten micrograms of total RNA was separated on 1.2% 
denaturing formaldehyde-agarose gels and the RNA transferred to a Gene 
Screen Hybridization Transfer Membrane (PerkinElmer, Boston, MA). RNA was 
cross-linked to the membrane using UV light and hybridized to 32P-labeled, PCR-
generated probes corresponding to the E2, E6 or E7 genes of HPV-16 or HPV-
18 as well as probes for the genes LAT1 and NAP1L3. Hybridization was carried 
out overnight at 42°C (Maniatis, et al., 1982). The membranes were subjected to 
autoradiography at -70°C. 
 
cRNA synthesis and microarray analysis 
 
Microarray analysis was carried out using the high-density oligonucleotide 
U133A GeneChip® expression microarray (Affymetrix, Santa Clara, CA) that 
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contains 22,215 transcript sets representing 14,820 human genes. RNA isolated 
from normal adult cervix from a pool of healthy women (Stratagene, La Jolla, CA) 
was used as a control in this study. For microarray analysis, total RNA isolated 
as described above was further purified by using the RNeasy Total RNA Isolation 
Kit (QIAGEN, Valencia, CA) to remove contaminating DNA.  This kit is based on 
a silica-gel column that specifically binds single-stranded RNA of more than 200 
nucleotides. Twenty micrograms of total RNA from each sample were used to 
generate double-stranded [ds] cDNA using the Superscript II Choice system 
(GIBCO-BRL, Rockville, MD). First-strand synthesis was carried out using a T7-
(dT)24 primer (Sigma-GenoSys, The Woodlands, TX) and Superscript II reverse 
transcriptase. This primer includes the promoter sequence for the T7 RNA 
polymerase.  The second-strand synthesis was performed using RNase H and 
DNA polymerase I. The resulting ds cDNA was used to synthesize cRNA using 
biotin-labeled ribonucleotides and T7 RNA polymerase utilizing the BioArray 
HighYield RNA transcript labeling kit (ENZO Life Sciences, Inc. Farmingdale, 
NY). The cRNA was fragmented to 35-200 bases length and hybridized to the 
Human Genome U133A GeneChip® expression microarray in the Affymetrix 
Hybridization Oven (Affymetrix, Santa Clara, CA). The GeneChips were washed, 
and then stained with streptavidin-phycoerythrin (SAPE) to generate fluorescent 
signals from biotin-labeled cRNA. The GeneChips were scanned using an 
Affymetrix GeneArray® scanner (Affymetrix, Santa Clara, CA). Each probed 
array was scanned twice to calculate an average of two images, define the probe 
cells and compute intensity for each cell.   
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 Microarray data analysis 
 
The .CEL image files obtained from the Affymetrix Microarray Suite 5.0 
were converted to .DCP files using the program dChip version 1.2 
(www.dchip.org). The dChip program was used to generate normalized and non-
normalized intensity signal data. Two different normalizations and statistical tests 
were used to analyze all the microarray data in order to identify differentially 
expressed genes that were robust enough to appear in both analysis: Non-
normalized intensity signal data from dChip were normalized (log-base2 
transformation, median within arrays, Global Mean Adjustment among arrays) 
and analyzed with a pooled variance t-Test at level alpha = 0.05 using the Gene 
Expression Data Analysis Tool (GEDA) program developed in the University of 
Pittsburgh (James Lyons-Weiler, University of Pittsburgh Cancer Institute, 
http://bioinformatics.upmc.edu) (Patel, et al., 2004). In the second analysis, 
normalized intensity signal data from dChip were used directly in the Significance 
Analysis of Microarray (SAM) program version 1.21 
(www.stat.stanford.edu/~tibs/SAM/) to identify differentially expressed genes. 
Genes with an expression ratio of at least 2-fold difference relative to the controls 
were considered differentially expressed in both analyses (in the SAM-Test for 
episomal versus integrated HPV-containing cell lines we used a 1.9-fold cut-off). 
After analyzing the data with the two statistical tests, we overlapped the lists of 
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differentially expressed genes in order to generate a list of differentially 
expressed genes that were expected to be more robust.  
  
Quantitative real-time RT-PCR analysis 
 
 We validated the microarray data by quantitative real-time RT-PCR (QRT-
PCR) analysis of a few representative genes using the QuantiTect SYBR Green 
one-step RT-PCR kit (QIAGEN, Valencia, CA).  Before cDNA synthesis, RNA 
was treated with amplification grade DNase I (Invitrogen, Rockville, MD) for 15 
min at room temperature to avoid DNA contamination. Approximately 400 ng of 
DNase I-treated total RNA from cell lines or the normal cervix was mixed with 25 
µl of 2 X QuantiTect SYBR Green RT-PCR Master Mix, 0.5 µM of specific 
forward and reverse primers and RNase-free water in a final volume of 50 µl. The 
amount of fluorescence emitted by SYBR Green I was quantified by the ABI 
Prism 7700 system software (Applied Biosystems, Foster City, CA). The 
following genes and primers were used in these studies:     
transcription factor AP-2 alpha (TFAP2A), forward primer: 5’- 
ATTTGGGACCACCTGGTATT -3’, reverse primer: 5’- 
TGATACATTGACAGGCATGG- 3’; carboxypeptidase A4 (CPA4), forward 
primer: 5’- CTTCCCTCCTCTTTGCCTTT -3’, reverse primer: 5’- 
CAGGATACCCCAGCACAAAT -3’; neurofilament, heavy polypeptide 200kDa 
(NEFH), forward primer: 5’-TGCCTTCTGTTTTCCAAAGG-3’, reverse primer: 5’- 
TGAACTCCAGTGGAAAGTGC-3’; solute carrier family 7 member 5 (LAT1), 
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forward primer: 5’-ACCCACCACAACAAGCAAGT-3’, reverse primer: 5’- 
CTGAGCATGACCACTGGAAA-3’;  sprouty homolog 1, antagonist of FGF 
signaling (SPRY1), forward primer: 5’- GACCTTGCCCATCTTCACTC-3’, reverse 
primer: 5’-ATCCAAGTGCCCTCAATGAC-3’; inhibitor of DNA binding 4, 
dominant negative helix-loop helix protein (ID4), forward primer: 5’-
TGCTTGCTACCAAAGGACAA-3’, reverse primer: 5’- 
ATCCCTGCTTGAAGGATTTG-3’; immunoglobulin superfamily, member 4 
(IGSF4), forward primer: 5’- AGCAGACGCAGACACAGCTA -3’, reverse primer: 
5’- TGGACACCTCATTGAAACAAA -3’; nucleosome assembly protein 1-like 3 
(NAP1L3), forward primer: 5’- TTCCAGCCCATAAGACTAAGG -3’, reverse 
primer: 5’- TTTCAAGCAGTCAAACTTCAAAA -3’; The following RT-PCR cycle 
parameters were used: reverse transcription at 50°C for 30 min, hot-start DNA 
polymerase activation 95°C for 15 min, 40 cycles of denaturation at 94°C for 15 
sec each, annealing at 58°C for 30 sec and extension at 72°C for 30 sec. Each 
reaction was run in triplicate in a 96-well plate. Relative expression of the target 
gene was calculated using the 2 delta CT method described previously:(Relative 
expression = 2-∆CT; where ∆CT = CT (Target gene) – CT (endogenous control gene)) where 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the 
endogenous control gene (Livak, et al., 2001). 
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In situ hybridization using tissue arrays 
 
 We detected the expression of NAP1L3 and LAT1 by in situ hybridization 
in tissue-arrays containing ~50 different cervical tumor samples and 4 normal 
cervix controls per slide (4 mm x 1 mm diameter, 4 µm thick per spot) 
(IMGENEX, Cat #: IMH-368). Individual information for all the tissue samples in 
the arrays is available on the web page: 
http://www.imgenex.com/tissue_array_tds.php?id=929. Briefly, we dewaxed the 
paraffin with xylene three times, 10 min each. Slides were hydrated sequentially 
in 100%, 95%, 80%, 70%, and 60% ethanol and water unitl the sections were 
clear. Tissue-arrays were then permeabilized with 0.2 M HCl for 20 min at RT, 
followed by 0.3% triton X-100 in PBS for 15 min at RT and 17 µg/ml proteinase K 
in 0.1 MTris, pH 7.5, and 50 mM ethylenediaminetetraacetic acid (EDTA) for 30 
min at 37°C. Tissues were rinsed in 0.2% glycine, pH 7.5, at RT and postfixed 
with 4% paraformaldehyde for 5 min and rinsed with 1X PBS. To decrease 
nonspecific background, sections were acetylated with 0.25% acetic anhydride in 
0.1 M triethanolamine for 10 min. Tissues were prehybridized in 50% deionized 
formamide, 2 X SSC, 10% dextran sulfate, 250 µg/ml herring sperm DNA, and 
0.5% sodium dodecyl sulfate (SDS) for 2 hr at 37°C (using a coverslip to reduce 
evaporation) and hybridized in the same solution with ~2 ng/ml of biotinylated 
probe overnight. The following day, slides were immersed in 4X SSC and 
coverslip removed. Tissue-arrays were washed twice at RT in 2X SSC for 15 min 
each, followed by a quick rinse with ELF mRNA Wash Buffer (ELF® 97 mRNA In 
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Situ Hybridization kit # 2, Cat # E-6605, Molecular Probes, Inc.). Blocking was 
done with ELF-97 mRNA Blocking Buffer for 30 min, followed by incubation with 
10 µg/ml streptavidin-alkaline phosphatase in the same buffer for 15 min at RT. 
Samples were washed with ELF-97 mRNA Wash Buffer, equilibrated in ELF-97 
mRNA Developing Buffer for 5 min, and incubated with 1:10 dilution of ELF-97 
substrate with a 1:1000 dilution of substrate additives 1 and 2. The probes for 
LAT1 and NAP1L3 were single-stranded oligonucleotides (Reverse primers from 
the QRT-PCR method) labeled at the 3’-end with biotin-ddUTP according to the 
manufacturer’s instructions (DIG Oligonucleotide 3’-End Labeling Kit (Cat # 
3353575, Roche Applied Science). 
 
3.3 RESULTS 
 
Southern blot analysis of the physical state of HPV-16 and HPV-18 DNA 
 
 Prior to carrying out microarray analysis, we confirmed the physical state 
of the HPV DNA in various cell lines by Southern blot analysis.  In Fig. 10, 
predictable bands of ~7.9 kb representing linearized full length episomes were 
obtained using HPV-16 single cutter restriction enzymes BamHI or NcoI and 
HPV-18 single cutters EcoRV or NcoI in the episomal 20863 (passage 35) and L-
18 (passage 17) cell lines, respectively. Digestion of DNA from the 20861 cell 
line (passage 16) with the same single cutter enzymes showed different sized 
bands, consistent with this cell line containing integrated HPV DNA. Similarly, 
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HPV-16 and HPV-18 double cutters KpnI and BamHI generated two predicted 
bands in 20863 and L-18 cell lines, but not in the integrated cell line 20861. The 
HPV-16 and HPV-18 noncutter BglII enzyme showed two bands in the episomal 
cell lines, corresponding to the supercoiled and open-circular forms of the DNA 
(Fig. 10).  By Southern blot analysis, we also confirmed that the HPV DNA in 
CaSki, SiHa and HeLa cell lines was integrated (not shown).  
 
Expression of the HPV-16 and HPV-18 early genes in various cell lines 
 
 Northern blot analysis was carried out to confirm the expression of HPV 
early transcripts in all the cell lines and the control cervical sample. As expected 
and consistent with previous data, the E6 and E7 viral oncogene transcripts (with 
different splicing variants) were present in all the cell lines containing integrated 
HPV sequences but not in the HPV-negative cell line C-33A or the normal cervix 
(Fig. 11) (Baker, et al., 1987). Interestingly, the 20863 and L-18 cell lines that 
contain episomal HPV DNAs also expressed significant levels of the E6 and E7 
transcripts (Fig. 11). E2 transcripts were present in cell lines 20863 and L-18 
containing episomal HPVs DNA as well as in the HPV-16 head to tail tandem 
integrated cell line, CaSki (Fig. 11). Interestingly, we found robust levels of a 
larger than expected E2 transcript in the 20861 cell line containing integrated 
HPV-16 DNA (Fig. 11). This larger E2 transcript presumably results from the 
disruption of the E2 gene and its fusion to a cellular transcript.  As expected, the 
SiHa, 201402 and HeLa cell lines in which the E2 gene is disrupted did not show  
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Fig. 10. PHYSICAL STATE OF HPV DNA IN CELL LINES 
 
 
 
Physical state of HPV DNA in cell lines, as determined by Southern blot analysis. 
Uncut and cut DNAs from a 7.9 kb plasmid were used as size markers. SC, 
supercoiled DNA; OC, open-circular DNA. 
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any E2 transcript (Fig. 11). The above results confirmed the appropriate 
expression of the HPV early genes in various cell lines, and RNA isolated from 
these cell lines was used for microarray analysis of cellular gene expression 
profiles.   
 
Microarray analysis of genes differentially expressed in HPV-positive cell lines 
compared to the normal cervix  
 
 In order to identify differentially expressed genes in HPV-16 positive 
(CaSki, SiHa, 201402, 20861, and 20863) and HPV-18 (HeLa and L-18) cervical 
cell lines compared to the normal cervix tissue, we used the Affymetrix 
oligonucleotide U133A GeneChip® that contains 22,215 transcript sets that 
represent 14,820 human genes. Normalization and differential gene expression 
analyses were carried out as described in material and methods. The microarray 
experiments were performed in duplicate (with the exception of the 20861 cell 
line) and only genes whose expression level was increased or decreased by 
more than 2-fold were selected. A total of 2,315 and 1,908 genes showed up- 
and down-regulation, respectively, using the pooled variance t-Test analysis 
when all the HPV-positive cervical cell lines were compared to the normal cervix 
(supplementary data, Table L). On the other hand, 544 and 1,634 genes were 
found to be up- and down-regulated, respectively, using the SAM-Test analysis 
(supplementary data, Table M). When the results of the above two statistical  
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Fig. 11. NORTHERN BLOT ANALYSIS OF THE HPV E6, 
E7 AND E2 GENES IN HPV-POSITIVE CELL LINES 
 
 
 
Hybridization probes are indicated on the far left. The gene glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) was used as the endogenous control gene. 
Approximate sizes of the various bands are shown on the right. 
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tests were overlapped, 272 genes were found to be upregulated and 605 
downregulated in HPV-positive cervical cell lines as compared to the normal 
cervix (Fig. 12). A representative list of differentially expressed genes is shown in 
Table 8 (a complete list of genes is shown in the supplementary data, Table N). 
Our analysis identified genes belonging to various cellular pathways such as cell 
cycle, DNA replication, repair and recombination, signal transduction, regulation 
of transcription, cell adhesion and immune response whose expression was 
altered in HPV-positive cells. Our experiments also identified several genes that 
were previously implicated in carcinogenesis in different tissues but not in 
cervical cancer (Table 8) (Imai, et al., 2005;Walter, et al., 2003). Some genes 
upregulated in HPV-positive cell lines were aurora kinase B (AURKB), flap 
structure-specific endonuclease 1 (FEN1), member of RAS oncogene family 
RAB32 (RAB32), carboxypeptidase A4 (CPA4), 8-oxoguanine DNA glycosylase 
(OGG1) and Rab9 effector p40 (RAB9P40), while the downregulated genes 
included claudin 10 (CLDN10), Cullin 5 (CUL5), inhibitor of DNA binding 4, 
dominant negative helix-loop-helix protein (ID4), deleted in malignant brain 
tumors 1 (DMBT1), methyl-CpG binding domain protein 4 (MBD4) and nidogen 
(NID) (Table 8). Our results also identified several differentially expressed genes 
that were also found in previous studies, suggesting a concordance and 
validation of our results. Some such upregulated genes included cyclin B1 
(CCNB1), cyclin-dependent kinase inhibitor 2A (CDKN2A), minichromosome 
maintenance deficient 7 (MCM7), transcription factor AP-2 alpha (TFAP2A),  
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Fig. 12. Venn diagram showing the number of 
differentially expressed genes that overlap between the 
two statistical analyses (pooled t-test and SAM-test) of 
the microarray data. 
 
 
 
 
 
The two principal sets indicate differentially expressed genes between all HPV-
positive cell lines and either normal cervix tissue or the HPV-negative cell line C-
33A. The overlap region shows the number of differentially expressed genes in all 
HPV-positive cell lines as compared to both the controls.   
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while the list of downregulated genes included immunoglobulin superfamily, 
member 4 (IGSF4), fibronectin (FN1), and interferon alpha-inducible protein 27 
(IFI27) (Table 8) (Beger, et al., 2001;Li, et al., 2005;Santin, et al., 
2005;Steenbergen, et al., 2004;Tan, et al., 2003). 
 
Differential gene expression profiles in HPV-positive cell lines compared to the 
HPV-negative cell line C-33A 
 
 We compared the gene expression profiles of all HPV-positive cervical cell 
lines with that of the HPV-negative cell line C-33A in order to identify cellular 
genes whose expression may be specifically altered due to the presence of HPV 
DNA (and not due to cellular immortalization). Using the pooled variance t-Test 
analysis, we found that 900 genes were upregulated 33A (supplementary data, 
Table O). and 1,342 downregulated in HPV-positive cell lines as compared to C-
The SAM test identified 641 upregulated and 561 downregulated genes in the 
HPV-positive cell lines (supplementary data, Table P). A comparison of the 
differentially expressed genes revealed that 305 upregulated and 232 
downregulated genes were common in t-Test and SAM analyses (supplementary 
data, Table Q). A representative list of such genes is shown in Table 9. Example 
of novel genes found to be differentially expressed in HPV-positive cervical cell 
lines compared to the HPV-negative cervical cell line C-33A as a control are: 
genes involved in metastasis (actinin, alpha 4 [ACTN4]), antiestrogen resistance  
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Table 8. DIFFERENTIALLY EXPRESSED GENES IN HPV-
POSITIVE CELL LINES COMPARED TO THE NORMAL CERVIX 
 
Gene Title Gene 
Symbol 
pooled 
t-Test 
SAM-
Test 
Upregulated genes    
Apoptosis    
     baculoviral IAP repeat-containing 5 (survivin) BIRC5 6.33 3.38 
     BCL2-antagonist of cell death BAD 2.43 2.12 
Cell cycle    
     aurora kinase B AURKB 6.51 3.84 
     cyclin B1 CCNB1 5.88 4.52 
     cyclin-dependent kinase inhibitor 2A CDKN2A 3.95 2.02 
     DNA replication factor CDT1 4.24 5.30 
     MCM7 MCM7 4.36 2.64 
Cell proliferation    
     MAD1 mitotic arrest deficient-like 1 (yeast) MAD1L1 2.50 2.15 
     SHC (Src homology 2 domain containing) 
     transforming protein 1 
SHC1 3.55 2.27 
     ubiquitin-conjugating enzyme E2C UBE2C 4.68 2.40 
     WD40 protein Ciao1 CIAO1 3.60 2.32 
Cell transport    
     adaptor-related protein complex 1, sigma 1 subunit AP1S1 4.38 2.08 
     metaxin 1 MTX1 3.42 2.26 
     Rab9 effector p40 RAB9P40 2.49 2.11 
Development and cell differentiation    
     pescadillo homolog 1, containing BRCT domain 
     (zebrafish) 
PES1 3.10 2.32 
DNA repair    
     8-oxoguanine DNA glycosylase OGG1 2.31 2.04 
     CHK1 checkpoint homolog (S. pombe) CHEK1 3.46 2.56 
     flap structure-specific endonuclease 1 FEN1 5.32 3.27 
     H2A histone family, member X H2AFX 3.76 2.33 
Nuclear organization and biogenesis    
     carboxypeptidase A4 CPA4 2.92 3.14 
Regulation of transcription    
     Cbp/p300-interacting transactivator CITED2 3.30 2.50 
     cofactor of BRCA1 COBRA1 3.90 2.17 
     transcription factor AP-2 alpha TFAP2A 4.30 2.86 
Signal transduction    
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     HMT1 hnRNP methyltransferase-like 2 HRMT1L2 4.71 2.24 
     RAB32, member RAS oncogene family RAB32 3.89 2.43 
     Ran GTPase activating protein 1 RANGAP1 5.93 2.53 
     v-Ha-ras HRAS 2.62 2.67 
Structural function    
     neurofilament, heavy polypeptide 200kDa NEFH 4.47 12.72 
     tubulin beta MGC4083 MGC4083 4.05 2.46 
     ZW10 interactor ZWINT 3.52 2.08 
Downregulated genes    
Cell adhesion    
     claudin 10 CLDN10 -15.61 0.175 
     fibronectin 1 FN1 -5.31 0.467 
     mucin 4, tracheobronchial MUC4 -7.78 0.273 
     nidogen (entactin) NID -3.99 0.097 
Cell cycle    
     cullin 5 CUL5 -2.14 0.479 
     cylindromatosis (turban tumor syndrome) CYLD -4.09 0.484 
     microtubule-actin crosslinking factor 1 MACF1 -5.15 0.444 
     p300/CBP-associated factor PCAF -3.03 0.383 
     Wilms tumor 1 WT1 -3.06 0.220 
Cell differentation    
     collagen, type I, alpha 1 COL1A1 -7.51 0.066 
     deleted in malignant brain tumors 1 DMBT1 -7.86 0.261 
     mal, T-cell differentiation protein MAL -7.38 0.101 
     Notch homolog 2 (Drosophila) NOTCH2 -2.32 0.385 
DNA repair    
     methyl-CpG binding domain protein 4 MBD4 -2.18 0.426 
     mutS homolog 3 (E. coli) MSH3 -3.35 0.300 
     REV3-like, catalytic subunit of DNA polymerase 
     zeta (yeast) 
REV3L -3.27 0.250 
Immune response    
     immunoglobulin superfamily, member 4 IGSF4 -9.16 0.410 
     interferon, alpha-inducible protein 27 IFI27 -4.21 0.076 
     interleukin 1 receptor, type II IL1R2 -4.46 0.392 
     major histocompatibility complex, class II, DQ beta 1 HLA-
DQB1 
-6.26 0.149 
Protein modification    
     cathepsin B CTSB -2.95 0.479 
     P21 (CDKN1A)-activated kinase 3 PAK3 -2.96 0.363 
Regulation of transcription    
     activating transcription factor 7 interacting protein ATF7IP -2.89 0.429 
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     Inhibitor of DNA binding 4 ID4 -3.94 0.122 
     SWI/SNF related, matrix associated, actin 
     dependent regulator of chromatin, subfamily a, 
     member 2 
SMARCA2 -3.44 0.392 
     zinc finger protein 198 ZNF198 -2.83 0.353 
RNA binding    
     Dicer1, Dcr-1 homolog (Drosophila) DICER1 -3.17 0.307 
     splicing factor, arginine/serine-rich 7, 35kDa SFRS7 -2.45 0.377 
     zinc finger protein 638 ZNF638 -2.60 0.443 
Structural function    
     SMC5 structural maintenance of chromosomes 5 
     like 1 (yeast) 
SMC5L1 -2.38 0.411 
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(breast cancer anti-estrogen resistance 3 [BCAR3]), mitogenic signaling 
(caveolin 1 [CAV1], caveolin 2 [CAV2]), angiogenesis (endothelial PAS domain 
protein 1 [EPAS1]) and double-strand DNA break repair via nonhomologous end-
joining (MRE11, meiotic recombination 11 homolog A [MRE11A]). 
 
 Down-regulated genes found in these analyses were those involved in 
transcriptional regulation (CBP/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 [CITED2]), apoptosis (DNA fragmentation factor, 
40kDa, beta polypeptide [DFFB]), cellular morphogenesis (myosin, heavy 
polypeptide 10, non-muscle [MYH10]), centrosome formation (pericentriolar 
material 1 [PCM1]) and mismatch repair (postmeiotic segregation increased 1 
[PMS1]) (Table 9). 
 
Genes differentially expressed in HPV-positive cell lines compared to both C-33A 
cells and the normal cervix 
 
 Results described above identified genes that are differentially expressed 
in HPV-positive cell lines as compared to the normal cervix or the HPV-negative 
cell line C-33A utilizing two different statistical analyses. To identify cellular 
genes whose expression might be specifically altered due to the presence of 
HPV sequences, we compared the data obtained for HPV-positive cell lines with 
those of both the normal cervix and the C-33A cell line.  This analysis revealed 
that a total of 20 genes were upregulated and 37 downregulated in the HPV-  
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Table 9. DIFFERENTIALLY EXPRESSED GENES IN HPV-
POSITIVE CELL LINES COMPARED TO HPV-NEGATIVE C-33A 
Gene Title Gene 
Symbol 
pooled 
t-Test 
SAM-
Test 
Upregulated genes    
Apoptosis    
     lectin, galactoside-binding, soluble, 1 (galectin 1) LGALS1 8.908 9.67513 
Cell adhesion    
     laminin, beta 1 LAMB1 4.694 6.82606 
     tenascin C (hexabrachion) TNC 2.728 3.08323 
Cell cycle    
     breast cancer anti-estrogen resistance 3 BCAR3 4.631 3.37527 
     cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 6.212 10.70517
     polo-like kinase 2 (Drosophila) PLK2 7.372 20.19033
Cell proliferation and angiogenesis    
     endothelial PAS domain protein 1 EPAS1 9.146 15.6005 
     insulin-like growth factor binding protein 7 IGFBP7 10.765 10.3496 
     jagged 2 JAG2 3.195 3.39671 
     S100 calcium binding protein A11 (calgizzarin) S100A11 15.295 54.11594
Development and cell differentiation    
     mesoderm specific transcript homolog (mouse) MEST 8.928 14.46237
DNA repair    
     growth arrest and DNA-damage-inducible, beta GADD45B 5.008 3.73185 
     MRE11 meiotic recombination 11 homolog A (S. 
     cerevisiae) 
MRE11A 2.119 2.43135 
Immune response    
     interferon, gamma-inducible protein 30 IFI30 5.345 3.23202 
     major histocompatibility complex, class I, E HLA-E 2.023 2.0984 
Nuclear organization and biogenesis    
     carboxypeptidase A4 CPA4 2.839 3.27686 
     neurofilament, heavy polypeptide 200kDa NEFH 2.078 3.29482 
Regulation of transcription    
     CCAAT/enhancer binding protein (C/EBP), beta CEBPB 3.737 2.44182 
     HIV-1 Tat interactive protein 2, 30kDa HTATIP2 10.801 3.63548 
     v-fos FBJ murine osteosarcoma viral oncogene 
     homolog 
FOS 3.409 3.11517 
     v-jun sarcoma virus 17 oncogene homolog (avian) JUN 2.313 2.15402 
Signal transduction    
     mitogen-activated protein kinase kinase kinase 5 MAP3K5 3.399 2.30119 
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     plasminogen activator, urokinase receptor PLAUR 2.312 3.59171 
Structural function    
     actinin, alpha 4 ACTN4 3.032 2.69455 
     caveolin 1, caveolae protein, 22kDa CAV1 5.406 16.81007
     caveolin 2 CAV2 7.068 12.5958 
     CDC42 effector protein (Rho GTPase binding) 4 CDC42EP4 7.203 2.68908 
Transport    
     aquaporin 3 AQP3 2.675 17.36881
     Ras and Rab interactor 2 RIN2 5.538 15.32698
     Sortilin-related receptor, L(DLR class) A repeats 
     containing 
SORL1 3.558 5.30152 
 
    
Downregulated genes    
Apoptosis    
     BCL2/adenovirus E1B 19kDa interacting protein 3 BNIP3 -2.31 0.47945 
     caspase 2, apoptosis-related cysteine protease CASP2 -2.896 0.41099 
     DNA fragmentation factor, 40kDa, beta 
     polypeptide (caspase-activated DNase) 
DFFB -3.427 0.46688 
     programmed cell death 8 (apoptosis-inducing 
     factor) 
PDCD8 -6.32 0.27251 
Cell cycle   
     cell division cycle 34 CDC34 -4.917 0.44664 
     cyclin-dependent kinase 5 CDK5 -3.499 0.49566 
Development and cell differentiation    
     homeo box B2 HOXB2 -4.604 0.23615 
     homeo box C6 HOXC6 -3.214 0.35205 
     myosin, heavy polypeptide 10, non-muscle MYH10 -2.339 0.39779 
     tumor protein D52 TPD52 -2.826 0.43865 
DNA repair    
     RuvB-like 2 (E. coli) RUVBL2 -2.692 0.44269 
     RAD51 homolog C (S. cerevisiae) RAD51C -2.333 0.45786 
     RAD51-like 1 (S. cerevisiae) RAD51L1 -8.702 0.32049 
     postmeiotic segregation increased 1 (S. cerevisiae) PMS1 -2.701 0.48804 
Immune response    
     regulatory factor X-associated ankyrin-containing 
     protein 
RFXANK -2.829 0.4833 
     G antigens 8, 4, 5, 7, 2, 6, 7B GAGE -2.759 0.44522 
     transcription factor 8 (represses interleukin 2 
     expression) 
TCF8 -4.298 0.30337 
Metabolism    
     aldehyde dehydrogenase 7 family, member A1 ALDH7A1 -2.848 0.22177 
Nuclear organization and biogenesis    
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     chromobox homolog 1 (HP1 beta homolog 
     Drosophila) 
CBX1 -2.387 0.48223 
     HMT1 hnRNP methyltransferase-like 2 (S. 
     cerevisiae) 
HRMT1L2 -3.007 0.46137 
     nucleosome assembly protein 1 like 3 NAP1L3 -6.355 0.40808 
Regulation of transcription    
     Cbp/p300-interacting transactivator, with Glu/Asp 
     rich carboxy-terminal domain, 2 
CITED2 -5.39 0.26298 
     chromobox homolog 6 CBX6 -3.153 0.42101 
     nuclear receptor subfamily 2, group F, member 1 NR2F1 -2.843 0.39402 
     pericentriolar material 1 PCM1 -3.163 0.41163 
     TAF12 RNA polymerase II, TATA box binding 
     protein (TBP)-associated factor, 20kDa 
TAF12 -6.651 0.47371 
Signal transduction    
     gap junction protein, alpha 1, 43kDa (connexin 
     43) 
GJA1 -2.278 0.14202 
     sprouty homolog 1, antagonist of FGF signaling 
     (Drosophila) 
SPRY1 -13.228 0.13179 
Transport    
     ATPase, H+ transporting, lysosomal 14kDa, V1 
     subunit F 
ATP6V1F -2.619 0.48982 
     heat shock 60kDa protein 1 (chaperonin) HSPD1 -2.043 0.46505 
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Table 10. DIFFERENTIALLY EXPRESSED GENES IN HPV-
POSITIVE CELL LINES COMPARED TO BOTH THE NORMAL 
CERVIX AND C-33A  
Gene Title Gene 
Symbol 
pooled 
t-Test 
normal 
cervix 
SAM-
Test 
normal 
cervix 
pooled 
t-Test 
C-33A 
SAM-
Test C-
33A 
Upregulated genes      
Apoptosis    
     serine/threonine kinase 17a 
     (apoptosis-inducing) 
STK17A 2.797 2.5915 3.341 3.45054
Cell cycle      
     breast cancer anti-estrogen 
     resistance 3 
BCAR3 3.5 2.44826 4.631 3.37527
Development and cell 
differentiation 
     
     neurofilament, heavy polypeptide 
     200kDa 
NEFH 4.474 12.72799 2.078 3.29482
     transcription factor AP-2 alpha TFAP2A 4.302 2.86491 7.049 8.32077
     tuftelin 1 TUFT1 2.817 2.39515 3.642 3.3442 
Functionally unclassified genes      
     DNA-damage-inducible transcript 
     4 (RTP801, REDD1)  
DDIT4 2.952 3.27046 2.909 4.15816
     kinesin family member C3 KIFC3 3.653 2.08519 5.539 3.21941
Immune response      
     prostaglandin E synthase PTGES 2.79 3.68109 4.031 7.93537
     protein C receptor, endotelial 
     (EPCR) 
PROCR 2.735 4.11815 5.63 15.0201
Ion binding      
     metallothionein 1G MT1G 2.715 2.00639 2.639 2.89159
     metallothionein 1H MT1H 2.515 2.33668 4.368 7.2314 
     metallothionein 1X MT1X 2.546 2.30442 3.022 4.0148 
Nuclear organization and 
biogenesis 
     
     carboxypeptidase A4 CPA4 2.924 3.14366 2.839 3.27686
     fascin homolog 1, actin-bundling 
     protein 
FSCN1 5.105 2.45535 4.055 2.48198
Signal transduction      
     dual specificity phosphatase 2 DUSP2 4.471 2.42672 5.089 2.94673
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     (PAC1) 
     RAB32, member RAS oncogene 
     family 
RAB32 3.896 2.43675 5.047 3.47442
Transport      
     solute carrier family 7 (LAT1), 
     member 5 
SLC7A5 7.454 6.68393 4.837 3.26239
      
Downregulated genes      
Cell adhesion      
     junctional adhesion molecule 3 JAM3 -4.777 0.19145 -
25.731 
0.13795
     multimerin 1 MMRN1 -3.545 0.21082 -
11.016 
0.06491
     nidogen (enactin) NID -5.643 0.48854 -2.369 0.30813
     slit homolog 2 (Drosophila) SLIT2 -3.182 0.49024 -9.427 0.30273
     syndecan 2 SDC2 -3.394 0.15779 -2.78 0.31783
Cellular defense against toxic 
compounds 
     
     glutathione S-transferase A4 GSTA4 -2.358 0.45777 -7.943 0.22224
Development and cell 
differentiation 
    
     homeo box B2 HOXB2 -2.548 0.40722 -4.604 0.23615
     inhibitor of DNA binding 2, 
     dominant negative helix-loop 
     helix protein 
ID2 -2.031 0.40894 -4.729 0.18137
     sprouty homolog 1, antagonist of 
     FGF signaling (Drosophila) 
SPRY1 -7.766 0.32769 -
13.228 
0.13179
     suppressor of cytokine signaling 2 SOCS2 -2.01 0.32378 -2.355 0.46024
Electron transport      
     aldehyde dehydrogenase 1 family, 
     member A1 
ALDH1A1 -5.032 0.11719 -5.089 0.14196
Functionally unclassified genes      
     annexin A6 ANXA6 -2.102 0.41035 -2.475 0.43148
Nuclear organization and 
biogenesis 
     
     B lymphoma Mo-MLV insertion 
     region (mouse) 
BMI1 -2.196 0.39872 -3.819 0.26948
     nucleosome assembly protein 1 
     like 3 
NAP1L3 -4.614 0.18303 -6.355 0.40808
Nucleotide biosynthesis      
     Ectonucleotide pyrophosphatase 4 ENPP4 -9.869 0.22956 -6.935 0.18048
Protein modification, catabolism 
and translation 
     
     matrix metalloproteinase 1 MMP1 -3.316 0.29692 -3.082 0.37765
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     (interstitial collagenase) 
     matrix metalloproteinase 10 
     (stromelysin 2) 
MMP10 -4.233 0.38217 -4.77 0.37865
Regulation of transcription      
     inhibitor of DNA binding 4, 
     dominant negative helix-loop 
     helix protein 
ID4 -3.943 0.12224 -8.888 0.07752
     zinc finger protein 91 (HPF7, 
     HTF10) 
ZNF91 -7.163 0.41156 -5.224 0.48333
RNA binding      
     CUG triplet repeat, RNA binding 
     protein 2 
CUGBP2 -3.745 0.30752 -7.223 0.10279
     decapping enzyme hDcp2 DCP2 -2.115 0.46469 -2.104 0.43709
Structural function      
     Microtubule-associated protein 
     1B 
MAP1B -2.51 0.20551 -3.547 0.19213
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positive cell lines as compared to both the normal cervix and C-33A (Fig.12 and 
Table 10).  Upregulated genes included those involved in cell stress by DNA 
damage (DNA-damage-inducible transcript 4 [DDIT4]), amino acid transporter 
involved in tumor progression (solute carrier family 7, member 5 
[SLC7A5/LAT1]), immune response (prostaglandin E synthase [PTGES]) and 
development (tuftelin 1 [TUFT1]). Genes involved in development (homeo box B2 
[HOXB2]), growth factor regulation and development (sprouty homolog 1, 
antagonist of FGF [SPRY1]), and cell adhesion (junctional adhesion molecule 3 
[JAM3]) were found to be downregulated (Table 10). 
 
Gene expression analysis in cell lines containing integrated versus episomal 
HPV DNA 
 
 Since the integration of HPV DNA into the cellular genome is usually 
associated with the progression of HPV-associated disease, we also analyzed 
gene expression differences between cell lines containing integrated or episomal 
HPV DNA. Due to the paucity of cell lines containing episomal HPV DNA, we 
grouped the 20863 and L-18 cell lines containing episomal HPV 16 and 18 DNA, 
respectively, into a single group.  Similarly, cell lines containing integrated HPV 
16 and 18 DNAs were grouped together.  A total of 411 and 805 genes were 
found to be up- and down-regulated, respectively, using the pooled variance t-
Test analysis in cell lines containing integrated HPV DNA (CaSki, SiHa, 201402, 
20861 and HeLa) compared to cell lines containing episomal HPV (20863 and L-
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18) (supplementary data, Table R). Also, 309 and 172 genes were up- and down-
regulated, respectively, using the SAM-Test analysis (supplementary data, Table 
S). When the differentially expressed genes from both the analyses were 
compared, 52 and 47 genes showed up- and down-regulation, respectively, in 
cell lines with integrated HPV DNA (Table 11). The upregulated genes included 
those involved in regulation of mitosis (centromere protein F, 350/400ka (mitosin) 
[CENPF]), cell growth and anti-adhesion (podocalyxin-like [PODXL]) and 
chromosome organization (SMC4 structural maintenance of chromosomes 4-like 
1 [SMC4L1]). Genes downregulated in cell lines containing integrated HPV DNA 
included those involved in defense response (GATA binding protein 3 [GATA3]), 
maintenance of chromatin architecture (high mobility group AT-hook 2 [HMGA2]) 
and epidermis development (laminin, gamma 2 [LAMC2]). Two upregulated 
genes identified in our study have previously been reported by Alazawi et al 
(Alazawi, et al., 2002). comparing the episomal HPV cell line 20863 and its 
subsequent passages lacking feeder cells (which is expected to result in HPV 
DNA integration). These genes are involved in vesicle coat assembly (bone 
marrow stromal cell antigen 2 [BST2]) and DNA topological changes 
(topoisomerase (DNA) II alpha 170kDa [TOP2A]) (Table 11). 
 
Gene expression analysis in HPV-18 containing cell lines compared to those 
containing HPV-16 
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 We also analyzed gene expression differences between cell lines 
containing HPV-16 and HPV-18 DNA. All HPV-16 positive cell lines (CaSki, SiHa, 
201402, 20863 and 20861) containing either integrated or episomal viral DNA 
were grouped together. Similarly, HeLa and L-18 cell lines containing HPV-18 
DNA were also grouped. A total of 443 and 330 genes showed up- and down-
regulation, respectively, in HPV-18 cell lines compared to HPV-16 cell lines using 
the pooled variance t-Test analysis (supplementary data, Table T). On the other 
hand, 80 and 3 genes showed up- and down-regulation, respectively, in HPV-18 
cell lines using the SAM-Test analysis (supplementary data, table U). When the 
genes identified by the two different statistical methods were compared, 36 
upregulated and 3 downregulated genes were found to be common (Table 12). 
Some of the up-regulated genes in HPV-18 positive cell lines included those  
involved in cytoskeleton organization (keratin 8 [KRT8], keratin 18 [KRT18]), cell 
adhesion (mesothelin [MSLN]), migration and proliferation (vimentin [VIM]) and 
calcium ion binding (S100 calcium binding protein A4 [S100A4]). Genes involved 
in cell differentiation (N-myc downstream regulated gene 1 [NDRG1]) and 
regulation of transcription (transcription factor AP-2 gamma [TFAP2C]) were 
found to be downregulated in HPV-18 containing cells compared to the HPV-16 
positive cell lines (Table 12). 
 
Validation of microarray data by Real time Quantitative RT-PCR and Northern 
blot analyses 
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 We carried out QRT-PCR analysis to study the expression of a few 
representative genes in order to validate the differential gene expression profiles 
obtained by microarray analysis. Four upregulated genes (transcription factor 
AP-2 alpha [TFAP2A], carboxypeptidase A4 [CPA4], neurofilament, heavy 
polypeptide 200kDa [NEFH], and solute carrier family 7 member 5 [LAT1]), and 
four downregulated genes (sprouty homolog 1, antagonist of FGF signaling 
[SPRY1], inhibitor of DNA binding 4, dominant negative helix-loop helix protein 
[ID4], immunoglobulin superfamily, member 4 [IGSF4], and nucleosome 
assembly protein 1-like 3 [NAP1L3]) were selected for validation (genes 
differentially expressed between HPV-positive cell lines compared to normal 
cervix or C-33A) (Fig. 13). These data showed that the results of QRT-PCR data 
were consistent with those of microarray analysis, although there were variations 
in the fold-difference determined by the microarray and QRT-PCR analysis. We 
also use northen blot analysis for one upregulated gene (LAT1) and one 
downregulated gene (NAP1L3) in order to confirmed the results obtained by the 
QRT-PCR. In the northern blot of fig. 13, we found high expression of LAT1 in all 
the HPV-positive cervical cell line and less expression in the HPV-negative cell 
line C-33A as well as no detectable expression of LAT1 in normal cervical tissue. 
In contrast, the northern blot for NAP1L3 shows no detectable expression in all 
the HPV-positive cell lines, a very faint band in C-33A and a detectable 
expression in normal cervical tissue (Fig. 13). Together, our QRT-PCR data and 
northern blot verified some of the differentially expressed genes found in our 
microarray experiments. 
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Table 11. DIFFERENTIALLY EXPRESSED GENES IN HPV-
INTEGRATED COMPARED TO HPV-EPISOMAL CELL LINES 
Gene Title Gene 
Symbol 
pooled t-
Test 
SAM-
Test 
Upregulated genes    
Cell cycle    
     activator of S phase kinase ASK 2.986 2.05485 
     cyclin-dependent kinase inhibitor 3 CDKN3 2.135 2.60898 
Cell proliferation    
     aldo-keto reductase family 1, member C3 AKR1C3 2.442 3.80378 
     bone marrow stromal cell antigen 2 BST2 2.342 18.48414
     disabled homolog 2, mitogen-responsive 
     phosphoprotein 
DAB2 2.185 2.47187 
DNA repair    
     RecQ protein-like (DNA helicase Q1-like) RECQL 2.039 2.12691 
DNA replication    
     CDC7 cell division cycle 7 (S. cerevisiae) CDC7 2.7 2.15410 
     centromere protein F, 350/400ka (mitosin) CENPF 2.513 2.28573 
     topoisomerase (DNA) II alpha 170kDa TOP2A 2.166 2.13678 
     topoisomerase (DNA) II binding protein 1 TOPBP1 2.267 2.01674 
Development and cell differentiation    
     podocalyxin-like PODXL 2.622 4.63347 
Nuclear organization and biogenesis    
     H1 histone family, member X H1FX 2.249 1.91310 
     SMC4 structural maintenance of chromosomes 
     4 like 1 
SMC4L1 2.001 1.97850 
    
Downregulated genes   
Cell adhesion    
     chondroitin sulfate proteoglycan 2 (versican) CSPG2 -2.21 0.46375 
     collagen, type XVI, alpha 1 COL16A1 -3.238 0.41036 
     fibronectin 1 FN1 -2.952 0.25825 
     laminin, gamma 2 LAMC2 -2.991 0.35576 
Cell proliferation    
     amphiregulin AREG -2.147 0.29429 
Development and cell differentiation    
     kallikrein 7 (chymotryptic, stratum corneum) KLK7 -2.712 0.27634 
     keratin 13 KRT13 -2.336 0.12282 
Immune response    
     GATA binding protein 3 GATA3 -2.093 0.45008 
Nuclear organization and biogenesis    
     high mobility group AT-hook 2 HMGA2 -2.982 0.22794 
     villin-like VILL -2.029 0.48133 
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Table 12 DIFFERENTIALLY EXPRESSED GENES IN HPV-18 
CONTAINING CELL LINES COMPARED TO HPV-16 POSITIVE 
CELL LINES  
Gene Title Gene 
Symbol 
pooled t-
Test 
SAM-
Test 
Upregulated genes    
Cell adhesion    
     collagen, type XV, alpha 1 COL15A1 2.445 8.02698 
     mesothelin MSLN 9.127 4.00520 
Development and cell differentiation    
     paired-like homeodomain transcription factor 2 PITX2 4.052 6.33972 
Electron transport    
     cytochrome c oxidase subunit VIIa polypeptide 1 COX7A1 2.235 4.95734 
Functionally unclassified genes  
     preferentially expressed antigen in melanoma PRAME 3.045 4.43197 
Immune response    
     D component of complement (adipsin) DF 2.104 3.26767 
     melanoma associated gene D2S448 3.457 3.00100 
Ion binding    
     S100 calcium binding protein A4 (metastasin) S100A4 2.356 2.76983 
     SNRPN upstream reading frame SNURF 11.682 5.41101 
Protein modification, catabolism and translation    
     eukaryotic translation initiation factor 1A, Y 
     linked 
EIF1AY 2.034 4.82245 
Regulation of transcription    
     nuclear receptor subfamily 2, group F, member 1 NR2F1 2.545 7.90107 
Signal transduction    
     Arg/Abl-interacting protein ArgBP2 ARGBP2 3.555 2.10753 
     chemokine (C-X-C motif) receptor 4 CXCR4 2.99 7.57239 
     dual specificity phosphatase 4 DUSP4 3.021 2.00880 
Structural function    
     keratin 18 KRT18 3.007 2.09911 
     keratin 8 KRT8 3.723 2.93771 
     microfibrillar associated protein 5 MFAP5 4.329 6.58325 
     vimentin VIM 2.158 2.57079 
     Wiskott-Aldrich syndrome protein interacting 
     protein 
WASPIP 3.036 3.42596 
    
Downregulated genes    
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Development and cell differentiation    
     N-myc downstream regulated gene 1 NDRG1 -6.132 0.29486 
Functionally unclassified genes    
     synaptogyrin 3 SYNGR3 -5.394 0.41355 
Regulation of transcription    
     transcription factor AP-2 gamma TFAP2C -3.737 0.46549 
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In situ hybridization of NAP1L3 and LAT1 in tissue arrays 
 
 In order to verify that the differentially expressed genes LAT-1 and 
NAP1L3 are not affected in HPV-positive cervical cell line as a consequence of in 
vitro immortalization or specific tissue culture variations, we carried out in situ 
hybridization for the mRNAs of these genes in tissue-arrays containing ~50 
different cervical tumor samples and 4 normal cervix controls per slide. When we 
used the NAP1L3 probe in the cervical carcinoma tissue-array, we found that 
most of these carcinomas were negative for NAP1L3 mRNA (Fig. 14B and 14C 
and Table 13). Interestingly, all the four normal cervical samples were positive for 
NAP1L3 transcripts (yellow fluorescent spots) (Fig. 14A), supporting the data 
obtained with the HPV-positive cervical cell lines (Fig. 13). On the other hand, 
when we hybridized the LAT1 probe to the cervical carcinoma tissue-arrays, 
most of the samples in the array were positive for LAT1 mRNA (Fig.14E and 
14F). The normal cervical tissues did not give a positive signal for LAT1 
transcripts (Fig. 14D and Table 13). Together, our data showed that NAP1L3 and 
LAT1 are also affected in cervical carcinoma tumor tissues in a manner similar to 
that observed with the cell lines, suggesting a possible role of these genes in the 
carcinogenesis of the cervix.  
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Fig. 13. VALIDATION OF MICROARRAY DATA IN HPV-
POSITIVE CELL LINES BY QUANTITATIVE RT-PCR AND 
NORTHERN BLOT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Four upregulated genes (TFAP2A, CPA4, NEFH and LAT1), and four 
downregulated genes (SPRY1, IGSF4, ID4 and NAP1L3) between HPV-positive cell 
lines compared to the normal cervix tissue or the HPV-negative cell line C-33A 
were selected for validation by QRT-PCR. All reactions were performed in 
triplicates. Relative expression of the target gene was calculated using the 2 delta 
CT method, where GAPDH was used as the endogenous control gene. For 
northern blot we used the probes for LAT1 and NAP1L3 in all the cell lines and 
normal cervix. GAPDH was used as a loading control. 
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Fig. 14. In Situ HYBRIDIZATION OF NAP1L3 AND LAT1 
IN A CERVICAL CARCINOMA TISSUE-ARRAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cervical carcinoma tissue-arrays (containing ~50 different cervical tumor samples 
and 4 normal cervix controls per slide) were used for NAP1L3 (Fig. 14A-14C) and 
LAT1 (Fig. 14D-14F) mRNA detection by in situ hybridization. Positive 
hybridization signal is shown as yellow fluorescent spots. Fig. 14A and 14D are 
normal cervical tissues. Fig. 14B, 14C, 14E and 14F are cervical carcinoma 
tissues. 
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Table 13. In Situ HYBRIDIZATION RESULTS FOR LAT1 AND 
NAP1L3 IN DIFFERENT CERVICAL CARCINOMA TISSUE 
SAMPLES PRESENT IN THE TISSUE-ARRAY SLIDES 
 
Tissue specimens No. of samples
LAT1 
Positive (%) 
NAP1L3 
Positive (%) 
Squamous Cell Carcinoma in situ 3 2 (66.6%) 0 (0%) 
Squamous Cell Carcinoma 37 32 (86%) 2 (5.4%) 
Adenosquamous Carcinoma 5 4 (80%) 1 (20%) 
Microinvasive Squamous Cell Carcinoma 5 5 (100%) 0 (0%) 
Metastatic Carcinoma (lymph node) 5 5 (100%) 0 (0%) 
Total Tissue-array Carcinoma Samples 50 43 (86%) 3 (6%) 
Normal Cervix 4 0 (0%) 4 (100%) 
Signal was recorded as negative if <5% of the tumor or normal tissue 
samples were positive  
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3.4 DISCUSSION 
 
 Cervical cancer represents an important health problem worldwide. An 
understanding of the molecular interactions between HPV and cervical cells is 
important for a better understanding of the pathogenesis of HPV-associated 
cancers as well as for early diagnosis and possible new treatment approaches 
for diseases caused by this virus. In this study, we used high-density microarrays 
to analyze gene expression differences in several HPV-positive and HPV-
negative cervical cell lines and related our findings to mechanisms or pathways 
altered in HPV-positive cells as a consequence of viral gene expression, 
integration, and other downstream effects.  A few investigators have previously 
studied gene expression profiles of HPV-containing cell lines using microarray 
analysis. These studies used a wide variety of microarray platforms, control 
samples, normalization approaches and statistical analyses that showed a range 
of differentially expressed genes (Alazawi, et al., 2002;Chang, et al., 2000;Chen, 
et al., 2003;Duffy, et al., 2003;Lee, et al., 2004;Schena, et al., 1996;Zhu, et al., 
1998). For example, the study by Chang et al. used HPV-31 transfected primary 
keratinocytes and a microarray with 7,075 human genes and expressed 
sequence tags (ESTs) (Chang, et al., 2000). Another analysis used cervical 
cancer tissues and a cDNA microarray containing 30,732 Unigene clones and 
normal tissue as control (Chen, et al., 2003). Ahn et al. used invasive cancer 
tissues and a 4,700 cDNA microarray and used the HaCat cells as a control 
(Ahn, et al., 2004). Alazawi et al. carried out microarray analysis using an 
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episomal HPV-16 W12 clone and compared it to a W12 clone containing 
integrated HPV DNA utilizing a 12,600 human transcript high-density microarray 
(Alazawi, et al., 2002). 
 
 A significant problem arises when comparing results of different 
microarray data from individual studies due to the use of a wide variety of 
statistical analyses that show different levels of false positive/negative rates (Tan, 
et al., 2003). To our knowledge, our study is the first to use two different types of 
normalizations (GEDA and dChip normalization) and two statistical tests (pooled 
variance t-Test and SAM-Test) in order to overlap the results of each analysis 
and identify a more robust panel of differentially expressed genes and possibly 
reduce the number of false positives. Our study also utilized a high density 
oligonucleotide microarray platform (Affymetrix U133A GeneChip® expression 
microarray) that represents a larger number of human transcripts (22,215). Only 
one recent report utilized this expression array and compared the gene 
expression profiles in primary cell lines derived from cervical cancer tissues and 
the normal cervix (Santin, et al., 2005). Many of the differentially expressed 
genes reported in this study were also found in our analyses.  
  
 Since episomal HPV DNA present in cell lines frequently integrates during 
in vitro propagation, we first confirmed by restriction enzyme and Southern blot 
analyses that the HPV-positive cell lines 20863 and L-18 contained episomal 
HPV-16 or HPV-18 DNA, respectively, after several passages as previously 
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reported (Alazawi, et al., 2002). We also confirmed the expression of the viral E6 
and E7 oncogenes in various HPV-positive cell lines by Northern blot analysis 
(Fig. 11). This analysis showed multiple transcripts corresponding to the E6 and 
E7 genes (Fig. 11), consistent with previous studies showing multiple splicing 
variants of these genes (Baker, et al., 1987). As expected, cell lines containing 
episomal HPV DNA generally expressed lower levels of the E6/E7 genes as 
compared to those containing integrated HPV DNA (Fig. 11). This is likely to be 
due to the repression of the p97 promoter transcribing the E6/E7 genes by the 
E2 protein and/or the chromatin structure of the episomes (Bechtold, et al., 
2003;May, et al., 1994).  The E2 gene is frequently interrupted or deleted upon 
integration of the HPV DNA into the chromosome (zur Hausen, 2002). As 
expected, the E2 protein was expressed in cell lines containing episomal HPV 
DNA (Fig. 11). As shown earlier (Baker, et al., 1987), the CaSki cell line 
containing integrated HPV-16 DNA also expressed high levels of the E2 
transcript due to heat-to-tail tandem integration of multiple copies of HPV DNA 
that restores an intact E2 open reading frame (Fig. 11). The 20861 cell line that 
contains integrated HPV DNA expressed significant levels of an E2 transcript of 
larger than expected size (Fig. 11). This is presumably due to the generation of a 
fusion transcript resulting from the fusion of E2 and a cellular gene.  
 
 After confirming appropriate expression of the viral genes in various cell 
lines, we analyzed the cellular gene expression profiles in order to identify 
differentially expressed genes in HPV-positive cervical cell lines compared to the 
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normal cervix tissue. We used two statistical methods, pooled t-Test and SAM-
Test, for data analysis and used a cut-off of two-fold to identify differentially 
expressed genes. A comparison of the differentially expressed genes using these 
two statistical methods showed that 272 upregulated and 605 downregulated 
genes were in common. Some upregulated genes identified in our study are 
known to be involved in various cellular pathways such as cell cycle (AURKB), 
DNA repair (FEN1,OGG1), Signal transduction (RAB32), Nuclear organization 
and biogenesis (CPA4), and cell transport (RAB9P40) (Table 8). Some examples 
of upregulated genes found in our analysis as well as in previous microarray 
studies are genes involved in cell cycle  (CCNB1,CDKN2A,MCM7), DNA repair 
(H2A histone family, member X [H2AFX]) and regulation of transcription 
(TFAP2A) (Table 8) (Beger, et al., 2001;Li, et al., 2005;Santin, et al., 
2005;Steenbergen, et al., 2004;Tan, et al., 2003). Other upregulated genes 
included those implicated in human carcinogenesis in previous studies (Santin, et 
al., 2005;Walter, et al., 2003). For example, high expression of the cell cycle 
regulator cyclin B1 has been seen in a wide variety of human tumors including 
cervical cancer, and is also associated with mutations or deletions of p53 (Santin, 
et al., 2005). It is likely that binding and degradation of p53 by the HPV E6 
protein results in overexpression of cyclin B1. Another molecule involved in cell 
cycle regulation that was found to be upregulated in our analysis was cyclin-
dependent kinase inhibitor 2A (CDKN2A). As suggested previously by Santin et 
al. (Santin, et al., 2005), overexpression of CDKN2A may result from the 
inactivation of pRB function by the HPV E7 protein, allowing the E2F1 
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transcription factor to inhibit cyclin D1-dependent kinase activity and 
consequently upregulate CDKN2A. Our studies also identified several genes that 
were previously not known to be upregulated in cervical cancer. For example, 
Rab9 effector p40 (RAB9P40) which is a small GTPase involved in lipid transport 
from the late endosomal-lysosomal system to the trans-Golgi network, was found 
to be upregulated in HPV-positive cell lines. The upregulation of RAB9P40 has 
been co-related with increased expression of the human telomerase reverse 
transcriptase (hTERT) in immortalized human cells (Walter, et al., 2003). 
Telomerase activation by high risk HPV E6 proteins could result in upregulation 
of RAB9P40 (Klingelhutz, et al., 1996).  
 
 Our microarray analysis identified several downregulated genes that were 
not reported in previous studies with HPV-positive cervical cell lines.  Such genes 
included those involved in cell adhesion (CLDN10,NID), cell cycle (CUL5), 
regulation of transcription (ID4), cell differentiation (DMBT1), and DNA repair 
(MBD4) (Table 8). DMBT1 (deleted in malignant brain tumor 1 gene) is a 
candidate tumor suppressor gene previously found to be downregulated in brain, 
esophageal, gastric, colorectal, lung and oral cancers (Imai, et al., 2005). DMBT1 
is known to trigger cellular differentiation when located in the extracellular matrix 
(Mollenhauer, et al., 2002). Thus, downregulation of DMBT1 may promote 
epithelial tumorigenesis as suggested earlier. Our results also confirm the 
downregulation of several genes identified in previous studies. Some of these 
genes have been shown to be involved in immune response (IGSF4, IFI27), cell 
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adhesion (FN1), cell differentiation (collagen, type I, alpha 1 [COL1A1]) and 
protein modification (cathepsin B [CTSB]). IGSF4 (tumor suppressor gene 
immunoglobulin superfamily, member 4) earlier known as TSLC1, SgIGSF or 
SynCAM, is a novel immunoglobulin (Ig)-like intercellular adhesion molecule 
involved in spermatogenic adhesion, mast-cell adhesion, formation of functional 
synapses, and probable cell-to-cell interactions of epithelial cells (Watabe, et al., 
2003). The silencing of IGSF4 has been associated with aberrant promoter 
hypermethylation in several human cancers, including cervical cancers and in 
HPV-positive cell lines (Li, et al., 2005;Steenbergen, et al., 2004). Reduced 
expression of IGSF4 in HPV-positive cell lines may disrupt the adhesion of 
epithelial cells and contribute to tumor cell motility.  
 
 Using the HPV-negative cervical carcinoma cell line C-33A as a control, 
we found 305 upregulated and 232 downregulated genes in all the HPV-positive 
cell lines (Table 9) by combining the results from the two statistical analyses. 
Upregulated genes belong to different cellular pathways such as metastasis 
(ACTN4), antiestrogen resistance (BCAR3), mitogenic signaling (CAV1, CAV2), 
angiogenesis (EPAS1) and double-strand DNA break repair via nonhomologous 
end-joining (MRE11A). Downregulated genes found in our analyses included 
those involved in transcriptional regulation (CITED2), apoptosis (DFFB), cellular 
morphogenesis (MYH10), centrosome formation (PCM1) and mismatch repair 
(PMS1) (Table 9). One of the genes found to be upregulated for the first time in 
HPV-positive cell lines was actinin, alpha 4 (ACTN4). This protein is involved in 
 116
actin cytoskeleton remodeling and  is known to promote cell motility and 
metastasis of colorectal cancer cells (Honda, et al., 2005). Another upregulated 
gene found in our analysis encodes carboxypeptidase A4 (CPA4) that is located 
at the putative prostate cancer-aggressiveness locus at 7q32 (Kayashima, et al., 
2003). CPA4 is expressed at extremely low levels in human adult tissues but is 
abundant in prostate cancer cell lines, suggesting that CPA4 may modulate the 
function of peptide hormones that play an essential role in the growth and 
differentiation of prostate epithelial cells (Kayashima, et al., 2003). It may play a 
similar role in the growth of HPV-positive cervical epithelial cells.  
 
 When cellular gene expression profiles of all HPV-positive cervical cell 
lines were compared to those of both the normal cervix and the HPV-negative 
cell line C-33A by the above two statistical methods, a total of 20 genes were 
found to be upregulated and 37 were downregulated (Table 10). Upregulated 
genes included those involved in cell stress by DNA damage (DDIT4), amino 
acid transporter involved in tumor progression (SLC7A5/LAT1), immune 
response (PTGES), and development (TUFT1). Downregulated genes included 
those involved in development (HOXB2), growth factor regulation and 
development (SPRY1), and cell adhesion (JAM3) (Table 10). One of the 
upregulated genes found in our analysis as well as in previous studies was the 
antimicrobial humoral response prostaglandin E synthase (PTGES) (Santin, et 
al., 2005). There is evidence that lung cancer cells secreting high levels of 
PTGES alter the cytokine balance in the tumor micro-environment and could help 
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in the immune evasion of neoplastic cells (Huang, et al., 1998). A similar immune 
evasion could play an important role in HPV pathogenesis.  
 
 Integration of HPV DNA usually occurs during the progression of HPV 
infection, and the DNA is found to be mostly integrated in high-grade lesions and 
cervical cancers (zur Hausen, 2002). We analyzed the differences in cellular 
gene expression profiles between cervical carcinoma cell lines containing 
integrated HPV DNAs (CaSki, SiHa, 201402, 20861 and HeLa) and those 
containing episomal HPV DNA that mimic low-grade lesions (20863 and L-18). 
Due to the limited number of available cell lines containing episomal HPV DNA, 
the 20863 and L-18 cell lines containing HPV-16 and HPV-18 DNA, respectively, 
were combined into a group. Data analysis using the two statistical methods 
showed that 52 genes were upregulated while 47 were downregulated in cell 
lines containing integrated HPV DNA compared to those containing episomal 
DNA (Table 11). The upregulated genes in HPV-16 or HPV-18 integrated cell 
lines included those involved in the regulation of mitosis (CENPF), cell growth 
and anti-adhesion (PODXL), and chromosome organization (SMC4L1). The 
downregulated genes included those involved in defense response (GATA3), 
maintenance of chromatin architecture (HMGA2), and epidermis development 
(LAMC2). The CENPF gene that encodes the centromere protein F, 350/400ka 
(mitosin) was found to be upregulated. CENPF overexpression may de-regulate 
kinetochore assembly at the G2/M checkpoint and facilitate defective 
chromosome segregation, promoting cervical carcinogenesis (de la Guardia, et 
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al., 2001). The upregulation of CENPF in cell lines containing integrated HPV 
DNA is consistent with E7 expression and chromosomal instability associated 
with HPV integration (Pett, et al., 2004). Our data also showed that the PODXL 
(mucin-like surface sialoglycoprotein podocalyxin-like) gene is upregulated in cell 
lines containing integrated HPV DNA. PODXL is an integral membrane 
glycoprotein that has different cell adhesion properties in different tissues and is 
repressed by the p53 protein at the transcriptional level (Stanhope-Baker, et al., 
2004). Increased expression of E6 in cell lines with integrated HPV DNA causes 
p53 degradation and  could result in an increase in PODXL expression (zur 
Hausen, 2002). Several genes that are downregulated in cell lines containing 
integrated HPV DNA were also identified (Table 11). The protein encoded by one 
such gene, GATA3 (essential transcription factor GATA binding protein 3), is part 
of the GATA family zinc-finger transcription factors that are involved in 
differentiation and development of different tissues in vertebrates (Lim, et al., 
2000). A recent study showed downregulation of GATA3 mRNA by differential 
display in HPV-immortalized keratinocytes, HG-SIL and cervical carcinomas 
suggesting that this is a late event in cervical tumorigenesis (Steenbergen, et al., 
2002). The increased expression of GATA3 may be co-related with integration of 
HPV DNA into the host genome and progression of cervical cancer. Two 
upregulated genes identified in our study have previously been reported by 
Alazawi et al. comparing the episomal HPV cell line 20863 and its subsequent 
passages lacking feeder cells (which is expected to result in the integration of 
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HPV DNA) (Alazawi, et al., 2002). These genes are involved in vesicle coat 
assembly (BST2) and DNA topological changes (TOP2A). 
 
 Although both HPV types 16 and 18 are high-risk viruses, HPV-16 is 
commonly associated with SCC, whereas HPV-18 is predominantly associated 
with AC (Burk, et al., 2003). In order to identify cellular pathways that may be 
specifically altered by the presence of HPV 16 or 18 DNA, we compared the 
cellular gene expression profiles of cell lines containing HPV 16 or 18 DNA. We 
found that 36 genes were upregulated while 3 were downregulated in HPV-18 
positive cells based upon a comparison of differentially expressed genes using 
two different statistical methods (Table 12). Of note, the keratin 8 (KRT8) and 
keratin 18 (KRT18) genes involved in cytoskeleton organization were found to be 
upregulated in HPV-18 containing cells as compared to the HPV-16 positive cell 
lines. The relatively few genes that were found to be differentially expressed in 
this analysis may suggest the involvement of predominantly similar pathways 
during the progression of cervical carcinogenesis induced by the high-risk HPV-
16 and HPV-18.   
 
 We carried out QRT-PCR and northern blot analyses in order to validate 
the differential gene expression profiles obtained by microarray analysis. All the 
eight differentially expressed genes used for QRT-PCR (TFAP2A, CPA4, NEFH, 
LAT1, SPRY1, ID4, IGSF4, and NAP1L3) showed data consistent with our 
microarray data (Fig. 13). We also used Northen blot analysis for one 
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upregulated gene (LAT1) and one downregulated gene (NAP1L3) in order to 
further confirm the results obtained with QRT-PCR. We found the same pattern 
of expression between this analysis and the QRT-PCR. In situ hybridization of 
NAP1L3 and LAT1 was done in tissue-arrays containing ~50 different cervical 
tumor samples and 4 normal cervix controls per slide in order to verify that these 
genes are not an artifact of in vitro immortalization or specific tissue culture 
variations. We found that most of the cervical carcinomas were negative for 
NAP1L3 mRNA, while most of the cervical carcinomas in the array were positive 
for LAT1 mRNA (Fig. 14 and Table 13). Together, our data showed that NAP1L3 
and LAT1 are also affected in cervical carcinoma tumor tissues suggesting a 
possible role in the carcinogenesis of the cervix.  
 
In summary, these results of global gene expression profile in HPV-
positive cervical cell lines could lead to the identification of new cellular pathways 
affected during the progression of HPV disease. 
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Chapter 4 
 
HUMAN PAPILLOMAVIRUS TYPE 16 REDUCES THE EXPRESSION OF 
MICRORNA-218 IN CERVICAL CARCINOMA CELLS 
 
 
 
Work described in this section has been submitted for publication.  The authors 
are Ivan Martinez, Amy S. Gardiner, Kathryn F. Board, Federico A. Monzon, 
Robert P. Edwards and Saleem A. Khan. 
 I. Martinez, A.S. Gardiner contributed equally to this work. K.F. Board performed 
part of tissue culture and control Northern blot experiments. F.A. Monzon and 
R.P. Edwards provided microarray assistance and tissue samples, respectively. 
I. Martinez and A.S. Gardiner performed most of the experiments. I. Martinez, 
A.S. Gardiner and S.A. Khan wrote the manuscript.  
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4.1 INTRODUCTION 
 
 Cervical cancer is the second most common malignancy in women 
worldwide (Pisani, et al., 2002). High-risk human papillomaviruses (HPVs) such 
as types 16 and 18 are causally involved in the carcinogenesis of the cervix (zur 
Hausen, 2002). HPVs are small double-stranded DNA viruses that contain two 
oncogenes E6 and E7 that are involved in cellular transformation (Hebner, et al., 
2006;Munger, et al., 2002;zur Hausen, 2002). Most low-grade cervical lesions 
contain HPV DNA in an episomal state. However, in most cases of cervical 
carcinomas the HPV DNA is found integrated into the host chromosomes, 
increasing expression of E6 and E7 (Hebner, et al., 2006;Munger, et al., 2002;zur 
Hausen, 2002). The E6 protein promotes ubiquitination and proteasomal 
degradation of the tumor suppressor protein p53 (Band, et al., 1993;Huibregtse, 
et al., 1991;Lechner, et al., 1992;Pim, et al., 1994;Scheffner, et al., 
1990;Thomas, et al., 1999;Werness, et al., 1990) and PDZ domain-containing 
disc large protein (DLG) (Gardiol, et al., 1999;Lee, et al., 2004). E6 also 
dysregulates the cell cycle (Shai, et al., 2007). The E7 protein binds to and 
inactivates the function of the pRB and related tumor suppressor proteins p107 
and p130 (Davies, et al., 1993;Dyson, et al., 1989;Munger, et al., 1989). E7 also 
interacts with additional cellular proteins such as TBP, histone H1 kinase and 
cyclin E (Davies, et al., 1993;Massimi, et al., 1996;McIntyre, et al., 1996). In 
addition, E6/E7 expression promotes chromosomal instability, foreign DNA 
 123
integration and other mutagenic events in the cell (Duensing, et al., 2000;Pett, et 
al., 2004;Schaeffer, et al., 2004).  
  
 Originally discovered in C. elegans, microRNAs (miRNAs) are small non-
coding RNAs that are conserved across many species and may regulate 
thousands of mRNA targets (Lee, et al., 1993;Lewis, et al., 2005). MiRNAs are 
transcribed in the nucleus (Cai, et al., 2004;Lee, et al., 2004), and after 
processing (Hutvagner, et al., 2001;Lee, et al., 2003;Lee, et al., 2002;Lund, et al., 
2004), they associate with the RISC complex and act as negative regulators of 
gene expression by binding to their complementary mRNA targets and either 
repressing translation or promoting mRNA degradation (Khvorova, et al., 
2003;Kim, 2005;Schwarz, et al., 2003). Recently, changes in the expression of 
miRNAs have been shown to be associated with human cancers (Calin, et al., 
2006;Esquela-Kerscher, et al., 2006;Lu, et al., 2005). For example, miR-15 and 
miR-16 which negatively regulate the Bcl-2 oncogene are usually 
underexpressed in chronic lymphocytic leukemia (CLL) (Calin, et al., 
2002;Cimmino, et al., 2005). The let-7 family of miRNAs regulates the ras 
oncogenes, and in lung cancer underexpression of these miRNAs results in 
overexpression of Ras (Johnson, et al., 2005;Takamizawa, et al., 2004). Also, 
the C-myc oncogene increases the expression of the miRNA cluster miR-17-92, 
and their overexpression has been observed in B cell lymphomas (O'Donnell, et 
al., 2005;Ota, et al., 2004).   
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 Little is known about miRNA expression in cervical carcinogenesis. In this 
study, we demonstrate differential expression of several miRNAs in HPV-16 
positive cervical cell lines and tissues compared to the normal cervical tissue and 
an HPV-negative cervical carcinoma cell line. We also demonstrate that miR-218 
and the tumor suppressor gene SLIT2, whose intron encodes miR-218, are 
specifically downregulated in several HPV-16 positive cervical cell lines and 
tissues, and this effect is likely mediated by the HPV-16 E6 oncogene. Finally, 
our studies show that LAMB3 is a possible target of miR-218 at a transcriptional 
level.   
 
4.2 MATERIALS AND METHODS 
 
Cell Lines  
  
 Cervical cancer cell lines CaSki, SiHa (HPV-16 positive) and C-33A (HPV-
negative) and their growth conditions have been described (Meissner, 
1999;Scheffner, et al., 1991). Three clonal populations of the HPV-16 cervical 
cell line W12 (Stanley, et al., 1989), 20863 (episomal HPV-16) and 20861 and 
201402 (integrated HPV-16) were obtained from the laboratories of Drs. 
Margaret Stanley and Paul Lambert (Medical Research Council, UK and 
University of Wisconsin, USA, respectively). The cell lines U2OS-Neo, U2OS-E6 
and U2OS-E7 (Duensing, et al., 2000) were obtained from Dr. Stefan Duensing 
(University of Pittsburgh, USA).   
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 Cervical Tissues Characteristics  
 
 Human cervical tissue samples were collected under an IRB approved 
protocol from patients with cervical preinvasive neoplasia undergoing leep 
excision or radical hysterectomy for invasive cervical cancer. Informed consent 
was obtained from all subjects. Parallel specimens of the same site were stained 
(Hemotoxylin and Eosin) to confirm the diagnosis. HPV-16 positivity was 
confirmed by RT-PCR.  Total RNA from normal human cervix was obtained from 
a pool of 2 different donors (Stratagene). 
 
MicroRNA Microarray Analysis 
 
 Total RNA was extracted using the Ultraspec™ RNA isolation system 
(BIOTECX) according to the manufacturer’s instructions. Total RNA from cell 
lines and normal cervix was used to isolate small RNAs (<200 nt) which includes 
miRNAs using the RNeasy Mini Kit and the MinElute Cleanup Kit (Qiagen).    
MirVana miRNA Bioarray (Ambion) was used to analyze miRNA expression in 
cervical cell lines. The Bioarray consist of 662 probes (~22 nt long antisense 
oligonucleotides) that include known human miRNAs (328), theoretical human 
microarrays known as ambi-miRs (152) as well as unique miRNAs from mouse 
(114) and rat (Scheffner, et al., 1991). Each array contains probes for all miRNAs 
in quadruplicate, and the signals obtained for each miRNA is represented as an 
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average of these four values and is subsequently used for statistical analysis. 
The enriched small RNA fractions obtained from 25 µg of total RNA was 
fluorescently labeled and hybridized to the Bioarrays according to the 
manufacturer’s instructions (Ambion). Each experiment was done twice. The 
Bioarrays were scanned using GenePix 4000B Scanner and the median 
fluorescent intensity was obtained after subtracting the background using the 
GenePix Pro 6.0 software. To identify differential miRNA expression between 
samples, the median fluorescent intensities were log2 transformed and 
normalized using the median within the array and the global mean adjustment 
among arrays using the GEDA program 
(http://bioinformatics.upmc.edu/Help/GEDADescription.html). After transformation 
and normalization, we used the Significance Analysis of Microarray (SAM) 
program version 1.21 (www-stat.stanford.edu/~tibs/SAM/) to obtain the 
differential expression profiles.  For the unsupervised hierarchical clustering 
analysis, we used the Genesis 1.0 program (http://genome.tugraz.at). The 
fluorescent ratios of all human miRNAs in the Bioarray were used to obtain the 
average linkage clustering based on the Pearson correlation coefficient similarity 
metric.  
 
MicroRNA Northern blot analysis 
 
 Enriched miRNA fractions obtained from 25 µg of total RNA were 
separated on 15% urea-containing polyacrylamide gels. RNA was then 
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transferred onto GeneScreen Plus membranes which were hybridized to 32P-
labeled oligonucleotide probes complementary to various cellular miRNAs. We 
hybridized a probe complementary to the housekeeping splicing-related small U6 
RNA for loading control. Hybridization was carried out overnight at 50°C and the 
membranes were subjected to autoradiography at -80°C.  
   
MicroRNA and mRNA Real-time Quantitative RT-PCR Analysis 
 
 DNase I-treated total RNA (10 ng) was subjected to qRT-PCR analysis 
using the TaqMan® miRNA Reverse Transcription Kit and miRNA Assays 
(Applied Biosystems), and the Real-Time thermocycler iQ5 (BioRad). The small 
nucleolar RNU43 was used as the housekeeping small RNA reference gene. For 
qRT-PCR analysis of SLIT2 and LAMB3 mRNAs, the following primers were 
used: (SLIT2, forward 5’-CTGTGAATGCAGCAGTGGAT-3’ and reverse 5’-
TTGTTTGGCAAGCAGCATAG-3’ (116-bp product); LAMB3, forward 5’- 
GGGAGACCATGGAGATGATG-3’and reverse 5’-
ACACGCTTCTCCAGTCCTGT-3’ (112-bp product). Also, 500 ng of total RNA 
from the cervical samples was amplified using the one step QuantiTect SYBR 
Green RT-PCR Master Mix (Qiagen). The primer sequences for the control β-
actin gene were: forward 5’- TGCGCAGAAAACAAGATGAG-3’ and reverse 5’- 
CACCTTCACCGTTCCAGTTT-3’ (114-bp product); primers for the control 
housekeeping glyceraldehyde-3-phosphate dehydrogenase gene (G3PDH) have 
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been described previously (Martinez, et al., 2007). Relative expression of RNAs 
was calculated using the 2 delta CT method (Livak, et al., 2001). 
 
HPV-16 E6 and E7 siRNA and Transfection Assays 
 
 Double-stranded small interfering RNAs (siRNAs) against HPV-16 E6 
(siRNA 209) and E7 (E7 siRNA) (Jiang, et al., 2002;Tang, et al., 2006) were 
obtained from Dharmacon. BLOCK-iTTM Fluorescent double-stranded oligo (with 
no human homologous sequence) was used as a negative control as well as to 
measure the transfection efficiency (Invitrogen). MiR-218 was expressed in cell 
lines by transfecting with a Pre-miRTM miR-218 precursor molecule (Ambion). 
Cell lines were seeded (1.5 X 105) into 6-well plates and after 24 hr transfected 
(125 nM per well of HPV siRNAs or 100 nM of Pre-miRTM miR-218 precursor 
Molecule) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. Cells were harvested after 72 hr and RNA extractions were carried 
out as described earlier. 
  
4.3 RESULTS 
 
MiRNA Expression in the Cervix 
 
 The basal expression of miRNAs in the normal cervix was identified using 
miRNA microarrays. We obtained the median fluorescent intensity of each 
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miRNA, and those having values of zero in 50% of their corresponding spots (4 
spots per array and two repetitions) were considered to be non-expressing. This 
analysis showed that approximately 220 known human miRNAs out of 328 
represented on the array were expressed in the normal cervix (supplementary 
data, table V). The miRNAs that were most highly expressed in the cervix were 
miR-145, miR-26a, miR-99a, let-7a, miR-143, let-7b, let-7c, miR-125b, miR-126, 
and miR-195 in that order.  
 
Differential Expression of MicroRNAs in Cervical Cell Lines Compared to the 
Normal Cervix 
 
 We investigated the miRNA expression profile in normal cervical tissue 
and cervical carcinoma cell lines SiHa and CaSki containing integrated HPV-16 
DNA (Meissner, 1999). We also used three clonal derivatives of the W12 cell line 
derived from a low-grade CIN I lesion (Stanley, et al., 1989): 20863 contains 
episomal HPV-16 DNA, while 20861 and 201402 contain integrated HPV-16 
DNA and show changes in gene expression that mimic neoplastic progression 
(Alazawi, et al., 2002). The 20863 cell line mimics early stages of HPV infection 
and is the only well-characterized cell line containing stable HPV-16 episomal 
DNA. SAM analysis showed that 24 miRNAs, including miR-126, miR-143, miR-
145 and miR-195 were underexpressed in all the integrated HPV-16 cervical cell 
lines compared to the normal cervix (Table 14). Only three miRNAs, miR-182, 
miR-183 and miR-210, were found to be overexpressed in the integrated HPV-16 
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cell lines (Table 1). Six miRNAs were underexpressed in the 20863 cell line 
containing episomal HPV-16 DNA compared to the normal cervix (Table 14). A 
direct comparison of the miRNA expression profiles of integrated vs. episomal 
HPV-16 cell lines did not reveal any significant differences (data not shown). 
This, at least in part, may result from the use of a 2-fold cut-off value and a q 
value of zero in statistical analysis.   
   
Differential Expression of MicroRNAs in HPV-16 Positive Cervical Cell Lines 
Compared to the HPV-Negative Cell Line C-33A 
 
 We compared the expression profile of cell lines containing HPV-16 DNA 
with that of the only available, well-characterized HPV-negative cervical 
carcinoma cell line C-33A (Scheffner, et al., 1991). Nine miRNAs in cell lines 
containing integrated HPV-16 DNA and 10 miRNAs in the episomal HPV-16 cell 
line 20863 were found to be expressed at much higher levels compared to the C-
33A cells (Table 15). Interestingly, miR-218 was the only miRNA that was 
underexpressed in cell lines containing integrated HPV-16 DNA as compared to 
both the HPV-negative cell line C-33A and the normal cervix (Tables 14 and 15). 
This suggested that miR-218 may be specifically affected in the presence of 
HPV-16. 
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TABLE 14.  miRNAs DIFFERENTIALLY EXPRESSED IN HPV-
16 POSITIVE CELL LINES COMPARED TO NORMAL CERVICAL 
TISSUE 
 
  
HPV16 
Integrated 
HPV16 
episomal 
miRNA Fold Change Fold Change 
Overexpressed     
hsa_miR_210 7.3   
hsa_miR_182 6.4   
hsa_miR_183 5.1   
Underexpressed     
hsa_miR_126 -14.5   
hsa_miR_145 -14.1 -35.5 
hsa_miR_451 -11.3   
ambi_miR_7029 -9.5   
hsa_miR_195 -8.3 -18.2 
hsa_miR_143 -8   
hsa_miR_199b -7.9   
hsa_miR_133a -7.6 -10.1 
hsa_miR_368 -7.6 -16.6 
hsa_miR_1 -7.2   
hsa_miR_495 -6.3   
hsa_miR_497 -6.2   
hsa_miR_133b -6   
hsa_miR_223 -5.4   
hsa_miR_146a -5.1   
hsa_miR_218 -4.8   
hsa_miR_126_AS -4.7   
hsa_miR_150 -4.4   
hsa_miR_376a -4.2   
hsa_miR_214 -4.1 -12.1 
hsa_miR_487b -4.1   
hsa_miR_10b -3.9   
ambi_miR_5021 -3.6   
ambi_miR_7070 -3.5   
hsa_miR_199a   -14.7 
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TABLE 15. miRNAs DIFFERENTIALLY EXPRESSED IN HPV-16 
POSITIVE CELL LINES COMPARED TO HPV NEGATIVE CELL 
LINE C-33A 
 
  HPV16 Integrated HPV16 episomal 
miRNA Fold Change Fold Change 
Overexpressed     
hsa_miR_200c 27.9 36 
hsa_miR_203 23.4 14.7 
hsa_miR_193b 21.2 10.6 
hsa_miR_34a 10.4   
hsa_miR_31 8.4 10.9 
hsa_miR_210 5.7   
hsa_miR_27a 5.4   
hsa_miR_503 5.4   
hsa_miR_27b 4.9   
hsa_miR_205   50.1 
hsa_miR_141   16.8 
ambi_miR_13258   8 
hsa_miR_200b   7 
hsa_miR_200a   5.3 
hsa_miR_224   5.1 
Underexpressed     
hsa_miR_218 -7.4   
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Differential Expression of MicroRNAs in the HPV-Negative Cell Line C-33A 
Compared to the Normal Cervix 
 
 The miRNA expression profile of the HPV-negative cell line C-33A showed 
that 4 miRNAs (miR-143, miR-145, miR-200c and miR-203) were 
underexpressed as compared to the normal cervix (Supporting Information, 
Table 16). In general, the downregulation of miRNAs in C-33A was more severe 
than that observed in the HPV-positive cell lines (Table 14 and 16). 
 
Validation of the MiRNA Microarray Expression Data by Quantitative Real-Time 
RT-PCR and Northern Blot Analyses 
 
 The miRNA microarray results were validated by qRT-PCR and Northern 
blot analyses of 8 representative miRNAs whose expression was either most 
affected, affected in other types of cancers, or one that appeared to be HPV-
specific (miR-218) (Fig. 15A and 15B). In general, the results of these analyses 
were consistent with the microarray data, although the fold-changes observed by 
qRT-PCR analyses were much greater than those obtained with the microarrays. 
Also, there were differences in individual miRNA levels between some HPV-16 
positive cell lines. For example, the expression pattern of miR-200c and miR-205 
in SiHa was different than the other HPV-positive cell lines, but similar to that of 
C-33A (Fig. 15A and  
 134
TABLE 16. MiRNAs DIFFERENTIALLY EXPRESSED IN HPV 
NEGATIVE CELL LINE C-33A COMPARED TO NORMAL 
CERVICAL TISSUE 
 
miRNA Fold Change 
Underexpressed   
hsa_miR_145 -29.7 
hsa_miR_143 -14.9 
hsa_miR_203 -13.7 
hsa_miR_200c -10 
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Fig. 15.  CONFIRMATION OF miRNA MICROARRAY 
EXPRESSION DATA IN VARIOUS CERVICAL CELL LINES AND 
NORMAL CERVICAL TISSUE 
 
 
 
(A) Northern blot analysis. The housekeeping splicing-related small U6 RNA was 
used as a loading control. (B) Real-time qRT-PCR analysis. All reactions were 
performed in triplicates and the error bar represents the standard deviation.  
RNU43 served as the endogenous control for miRNAs.  
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15B). The “band” seen in the Northern blot for miR-368 in the 20861 sample is a 
gel artifact and does not represent a miRNA signal. 
 
Clustering Analysis of MiRNA Expression Patterns in Various Cell Lines 
 
 Unsupervised hierarchical clustering analysis revealed two major miRNA 
expression clusters (Fig. 16). Cluster 1 contained six miRNAs which were 
expressed to much higher levels in the normal cervix and the HPV-positive cell 
lines compared to C-33A. The only exception was the HPV-16 positive cell line 
SiHa which showed a pattern similar to that of C-33A and had low-level 
expression of the miRNAs in cluster 1. The expression data for miR-200c and 
miR-205 obtained by Northern blot and qRT-PCR analyses for all the above 
samples (Fig. 15B) were also consistent with those found in cluster 1 (Fig. 16). 
Cluster 2 contained 28 miRNAs that, in general, showed lower expression in all 
the cervical cell lines compared to the normal cervix (Fig. 16).   
 
Expression Patterns of MiRNAs in HPV-16 Positive Cervical Lesions and 
Cervical Cancer Tissues 
 
 We also analyzed the expression profile of six miRNAs in three HPV-16 
positive cervical intraepithelial neoplasia grade III (CIN III) tissues and five HPV-
16 positive cervical cancer tissues (CaCx) by qRT-PCR analysis. Due to the  
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Fig. 16. HIERARCHICAL CLUSTERING ANALYSIS OF miRNAs IN 
CERVICAL CELL LINES AND NORMAL CERVICAL TISSUE 
 
 
 
 
Hierarchical clustering analysis of miRNAs in cervical cell lines and normal 
cervical tissue. Red and green indicates high or low expression, respectively. 
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 limited amount of RNA available from the tissues, miRNA microarray analysis 
could not be done. The expression pattern of the above miRNAs in the tissues 
was generally consistent with that of the HPV-positive cell lines (Fig. 17). 
Although the relative levels of various miRNAs varied between the individual 
samples, miRNAs that were underexpressed in the HPV-16 positive cell lines 
were generally also underexpressed in the HPV-positive tissues compared to the 
normal cervical tissue (Fig. 17). The CIN III samples generally showed a more 
limited underexpression of the miRNAs compared to the CaCx tissues, although 
this correlation was not absolute. The results obtained with the tissues provide 
further validation of the data obtained with the cervical cell lines. Importantly, 
miR-218 was found to be underexpressed in all the CIN III and CaCx samples 
compared to the normal cervix (Fig. 17). Since miR-218 is encoded by an intron 
of the SLIT2 tumor suppressor gene (Griffiths-Jones, 2004;Griffiths-Jones, et al., 
2006), we tested whether their expression is correlated. Previous analysis of 
global gene expression (manuscript in preparation) has also shown that SLIT2 
was underexpressed in the HPV-positive cell lines. The qRT-PCR results showed 
that SLIT2 expression paralleled that of miR-218, and both of these were 
underexpressed in the CIN III and CaCx tissues (Fig. 17). These results suggest 
that the expression of miR-218 and SLIT2 is similarly affected in HPV-positive 
lesions and CaCx tissues. 
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Fig. 17. EXPRESSION OF miRNAs AND THE SLIT2 GENE IN 
CERVICAL TISSUES 
 
 
MicroRNAs and SLIT2 qRT-PCR analysis of three cervical intraepithelial 
neoplasias type III (CIN III), five cervical carcinomas (CaCx) and the normal cervix. 
All reactions were performed in triplicates. G3PDH served as the endogenous 
control for SLIT2. 
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HPV-16 E6 Oncogene Downregulates MiR-218 
 
 We wished to determine whether E6 and/or E7 expression is directly 
correlated with reduced expression of miR-218.  For this, we utilized the 
osteosarcoma cell line U2OS (Duensing, et al., 2000) either expressing the HPV-
16 E6 or E7 gene, or the control neomycin resistance gene. The qRT-PCR 
results showed that both miR-218 and SLIT2 were underexpressed in the E6-
expressing U2OS cell line compared to the E7-expressing U2OS and the control 
U2OS-Neo cell line (Fig. 18A). In another approach, the 20861 cell line 
containing integrated HPV-16 was transfected with HPV-16 E6/E7 siRNAs. Since 
E6 and E7 are derived from alternative splicing of the same RNA, a specific 
siRNA for E6 alone could not be used. The E6/E7 siRNAs reduced expression of 
these genes while increasing the expression of both miR-218 and the SLIT2 
gene in 20861 cells (Fig. 18B). These results indicate that the HPV-16 E6 gene is 
involved in the downregulation of miR-218 and the SLIT2 gene in HPV-16 
positive cell lines.    
 
Laminin 5 β3 is a Possible Transcriptional Target of MiR-218 
 
 To identify possible miR-218 targets, we compared computationally 
predicted targets in the miRBase Registry (Griffiths-Jones, 2004;Griffiths-Jones, 
et al., 2006) with our gene expression data (manuscript in preparation), and then 
used the program rna22 [http://cbcsrv.watson.ibm.com/rna22.html]. The resulting  
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Fig. 18. HPV-16 E6 oncogene reduces the expression of miR-218 
 
 
 
 
 
 
(A) qRT-PCR analysis of miR-218, SLIT2, and β-actin in U2OS-Neo, U2OS-E6, and 
U2OS-E7. (B) Expression of HPV-16 E6 and E7, miR-218, SLIT2, and β-actin 
(housekeeping control) in the 20861 cell line with or without RNAi against HPV-16 
E6/E7.   
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6 possible targets were analyzed by qRT-PCR in SiHa and 20861 cell lines 
transfected with an artificial miR-218 precursor molecule. After confirming the 
expression of mature miR-218 (data not shown), we found that only the LAMB3 
transcript was significantly underexpressed in miR-218 expressing cells (Fig. 
19A). We also found that LAMB3 was underexpressed in the 20861 cell line in 
the presence of the E6/E7 siRNAs compared to a control oligo (Fig. 19B). 
Furthermore, U2OS-E6 cells showed an increase in the levels of LAMB3 mRNA 
as compared to the U2OS-Neo cells (Fig. 19B). Taken together, these results 
demonstrate that miR-218 reduces LAMB3 expression at the transcriptional level. 
 
4.4 DISCUSSION 
 
The microarray data showed that 24 miRNAs were underexpressed and 3 
overexpressed in integrated HPV-16 cell lines compared to the normal cervix 
(Table 14). We also validated these data by Northern blot and qRT-PCR 
analyses for five miRNAs that were underexpressed (miR-143, miR-145, miR-
218, miR-368 and miR-497) and three that were overexpressed (miR-193b, miR-
200c and miR-205) in the cell lines compared to the normal cervix (Fig. 15). The 
probable targets of the above eight miRNAs are shown in supplementary data, 
table W. Our studies identified 10 underexpressed miRNAs in integrated HPV-16 
cell lines that are not known to be altered in any cancers. These included 7 
known human miRNAs,  
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Fig. 19. EXPRESSION OF LAMB3 IS AFFECTED IN THE 
PRESENCE OF miR-218 
 
 
 
 
 
(A) qRT-PCR analysis of LAMB3 in SiHa and 20861 cell lines transfected with a 
precursor of miR-218. (B) Expression of LAMB3 in the 20861 cell line with or 
without RNAi against HPV-16 E6/E7, and in the U2OS-Neo, U2OS-E6, and U2OS-E7 
cell lines. G3PDH served as the endogenous control for LAMB3. 
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miR-1, miR-133a, miR-126-AS, miR-376a, miR-451, miR-487b, miR-495, and 3 
predicted miRNAs, ambi-miR-5021, ambi-miR-7029, and ambi-miR-7070. Many 
of the differentially expressed miRNAs in integrated HPV-16 cell lines have been 
previously associated with various types of cancers. For example, miR-143 and 
miR-145 are underexpressed in colon and breast cancers (Iorio, et al., 
2005;Michael, et al., 2003;Volinia, et al., 2006) and they are also found in 
chromosomal fragile sites in many cancers (Calin, et al., 2004). Since miR-143 
and miR-145 are underexpressed in all cervical cell lines including C-33A 
(Supporting Information, Table 4), our results suggest that they may be important 
in cervical carcinogenesis independent of HPV infection. MiR-368 is 
underexpressed in colon cancer cell lines (Bandres, et al., 2006), miR-497 is 
altered in papillary thyroid carcinomas (Pallante, et al., 2006), and miR-193b is 
underexpressed in colon cancer cell lines with a Dicer mutation (Cummins, et al., 
2006). Interestingly, miR-218 was the only miRNA found to be underexpressed in 
integrated HPV-16 cell lines compared to both the normal cervix and C-33A cells, 
suggesting that it may be a specific cellular target of HPV-16. MiR-218 is also 
underexpressed in several cancers and the DNA encoding miR-218 is also 
deleted in ovarian, breast, and melanoma cancers (Volinia, et al., 2006;Zhang, et 
al., 2006). Of the miRNAs overexpressed in integrated HPV-16 cell lines, miR-
210 is overexpressed in many epithelial cancers (Volinia, et al., 2006), while miR-
182 and miR-183 are overexpressed in colon cancer cell lines (Bandres, et al., 
2006). We also found that 6 miRNAs have reduced expression in the episomal 
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HPV-16 cell line 20863 compared to the normal cervix (Table 14). These 
miRNAs may represent early targets of HPV-16 infection.   
 
 Hierarchical clustering analysis revealed miRNAs that exhibit similar 
expression patterns in various cell lines. Cluster 1 includes miR-200a and miR-
200b which are part of the same miRNA family located on chromosome 1p36.33, 
while miR-200c and miR-141 are part of another family located on chromosome 
12p13.31 (Griffiths-Jones, 2004;Griffiths-Jones, et al., 2006). This suggests that 
these miRNAs may be subject to common transcriptional regulation. Cluster 2 
contained 28 miRNAs that in general had lower expression in all the cervical cell 
lines compared to the normal cervix (Fig. 16). Two of these miRNAs, miR-368 
and miR-497, were also found to be underexpressed in most of CIN III and CaCx 
tissues (Fig. 17). Interestingly, 11 miRNAs in cluster 2 (miR-126, miR-195, miR-
150, miR-142-5p, miR-133a, miR-1, miR-296, miR-101, miR-146a, miR-223 and 
miR-214) are also underexpressed in leukemia and lymphoma cell lines 
compared to normal B-cells (Lu, et al., 2005) suggesting that reduced expression 
of these miRNAs could be a common mechanism during immortalization and/or 
transformation.   
 
 Analysis of 6 miRNAs (miR-143, miR-145, miR-200c, miR-218, miR-368 
and miR-497) in CIN III and CaCx tissues by qRT-PCR showed expression 
patterns that were generally similar to those of the HPV-positive cell lines (Fig. 15 
and 17). Importantly, miR-218 was also underexpressed in CIN III and CaCx 
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tissues (Fig. 17). These results suggest that miR-218 underexpression is likely 
linked to the process of HPV-associated carcinogenesis in vivo. The parallel 
expression of miR-218 and the SLIT2 gene (which encodes miR-218) in all the 
tumor tissues (Fig. 17) suggests that they may be coordinately regulated. 
Previous studies have shown that the SLIT2 tumor suppressor gene is frequently 
inactivated in lung and breast cancers (which have reduced miR-218 levels) 
(Dallol, et al., 2002;Volinia, et al., 2006). Whether regulation of SLIT2 plays a role 
in the pathogenesis of HPV-associated malignancies is currently unknown.      
 
 Our results showed that both miR-218 and SLIT2 were underexpressed in 
the U2OS-E6 cell line (Fig. 18A), suggesting that E6 may contribute to their 
downregulation. This possibility is also supported by our observations that 
expression of E6/E7 siRNAs in 20861 cells increases miR-218 and SLIT2 mRNA 
levels (Fig. 18B). Interestingly, SLIT2 is a possible target of miR-200c 
(overexpressed in our HPV-positive cell lines and tissues) (supplementary data, 
table W). One study has shown that the absence of the p53 gene increases miR-
200c expression (Xi, et al., 2006). Thus, it is possible that E6-dependent 
degradation of the p53 protein results in miR-200c overexpression which in turn 
reduces the levels of miR-218 and SLIT2 mRNA.  
 
Our studies showed that introduction of miR-218 or E6/E7 siRNAs into 
SiHa and/or 20861 cell lines reduces Laminin 5 β3 gene (LAMB3) expression 
(Fig. 19A and 19B). Also, E6 expression in U2OS cells increases LAMB3 
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expression (Fig. 19B) presumably by reducing miR-218 expression. The above 
studies suggest that miR-218 may regulate LAMB3 expression at the 
transcriptional level. LAMB3 protein is part of the polymeric cell surface receptor 
laminin 5 that is expressed in the basal lamina of the epithelium and is 
overexpressed in cervical cancers (Kohlberger, et al., 2003;Skyldberg, et al., 
1999). LAMB3 increases cell migration and tumorigenicity in SCID mice, and in 
collaboration with its ligand α6β4-integrin promotes tumorigenesis in human 
keratinocytes (Calaluce, et al., 2004;Dajee, et al., 2003). A recent study suggests 
that secreted laminin 5 can be used by HPV as a transient receptor to aid the 
virus in the infection of basal cells that express α6β4-integrin (Culp, et al., 2006). 
Thus, downregulation of miR-218 by E6 and the consequent overexpression of 
LAMB3 may promote viral infection of the surrounding tissue and contribute to 
eventual tumorigenesis. 
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 Cervical and oropharyngeal cancers represent an important health 
problem worldwide. A better understanding of the interactions between HPV and 
these tumor cells is important for the identification of the molecular mechanisms 
involved in HPV-associated diseases as well as for the identification of diagnostic 
and prognostic markers and approaches towards treatment. In these studies, we 
used high-density microarrays (Affymetrix U133A GeneChip® expression 
microarray containing 22,215 human transcripts) to analyze gene expression 
differences in several HPV-positive and HPV-negative cervical cell lines and 
SCCHN tissues in order to identify the pathways altered in HPV-positive cells as 
a consequence of viral gene expression, integration, and other downstream 
events.   
 
 Infection with high-risk HPVs has been implicated in a subset of 
squamous cell carcinoma of the head and neck (SCCHN). Part of our study was 
to compare the cellular gene expression profiles of HPV16-positive and HPV-
negative oropharyngeal carcinomas with those of the normal oral epithelium. 
Although the number of specimens used in our study was small, a unique feature 
of this study was that we have exclusively utilized tissues derived from the 
oropharyngeal site. While HPV infection can be identified throughout tumors of 
the head and neck, a disproportionately high incidence is observed in the 
oropharynx (approximately 50%). Thus, utilizing tumors from this region reduces 
sample heterogeneity and eliminates variability due to different tumor sub-sites 
which has been observed in previous studies. After confirming the expression of 
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the HPV-16 E6 and E7 genes in the HPV-positive SCCHN, we proceeded with 
the global gene expression analysis. We found that 228 genes were upregulated 
and 169 downregulated in HPV-positive SCCHN samples as compared to the 
normal oral tissues (Table 2). The upregulated genes included those involved in 
DNA replication and cell cycle regulation such as CDKN2A (p16INK4a), MCM2, 
PCNA, TOP2A and RBL1 that have been previously identified to be affected in 
HPV-infected cervical and oral carcinomas (Li, et al., 2004;Ren, et al., 
2002;Santin, et al., 2005). Several studies have shown either direct or indirect 
regulation of these genes by the tumour suppressor protein p53 (RBL1, PCNA, 
TOP2A) or by E2F transcription factors (CDKN2A and MCM2) (Ren, et al., 
2002;Wei, et al., 2006). One possible explanation for the transcriptional 
deregulation of this group of genes may be the degradation of p53 and pRB (that 
bind and repress the activity of the family of E2F transcription factors) by the viral 
oncogenes E6 and E7, respectively (Kannan, et al., 2001;Ren, et al., 2002;Wei, 
et al., 2006;Zhao, et al., 2000). These data support the notion that HPV-positive 
SCCHN has a specific transcription profile partly dependent on E6 and E7 
expression. When we compared the HPV-negative SCCHN against normal 
oropharyngeal squamous mucosa, we found 79 upregulated and 83 
downregulated genes (Table 3). We found upregulated genes such as AKR1C3 
and SNAPC1 and downregulated genes such as CLU and RBM3 that were 
previously not known to be differentially expressed in SCCHN. AKR1C3 is a 
hydroxysteroid dehydrogenases involved in the regulation of local concentration 
of androgens and estrogens in hormone-dependent tissues such as prostate, 
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breast and endometrium (Penning, et al., 2006). AKR1C3 has been found to be 
overexpressed at both the mRNA and protein levels in prostate cancer 
specifically in the stromal cells (Penning, et al., 2006). SNAPC1 is a subunit of 
the TBP-TAF complex involved in the transcription of both RNA polymerase II 
and III dependent small nuclear RNA genes. SNAPC1 has been linked to the 
tumorigenesis of breast cancers (Xie, et al., 2002). CLU is a multifunctional gene 
which is involved in spermatogenesis and in the control of the immunological 
complement cascade (Scaltriti, et al., 2004). It has recently been shown that CLU 
is downregulated in low- and high-grade human prostate cancers and it may be 
involved in supporting cell survival and the induction of programmed cell death 
(Scaltriti, et al., 2004). RBM3, a glycine-rich RNA-binding protein induced by 
cold-stress, has recently been found to have apoptotic modulatory capabilities 
with a possible role as a tumor suppressor gene (Sutherland, et al., 2005). 
Interestingly, there is evidence that RBM3 can change the expression of some 
microRNAs and enhance global protein synthesis suggesting the involvement of 
a homeostatic mechanism that regulates global levels of protein synthesis under 
normal and cold-stress conditions (Dresios, et al., 2005). Interesting data were 
also obtained when we compared the HPV-positive SCCHN against HPV-
negative SCCHN. We found that 124 genes were upregulated and 42 genes 
were downregulated in HPV-positive SCCHN as compared to HPV-negative 
SCCHN (Table 4). Among this group of genes, we found a subset of genes (41 
upregulated and 19 downregulated) that were also differentially expressed in 
HPV-positive SCCHN as compared to the normal oropharyngeal mucosa (Table 
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5). It is likely that the differential expression of these 60 genes is a consequence 
of the presence of HPV-16. This group of genes included the upregulated genes 
SYCP2, RFC5, ZNF238 and DNMT1, and the downregulated genes KLK8 and 
CRABP2. SYCP2 is part of the synaptonemal complex involved in forming lateral 
elements and cross bridges that contribute to pairing of sister chromatids during 
meiosis and probably are involved in the interaction between chromatin and 
nuclear envelope (Shakib, et al., 2005). There is evidence that HPV infection in 
cervical cells promotes morphological changes in the nuclear membrane as well 
as condensation of chromatin attached to the inner part of the nuclear membrane 
(Bollmann, et al., 2005). Thus, it is possible that SYCP2 may be involved in 
chromatin-nuclear envelope interactions in HPV-positive SCCHN. A recent study 
by Slebos and colleagues also reported up-regulation of the SYCP2 in HPV-
positive SCCHN as compared to HPV-negative SCCHN, supporting the idea that 
this gene may play important roles in the carcinogenesis of HPV-related SCCHN 
(Slebos, et al., 2006). The transcription factor ZNF238 (also known as RP58) is a 
component of a C2H2-type DNA-binding zinc finger protein that acts as a 
repressor of transcriptionally silent heterochromatin regions. Interestingly, the 
DNA methyltransferase protein Dnmt3a directly interacts with ZNF238 and 
promotes the repression of specific genes by histone deacetylation 
independently of its methyltransferase activity (Fuks, et al., 2001). The 
overexpression of ZNF238 could explain the downregulation of several genes in 
HPV-positive SCCHN as a consequence of chromatin condensation by histone 
deacetylation. CRABP2 is a transcription factor that functions as a cytoplasmic 
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retinoic acid binding protein that is highly expressed in human skin. Similar to our 
results showing its downregulation in HPV-positive SCCHN, CRABP2 is also 
downregulated in prostate cancer (Okuducu, et al., 2005). In order to understand 
why some of these genes are differentially expressed in the HPV-positive 
SCCHN, we used an unsupervised hierarchical clustering analysis. We were able 
to identify a group of genes in five different clusters with significant variation 
between HPV-positive SCCHN as compared to HPV-negative SCCHN as well as 
normal oropharyngeal epithelium (Fig. 7). Some of the genes found to be 
differentially expressed in our microarray analysis were also found in these 
clusters such as ZNF238, DNMT1, MCM3, AKR1C3, GRB10, TYK2 and SART3  
(underlined in Fig. 7). After detecting these five different clusters, we identified 
the localization of these genes to particular chromosomes (Fig. 8). Two regions 
in chromosome 1 (p34-p36) and 12 (q21-q240) showed a significant number of 
differentially expressed genes, particularly upregulated genes in HPV-positive 
SCCHN. Interestingly, there are two previous publications showing chromosomal 
aberrations and amplification in chromosome 1 and chromosome 12q24 in HPV-
positive cervical intraepithelial neoplasias and head and neck carcinomas, 
respectively. This may suggest that some of these chromosomal regions are 
important in the carcinogenesis of HPV-positive SCCHN. We also attempted to 
identify possible transcription factor binding sites in the promoter regions of 
various gene clusters that could be involved in regulating gene expression. After 
obtaining the promoter sequences of all the genes from cluster 4 and 5 (genes 
mostly downregulated in HPV-positive SCCHN), we found that all these genes 
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shared the binding sequence for the transcription factor GATA3 (data not 
shown). Interestingly, a recent study showed downregulation of GATA3 mRNA 
by differential display in HPV-immortalized keratinocytes, HG-SIL and cervical 
carcinomas suggesting that this is a late event in cervical tumorigenesis 
(Steenbergen, et al., 2002). This data suggests that the absence of GATA3 could 
be responsible for the down-regulation of these cluster of genes in HPV-positive 
SCCHN. In summary, our data demonstrates specific changes in cellular gene 
expression profiles in HPV-positive SCCHN which also express the viral 
oncogenes.  
 
 In another study, we analyzed the global gene expression profile of HPV-
positive cervical cell lines in comparison with one HPV-negative cervical cell line 
named C-33A and normal cervical tissue. After confirming appropriate 
expression of the viral genes and the physical state of the HPV DNA in various 
cell lines, we analyzed the cellular gene expression profiles of these cervical cell 
lines. Our results showed that 272 genes were upregulated while 605 were 
downregulated in all the HPV-positive cell lines compared to the normal cervix 
tissue. A representative list of differentially expressed genes is shown in Table 8. 
We then compared the global gene expression between all the HPV-positive 
cervical cell lines and the HPV-negative cervical carcinoma cell line C-33A. We 
found that 305 genes were upregulated and 232 genes were downregulated in all 
the HPV-positive cell lines compared to C-33A (Table 9). In order to identify 
cellular genes whose expression might be specifically altered due to the 
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presence of HPV sequences, we compared the data obtained for HPV-positive 
cell lines with those of both the normal cervix and the C-33A cell line.  This 
analysis revealed that a total of 20 genes were upregulated and 37 
downregulated in the HPV-positive cell lines as compared to both the normal 
cervix and C-33A (Table 10). Some of the differentially expressed genes found in 
our analysis have been previously described in other cervical cancer microarray 
studies such as TFAP2A (involved in transcription regulation) and IGSF4 (may 
involved in cell-cell adhesion). Other genes such as CPA4, NEFH, LAT1, 
SPRY1, ID4 and NAP1L3 have not been previously been shown to de 
differentially expressed in cervical cancer cell lines. Nuclear organization and 
biogenesis CPA4 gene is expressed at extremely low levels in human adult 
tissues but is abundant in prostate cancer cell lines, suggesting that it may 
modulate the function of peptide hormones that play an essential role in the 
growth and differentiation of prostate epithelial cells (Kayashima, et al., 2003). It 
may play a similar role in the growth of HPV-positive cervical epithelial cells. The 
L-type amino acid transporter 1 (LAT1, also known as SLC7A5) found to be 
upregulated in all the HPV-positive cell lines compared to both the normal cervix 
and HPV-negative C-33A cell line (Table 10 and Fig. 13), is an amino acid 
transporter essential for growth and proliferation. The y+ system L-amino acid 
transporters are responsible for the Na+-independent transport of neutral amino 
acids, including several essential amino acids. LAT1 has been found to be 
overexpressed in astrocytic tumors suggesting that some tumors including 
cervical cancer may require more nutrient transport for growth and cell 
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proliferation. Another gene found to be downregulated in our study is the 
nucleosome assembly protein 1-like 3 (NAP1L3) gene. NAP1L3 is part of the 
nuclesome assembly complex that probably plays a role in gene expression 
during brain development. Interestingly, NAP1L3 has been found to be down-
regulated in uterus carcinomas suggesting that the disruption of this gene could 
be frequent in tumors of the female reproductive epithelium. To verify that LAT-1 
and NAP1L3 are not affected in HPV-positive cervical cell line as a consequence 
of in vitro immortalization or growth in tissue culture, we carried out in situ 
hybridization to detect LAT1 and NAP1L3 mRNA in tissue-arrays containing ~50 
different cervical tumor samples and 4 normal cervix controls per slide. Our data 
showed that similar to the cervical carcinoma cell lines, these genes were also 
differentially expressed in cervical carcinoma tissues suggesting a possible role 
in the carcinogenesis of the cervix. Because the integration of HPV DNA usually 
occurs during the progression of HPV infection and the DNA is found to be 
mostly integrated in high-grade lesions and cervical cancers (zur Hausen, 2002), 
we also analyzed the differences in cellular gene expression profiles between 
cervical carcinoma cell lines containing integrated HPV DNAs (CaSki, SiHa, 
201402, 20861 and HeLa) and cell lines containing episomal HPV DNA that 
mimic low-grade lesions (20863 and L-18). Our data showed that 52 genes were 
upregulated while 47 were downregulated in cell lines containing integrated HPV 
DNA (Table 11). The upregulated genes in HPV-16 or HPV-18 integrated cell 
lines included those involved in the regulation of mitosis (CENPF) and cell growth 
and anti-adhesion (PODXL). The downregulated genes included those involved 
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in host defense response like GATA3. The CENPF gene that encodes the 
centromere protein F, 350/400ka (mitosin) may de-regulate kinetochore 
assembly at the G2/M checkpoint and facilitate defective chromosome 
segregation, promoting cervical carcinogenesis (de la Guardia, et al., 2001). The 
upregulation of CENPF in cell lines containing integrated HPV DNA is consistent 
with E7 expression and chromosomal instability associated with HPV integration 
(Pett, et al., 2004). Our data also showed that the PODXL (mucin-like surface 
sialoglycoprotein podocalyxin-like) gene is upregulated in cell lines containing 
integrated HPV DNA. PODXL is an integral membrane glycoprotein that has 
different cell adhesion properties in different tissues and is repressed by the p53 
protein at the transcriptional level (Stanhope-Baker, et al., 2004). Increased 
expression of E6 in cell lines with integrated HPV DNA causes p53 degradation 
and  could result in an increase in PODXL expression (zur Hausen, 2002). One 
gene found downregulated in HPV-integrated cell lines compared to HPV-
episomal cel lines was GATA3 (essential transcription factor GATA binding 
protein 3). GATA3 is part of the GATA family of zinc-finger transcription factors 
that are involved in differentiation and development of different tissues in 
vertebrates (Lim, et al., 2000). A recent study showed downregulation of GATA3 
mRNA by differential display in HPV-immortalized keratinocytes, HG-SIL and 
cervical carcinomas suggesting that this is a late event in cervical tumorigenesis 
(Steenbergen, et al., 2002). The increased expression of GATA3 may be co-
related with the integration of HPV DNA into the host genome and progression of 
cervical cancer. Interestingly, two upregulated genes identified in our study BST2 
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(involved in vesicle coat assembly) and TOP2A (involved in DNA topological 
changes) have previously been reported by Alazawi et al. comparing the 
episomal HPV cell line 20863 and its subsequent passages lacking feeder cells 
(which is expected to result in the integration of HPV DNA) (Alazawi, et al., 
2002). These genes could be important in the process of HPV integration into the 
host genome and consequently in cervical carcinogenesis. Although both HPV 
types 16 and 18 are high-risk viruses, HPV-16 is commonly associated with 
SCC, whereas HPV-18 is predominantly associated with adenocarcinoma (Burk, 
et al., 2003). In order to identify differences in host gene expression when they 
are infected by one of these two high-risk HPVs, we compared the gene 
expression profiles in cell lines containing HPV-18 with those in cell lines 
containing HPV-16 DNA. We found that 36 genes were upregulated while 3 were 
downregulated in HPV-18 positive cells compared to the HPV-16 positive cells 
(Table 12). Of note, the keratin 8 (KRT8) and keratin 18 (KRT18) genes involved 
in cytoskeleton organization were found to be upregulated in the presence of 
HPV-18 compared to cells containing HPV-16. The relatively few genes that were 
found to be differentially expressed in this analysis may suggest the involvement 
of predominantly similar pathways during the progression of cervical 
carcinogenesis induced by the high-risk HPV-16 and HPV-18.  In summary, our 
data demonstrate specific changes in cellular gene expression profiles in HPV-
positive cervical cell lines that could be used as a basis for identifying molecular 
mechanisms involved in the pathogenesis of HPV-associated cervical cancers. 
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 After identifying the global gene expression profiles in HPV-positive 
cervical cell lines and HPV-positive SCCHN, we compared the above two sets of 
data to identify genes that may be differentially expressed in both of these types 
of HPV-positive cancers, and therefore may provide a molecular signature of 
HPV infection. When we compared the data obtained with “HPV-positive cervical 
cell lines vs normal cervical tissue” against “HPV-positive SCCHN vs normal oral 
tissue”, we found that 20 upregulated genes and 27 downregulated genes were 
shared between these cancers (Table 17). Several of the upregulated genes 
such as CKS1B, CDC6, CDKN2A, FEN1, MAD2L1, MCM7 and RNASEH2A are 
involved in cell cycle and DNA replication, while many of the downregulated 
genes are involved in  immune response (CCL14, CCL15, CRISP3, LTF and 
SPINK5), cell differentiation (DMBT1,  SCEL and MAL), and cell cycle arrest 
(PCAF). Future studies of these particular genes will be important to validate this 
data and understand the influence of HPV presence in the regulation of host 
genes that could be involved in the carcinogenesis of these epitheliums. 
 
 We were also interested in identifying the mechanisms by which HPVs 
may affect cellular gene expression.  Recently, the discovery of microRNAs 
which are small non-coding RNAs that can regulate gene expression at a 
posttranscriptional level have revolutionized our understanding of gene regulation 
in eukaryotic cells. Therefore, we undertook a study to identify human 
microRNAs which may be targeted by HPVs and whose expression may be  
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Table 17. DIFFERENTIALLY EXPRESSED GENES FOUND IN 
COMMON BETWEEN “THE HPV-POSITIVE CERVICAL CELL 
LINES VS NORMAL CERVICAL TISSUE DATA” AND “THE HPV-
POSITIVE SCCHN VS NORMAL ORAL TISSUE DATA”  
Gene Title Gene Symbol GO Biological Process Description 
Upregulated genes     
CDC28 protein kinase regulatory subunit 1B CKS1B cell cycle /// cytokinesis 
CDC6 cell division cycle 6 homolog (S. cerevisiae) CDC6 
DNA replication checkpoint /// cell cycle /// cytokinesis /// 
mitosis 
cofactor of BRCA1 COBRA1 regulation of transcription, DNA-dependent 
cyclin B2 CCNB2 cytokinesis /// mitosis /// regulation of cell cycle 
cyclin-dependent kinase inhibitor 2A CDKN2A 
cell cycle checkpoint /// negative regulation of cell 
proliferation 
dual specificity phosphatase 14 DUSP14 protein amino acid dephosphorylation 
flap structure-specific endonuclease 1 FEN1 
DNA replication /// UV protection /// double-strand break 
repair 
frizzled homolog 2 (Drosophila) FZD2 
Wnt receptor signaling pathway /// development /// 
establishment of tissue polarity 
glutathione S-transferase omega 1 GSTO1 metabolism 
MAD2 mitotic arrest deficient-like 1 (yeast) MAD2L1 cell cycle /// mitosis /// mitotic checkpoint 
maternal embryonic leucine zipper kinase MELK protein amino acid phosphorylation 
MCM7 minichromosome maintenance deficient 7 MCM7 
DNA replication initiation /// cell cycle /// regulation of 
transcription 
Opa-interacting protein 5 OIP5 cell communication 
pescadillo homolog 1, containing BRCT domain (zebrafish) PES1 morphogenesis 
proteasome (prosome, macropain) subunit, beta type, 5 PSMB5 ubiquitin-dependent protein catabolism 
ribonuclease H2, large subunit RNASEH2A DNA replication /// RNA catabolism 
S-phase kinase-associated protein 2 (p45) SKP2 
G1/S transition of mitotic cell cycle /// cell proliferation /// 
ubiquitin cycle 
thioesterase superfamily member 2 THEM2 --- 
thymidine kinase 1, soluble TK1 DNA metabolism 
ubiquitin-conjugating enzyme E2C UBE2C 
cell cycle /// cytokinesis /// mitosis /// positive regulation of 
cell proliferation 
Downregulated genes     
aldehyde dehydrogenase 1 family, member A1 ALDH1A1 aldehyde metabolism 
amylase, alpha 2A; pancreatic AMY2A carbohydrate metabolism 
chemokine (C-C motif) ligand 14 /// chemokine (C-C motif) 
ligand 15 
CCL14 /// 
CCL15 immune response /// cell-cell signaling /// chemotaxis 
chromosome 6 open reading frame 29 C6orf29 --- 
cysteine-rich secretory protein 3 CRISP3 
cell-cell adhesion /// innate immune response /// 
spermatogenesis 
deleted in malignant brain tumors 1 DMBT1 epithelial cell differentiation /// innate immune response 
flavin containing monooxygenase 3 FMO3 electron transport 
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glycine amidinotransferase GATM biosynthesis /// creatine biosynthesis 
glycoprotein M6A GPM6A --- 
homeodomain-only protein /// homeodomain-only protein HOP regulation of transcription, DNA-dependent 
kallikrein 13 KLK13 proteolysis and peptidolysis 
lactotransferrin LTF 
humoral immune response /// iron ion homeostasis /// iron 
ion transport 
LIM domain only 2 (rhombotin-like 1) LMO2 cell growth and/or maintenance /// development 
loss of heterozygosity, 11, chromosomal region 2, gene A LOH11CR2A --- 
mal, T-cell differentiation protein MAL 
apical protein localization /// cell differentiation /// induction 
of apoptosis 
multimerin 1 MMRN1 blood coagulation /// cell adhesion 
p300/CBP-associated factor PCAF 
cell cycle arrest /// chromatin remodeling /// protein amino 
acid acetylation 
paternally expressed 3 PEG3 --- 
prominin 1 PROM1 visual perception 
sciellin SCEL epidermis development 
selenium binding protein 1 SELENBP1 --- 
serine protease inhibitor, Kazal type 4 SPINK4 --- 
serine protease inhibitor, Kazal type 5 SPINK5 
anti-inflammatory response /// antimicrobial humoral 
response (sensu Vertebrata) 
transcobalamin I  TCN1 cobalamin transport /// cobalt ion transport /// transport 
tryptase, alpha TPS1 defense response /// proteolysis and peptidolysis 
zinc finger protein 254 /// zinc finger protein 539 
ZNF254 /// 
ZNF539 negative regulation of transcription from Pol II promoter 
zinc finger protein 91 (HPF7, HTF10) ZNF91 
carbohydrate metabolism /// regulation of transcription, 
DNA-dependent 
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affected by the viral oncogenes.  First, by using miRNA microarrays our studies 
demonstrate for the first time that approximately 220 miRNAs are expressed in 
the normal cervix (Supplementary data, table V). The ten most highly expressed 
miRNAs in the cervix were miR-145, mir-26a, miR-99a, let-7a, miR-143, let-7b, 
let-7c, miR-125b, miR-126, and miR-195. These miRNAs may be important for 
the maintenance of a certain phenotype in the cervical tissue.  After this analysis, 
we compared the miRNA profiles in five HPV-16 positive cervical cell lines (four 
HPV-16 integrated and one HPV-16 episomal cell lines) with that of the normal 
cervical tissue. The microarray data showed that 24 human miRNAs were 
underexpressed and 3 overexpressed in integrated HPV-16 cell lines compared 
to the normal cervix (Table 14). Many of the differentially expressed miRNAs in 
integrated HPV-16 cell lines have previously been found to be associated with 
various types of cancers.  MiR-143 and miR-145 are underexpressed in colon 
and breast cancers (Iorio, et al., 2005;Michael, et al., 2003;Volinia, et al., 2006). 
Also, several miRNAs are located in chromosomal fragile sites, such as miR-195, 
and 199b (Calin, et al., 2004).  Of the miRNAs that were found to be 
overexpressed in integrated HPV-16 cell lines, miR-182 and miR-210 are 
expressed at low levels and miR-183 is not expressed in the normal cervix 
(Supplementary data, Table V).  MiR-210 is also known to be overexpressed in 
breast, colon, lung, pancreatic, prostate, and stomach cancers (Volinia, et al., 
2006), while miR-182 and miR-183 are overexpressed in colon cancer cell lines 
(Bandres, et al., 2006).  We also found that 6 miRNAs, miR-145, miR-195, miR-
368, miR-199a, miR-214, and miR-133a have reduced expression in the 
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episomal HPV-16 cervical cell line 20863 as compared to the normal cervix 
(Table 1). Changes in miRNA expression in the episomal cell line may represent 
early targets of HPV-16 infection. We also compared the miRNA expression 
profiles of HPV-16 positive cervical cell lines against the HPV-negative cervical 
carcinoma cell line C-33A. This cell line contains a number of mutations including 
those in p53 that most likely contribute to its carcinogenic phenotype (Scheffner, 
et al., 1991).  We performed this comparison in order to filter the miRNAs that 
may be differentially expressed due to the presence of HPV-16. We found that 9 
miRNAs exhibit higher expression and one miRNA, miR-218, exhibits lower 
expression in the integrated HPV-16 cell lines as compared to the C-33A cell line 
(Table 2). Importantly, miR-218 is underexpressed in HPV-16 positive cell lines 
as compared to both the normal cervix and C-33A cells.  MiR-218 is also 
underexpressed in breast, colon, lung, pancreatic, prostate, and stomach 
cancers (Volinia, et al., 2006). A comparison of miRNA expression in C-33A cells 
with that of the normal cervix showed that 4 miRNAs, miR-145, miR-143, miR-
203, and miR-200c were significantly underexpressed in C-33A cells (Table 16).  
Since miR-143 and miR-145 were also underexpressed in all the HPV-positive 
cell lines, our results suggest that these miRNAs may be important in cervical 
carcinogenesis independent of HPV infection. Hierarchical clustering analysis 
was done in order to identify specific miRNA expression patterns in the cervical 
cell lines and normal cervix (Fig. 16).  Cluster 1 contained six miRNAs which 
were expressed to much lower levels in the HPV-negative C-33A cell line as 
compared to the normal cervix as well as the HPV-positive cell lines.  The only 
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exception was the HPV-16 positive cervical carcinoma cell line SiHa which 
showed a pattern similar to that of C-33A and had low-level expression of the 
miRNAs in cluster 1.  Of the miRNAs in cluster 1, miR-200a and miR-200b are 
part of the same miRNA family localized on chromosome 1 p36.33, while miR-
200c and miR-141 are part of another miRNA family localized on chromosome 
12 p13.31 (47, 48).  This pattern suggests that miRNAs of the above two families 
may be subject to a common transcriptional regulation even though they are 
located in different chromosomal regions.  Cluster 2 contained 28 miRNAs that in 
general had lower expression in all the cervical cell lines as compared to the 
normal cervix (Fig. 16). Interestingly, 11 miRNAs in cluster 2 (miR-126, miR-195, 
miR-150, miR-142_5p, miR-133a, miR-1, miR-296, miR-101, miR-146a, miR-223 
and miR-214) were also found to be overexpressed in the normal B-cells as 
compared to leukemia and lymphoma cell lines (23) suggesting that reduced 
expression of these miRNAs could be a common mechanism during 
immortalization and/or transformation. We also utilized three CIN III tissues and 
five cervical cancer tissue samples in our studies to rule out the possibility that 
deregulation of miRNAs observed in the cell lines is simply a result of their in 
vitro growth in culture.  We performed qRT-PCR analysis of five miRNAs, miR-
143, miR-145, miR-218, miR-368 and miR-497 that were underexpressed in 
cervical cell lines, and miR-200c that was overexpressed in the cell lines.  The 
results obtained with the CIN III and cervical cancer tissues (Fig. 17) were 
generally consistent with the data obtained with the cell lines (Fig. 15).  
Importantly, miR-218 which is underexpressed in integrated HPV-16 cell lines 
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compared to both the normal cervix and C-33A, was also underexpressed in the 
CIN III and cervical cancer tissues (Fig. 17). These results suggest that changes 
in miR-218 expression are likely linked to the process of HPV-associated cervical 
carcinogenesis and not to other abnormalities that may accumulate in 
immortalized cells in vitro.  It is known that miR-218 is encoded by an intron of 
the SLIT2 tumor suppressor gene (Dallol, et al., 2002).  qRT-PCR analysis of the 
tissue samples showed that SLIT2 expression was also reduced in all the tumor 
tissues (Fig. 3).  Thus, the expression of miR-218 parallels that of SLIT2 
suggesting that miR-218 production may be regulated through the promoter of 
the tumor suppressor gene SLIT2. Since the HPV E6 and E7 oncogenes play 
important roles in viral-associated carcinogenesis, we tested whether their 
expression affects the cellular levels of miR-218 and SLIT2 mRNA.  For this, we 
utilized the osteosarcoma cell line U2OS that has previously been used 
successfully to study the downstream effects of E6 and E7 (Duensing, et al., 
2000).   Utilizing the U2OS-Neo cell line, or its derivatives expressing the HPV-16 
E6 or E7 gene, we found that both miR-218 and SLIT2 were underexpressed in 
the E6-expressing U2OS cell line as compared to the control U2OS-Neo by qRT-
PCR (Fig. 18A).  The levels of miR-218 or SLIT2 were not significantly affected in 
E7-expressing U2OS cells. These results suggest that the HPV-16 E6 gene may 
be involved in the downregulation of miR-218 and SLIT2 gene.  We further 
studied the effect of E6 on miR-218 and SLIT2 expression by using siRNA 
against the HPV-16 E6/E7 genes.  Transfection of the integrated HPV-16 cell line 
20861 with an siRNA directed against E6/E7 reduced their expression 
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significantly and resulted in a concomitant increase in the levels of miR-218 and 
the SLIT2 mRNA as shown by qRT-PCR (Fig. 18B).  These results suggest that 
miR-218 and SLIT2 expression may either be linked to one or more pathways 
known to be affected by E6 expression (for example, the p53 pathways) or an 
unknown pathway that targets miR-218. Interestingly, one of the possible mRNA 
targets of miR-200c (generally overexpressed in HPV-positive cell lines and 
tissues in our analysis) is the SLIT2 gene. A recent study has also shown that the 
p53 tumor suppressor gene downregulates miR-220c expression (Xi, et al., 
2006). Thus, it is possible that E6-dependent degradation of the p53 protein 
results in miR-200c overexpression which in turn reduces the levels of miR-218 
and SLIT2 mRNA.  Future studies should identify the precise mechanism by 
which E6 affects the levels of these RNAs.   
 
Finally, to investigate the potential involvement of miR-218 in the 
carcinogenesis of the cervix, we attempted to identify possible mRNA targets of 
miRNA-218.  After using two different programs to identify possible targets of 
miRNAs, we found that six mRNA that showed overexpression in our previous 
study using high-density microarrays could be possible targets of miR-218 at the 
transcriptional level. Out of these six possible targets, only the expression of the 
Laminin 5 β3 gene (LAMB3) was reduced when the SiHa and 20861 cell lines 
containing integrated HPV-16 DNA were transfected with an artificial miR-218 
precursor (Fig. 19A).  We also found that the 20861 cell line transfected with the 
E6/E7 siRNA expressed lower levels of LAMB3 (Fig. 19B), further suggesting 
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that miR-218 may target LAMB3.  Also, the expression of E6 in U2OS-Neo cells 
resulted in an increase in LAMB3 expression (Fig. 19B).  This effect on LAMB3 
was presumably a consequence of reduced expression of miR-218 in the 
presence of E6.  The above studies also suggest that miR-218 may regulate the 
expression of its target gene LAMB3 at the transcriptional level. LAMB3 is part of 
the polymeric transmembrane cell surface receptor named laminin 5 (consisting 
of 3 different chains, α, β and γ) that is expressed in the basal lamina of the 
epithelium, and it is overexpressed in cervical cancers (Kohlberger, et al., 
2003;Skyldberg, et al., 1999).  LAMB3 has been found to increase cell migration 
and tumorigenicity in SCID mice, and its expression along with that of one of its 
ligands α6β4-integrin (a component of the hemidesmosome structure of basal 
epithelial cells) has been shown to be necessary for tumorigenesis in human 
keratinocytes with mutations in laminin 5 and β4-integrin genes (Calaluce, et al., 
2004;Dajee, et al., 2003). A recent study has shown that secreted laminin 5 can 
be used by HPV as a transient receptor to help the virus in the infection of basal 
cells that express α6β4-integrin (Culp, et al., 2006).  Thus, downregulation of 
miR-218 by the HPV E6 oncogene and the consequent overexpression of 
LAMB3 may promote viral infection of the surrounding tissue and contribute to 
eventual tumorigenesis. In summary, our study demonstrate specific changes in 
miRNA expression profiles in HPV-positive cervical cell lines and tumors that 
some of these could be a consequence of the expression of the HPV viral 
oncogenes.   
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5.1 FUTURE DIRECTIONS  
 
The results of studies described in this thesis raise several important 
issues that can be pursued in the future to get a better understanding of the 
mechanisms by which HPVs may alter the expression of cellular genes, including 
those encoding miRNAs.  
 
 One of the next steps after the study of global gene expression in HPV-
positive SCCHN could be the use of tissue-arrays in order to get further 
validation of the differentially expressed genes. These experiments may reveal 
how frequently genes such as SYCP2 and KLK8 are affected in HPV-positive 
SCCHN, and if there is any correlation with tumor behavior (invasion and 
metastasis) and/or patient survival. These findings may identify important 
molecular markers and provide better patient diagnosis and prognosis. Another 
important experiment could involve the manipulation of gene expression of some 
affected cellular genes as well as HPV genes in order to understand their 
importance in the carcinogenesis of the Head and Neck tissues. These 
experiments may involve knocking-down the expression of the upregulated 
genes (such as SYCP2) or the viral genes such as E6 and E7 in HPV-positive 
SCCHN by using specific siRNAs in SCCHN cell lines containing or lacking HPV 
DNA. To study the role of cellular genes downregulated in HPV-positive SCCHN 
such as KLK8, one could transiently or stably overexpress such genes in HPV-
positive SCCHN cell lines. Identification of phenotypical changes (cell death, 
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growth suppression, etc.) in the above cell lines may provide clues about the role 
of the particular cellular gene in the development of HPV-associated SCCHN.   
 In the project dealing with the global expression profiles in HPV-positive 
cervical cell lines, the next series of experiments should involve the verification of 
differentially gene expression in cervical tumor tissues by microarray, qRT-PCR 
or tissue-array analyses. These studies will help identify genes whose expression 
may be affected due to cellular growth in vitro. Another experiment could involve 
the manipulation of expression of the upregulated LAT-1 and the downregulated 
NAP1L3 genes in HPV-positive cervical cell lines in order to understand their 
importance in cervical carcinogenesis (by using LAT1 siRNA or an expression 
vector containing NAP1L3). Another important study would be to identify cellular 
pathways affected by the expression of HPV oncogenes. This can be done by 
expressing E6 and E7 siRNAs in HPV-positive cell lines and then hybridizing the 
cellular mRNAs to microarrays containing probes for specific cellular pathways 
such as cell cycle, DNA repair, or apoptosis. Similarly, the gene expression 
profiles of cervical keratinocytes transfected with vectors expressing the HPV E6 
and/or E7 genes can be compared to those of non-transfectedcells using the 
above pathway arrays.  Such studies may provide interesting information on the 
mechanisms by which HPVs promote cervical carcinogenesis. 
 
 Finally, a number of exciting studies can be done to identify the specific 
roles of cellular and viral miRNAs in HPV pathogenesis. An important study 
would be to identify changes in cellular miRNA expression in HPV-positive 
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SCCHN tumor tissues and cell lines. This information will be important in order to 
identify miRNAs that are expressed in a tissue-specific manner (cervix vs 
oropharyngeal tissue) as well as possible miRNAs that are affected by the 
presence of the HPV oncogenes in both types of epitheliums. Another 
experiment could involve the identification of additional potential mRNA targets of 
some of the cervical cancer related miRNAs by comparing their expression to 
those of cellular mRNAs. An inverse correlation between the expression levels of 
a particular miRNA and its predicted mRNA target would provide a basis for a 
more in-depth future analysis of miRNA-dependent gene regulation in HPV-
positive cancers.  Similarly, the protein expression levels of the predicted miRNA 
targets can be measured and correlated with the particular miRNA levels in HPV-
positive cells. The levels of specific miRNA can also be experimentally 
manipulated in cell lines by using a miRNA expressing plasmid or a miRNA-
siRNA, and the effect of such changes on predicted mRNA/protein target 
determined. Another interesting project would involve studies on Dicer 
expression in some of the HPV-positive cervical and oropharyngeal cell lines and 
tissues. Dicer is a ribonuclease involved in the maturation of miRNAs. Most of 
the differentially expressed miRNAs that we found in the cervical cell lines and 
tumor tissues were underexpressed. One possible explanation of these findings 
is the underexpression of the enzymes involved in the maturation of miRNAs 
such as Drosha and Dicer. Interestingly, our gene expression profiling studies 
showed that Dicer 1 was downregulated in the HPV-positive cervcal cell lines 
compared to the control cervical tissue (Table 8). By qRT-PCR, western blotting 
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and sequencing we could further study Dicer 1 expression and identify the basis 
for its downregulation, if any, for example due to a mutation. Finally, another  
interesting study would be the identification of possible miRNAs encoded by 
HPVs. Several viruses have recently been shown to encode miRNAs. There is 
no evidence yet that HPVs encode miRNAs, but this may be due to the lack of 
sensitive technologies. Also, unlike other viruses HPVs can not be grown to high 
titers in tissue culture which may hamper efforts to identify HPV miRNAs.  Amy 
Gardiner, a graduate student in the laboratory of Dr. Saleem Khan has 
developed a microarray containing the complete genome of HPV-16 in order to 
detect possible miRNAs expressed by HPVs. 
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